{"custom_id":"syn24875850","result":{"type":"succeeded","message":{"id":"msg_01LjpipKjX1VCFW6R8PEaJYP","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"I'll create high-quality dataset metadata for this DNA methylation project following the schema requirements.\n\n```json\n[\n  {\n    \"title\": \"DNA methylation signatures in peripheral leukocytes of patients with Schwannomatosis or sporadic schwannoma\",\n    \"creator\": [\n      \"Gelareh Zadeh\",\n      \"Sheila Mansouri\"\n    ],\n    \"contributor\": [\n      \"Robert Allaway\",\n      \"University Health Network of Toronto\"\n    ],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\n      \"DNA methylation\",\n      \"peripheral leukocytes\",\n      \"Schwannomatosis\",\n      \"sporadic schwannoma\",\n      \"immune cell types\",\n      \"neutrophil to lymphocyte ratio\",\n      \"blood biomarkers\"\n    ],\n    \"dataType\": [\n      \"chromatinActivity\"\n    ],\n    \"studyId\": \"syn24875850\",\n    \"diseaseFocus\": [\n      \"SMARCB1-related schwannomatosis\",\n      \"LZTR1-related schwannomatosis\",\n      \"Schwannomatosis-NOS\"\n    ],\n    \"funder\": [\n      \"CTF\"\n    ],\n    \"description\": \"DNA methylation profiling on whole genomic DNA isolated from peripheral blood leukocytes from schwannomatosis patients and patients with sporadic non-syndromic schwannomas. The study evaluates the proportion of immune cell types in blood and shows different patterns between schwannomatosis and sporadic schwannoma patients.\",\n    \"individualCount\": 54,\n    \"specimenCount\": 54,\n    \"species\": [\n      \"Homo sapiens\"\n    ],\n    \"measurementTechnique\": [\n      \"methylation array\"\n    ],\n    \"subject\": [\n      \"DNA methylation\",\n      \"Schwannomatosis\",\n      \"Peripheral nerve sheath tumors\",\n      \"Biomarkers\"\n    ],\n    \"dataUseModifiers\": [\n      \"Health or Medical or Biomedical Research\"\n    ]\n  }\n]\n```"}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":6037,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":515}}}}
{"custom_id":"syn21355225","result":{"type":"succeeded","message":{"id":"msg_01CTFk7N7zuMfKrN2xieajnL","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"I'll create the dataset metadata for the table in this project according to the schema.\n\n```json\n[\n  {\n    \"title\": \"Patient Data for Antisense Oligonucleotide Therapy in NF2\",\n    \"creator\": [\"Elisabeth Castellanos\", \"James Moon\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"antisense oligonucleotides\", \"NF2\", \"exon skipping\", \"personalized therapy\", \"PMOs\", \"fibroblasts\"],\n    \"dataType\": [\"drugScreen\"],\n    \"studyId\": \"syn21355225\",\n    \"diseaseFocus\": [\"NF2-related schwannomatosis\"],\n    \"funder\": [\"CTF\"],\n    \"description\": \"This dataset contains patient data from primary fibroblast cultures derived from NF2 patients used to evaluate the use of antisense oligonucleotides as a personalized therapy. It includes results from experiments using phosphorodiamidate morpholino oligomers (PMOs) targeting specific exons and splicing mutations.\",\n    \"contributor\": [\"Catas√∫s, N.\", \"Rosas, I.\", \"Bonache, S.\", \"Negro, A.\", \"Torres-Martin, M.\", \"Plana-Pla, A.\"],\n    \"dataUseModifiers\": [\"General Research Use\"],\n    \"individualCount\": 15,\n    \"measurementTechnique\": [\"polymerase chain reaction\"],\n    \"species\": [\"Homo sapiens\"],\n    \"manifestation\": [\"Schwannoma\"],\n    \"subject\": [\"Neurofibromatosis type 2\", \"Gene therapy\", \"Antisense oligonucleotides\", \"Personalized medicine\"]\n  }\n]\n```"}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":7143,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":416}}}}
{"custom_id":"syn4984604","result":{"type":"succeeded","message":{"id":"msg_015acAkMBaUtSdXpJ5TfmcUx","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"Based on the provided information, I'll create high-quality dataset metadata that conforms to the JSON schema. I'll analyze each table and ensure all required fields are properly populated with accurate values.\n\n```json\n[\n  {\n    \"title\": \"Immunohistochemistry Data for Cutaneous Neurofibromas\",\n    \"creator\": [\"Robert Allaway\"],\n    \"contributor\": [\"Children's Tumor Foundation\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"description\": \"Immunohistochemistry data from cutaneous neurofibroma samples collected through the CTF Biobank. These data are part of a pilot project to characterize the molecular landscape of cutaneous neurofibromas in NF1 patients.\",\n    \"keywords\": [\"immunohistochemistry\", \"cutaneous neurofibroma\", \"NF1\", \"biobank\"],\n    \"dataType\": [\"image\"],\n    \"studyId\": \"syn4984604\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"CTF\"],\n    \"manifestation\": [\"Cutaneous Neurofibroma\"],\n    \"species\": [\"Homo sapiens\"],\n    \"measurementTechnique\": [\"immunohistochemistry\"],\n    \"subject\": [\"Neurofibromatosis\", \"Cutaneous Neurofibroma\"]\n  },\n  {\n    \"title\": \"NFOSI Processing Data 2023-07-21\",\n    \"creator\": [\"Thomas Yu\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"NF1\", \"fastq\", \"sequencing data\"],\n    \"dataType\": [\"AlignedReads\"],\n    \"studyId\": \"syn4984604\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"CTF\"],\n    \"manifestation\": [\"Cutaneous Neurofibroma\"],\n    \"species\": [\"Homo sapiens\"]\n  },\n  {\n    \"title\": \"Proteomics Data for Cutaneous Neurofibromas\",\n    \"creator\": [\"Sara Gosline\"],\n    \"contributor\": [\"Children's Tumor Foundation\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"description\": \"Proteomics data from 40 cutaneous neurofibroma samples from 11 individuals, generated using MudPIT technology. Part of a pilot project to characterize the molecular landscape of cutaneous neurofibromas in NF1 patients.\",\n    \"keywords\": [\"proteomics\", \"MudPIT\", \"cutaneous neurofibroma\", \"NF1\"],\n    \"dataType\": [\"proteomics\"],\n    \"studyId\": \"syn4984604\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"CTF\"],\n    \"manifestation\": [\"Cutaneous Neurofibroma\"],\n    \"species\": [\"Homo sapiens\"],\n    \"individualCount\": 11,\n    \"specimenCount\": 40,\n    \"measurementTechnique\": [\"MudPIT\"]\n  },\n  {\n    \"title\": \"RNA-Seq Data for Cutaneous Neurofibromas\",\n    \"creator\": [\"Thomas Yu\", \"Sara Gosline\", \"Robert Allaway\"],\n    \"contributor\": [\"Children's Tumor Foundation\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"description\": \"RNA sequencing data from cutaneous neurofibroma samples collected through the CTF Biobank. Includes processed alignment files (BAM), expression quantification, and related analysis files.\",\n    \"keywords\": [\"RNA-seq\", \"gene expression\", \"cutaneous neurofibroma\", \"NF1\"],\n    \"dataType\": [\"geneExpression\"],\n    \"studyId\": \"syn4984604\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"CTF\"],\n    \"manifestation\": [\"Cutaneous Neurofibroma\"],\n    \"species\": [\"Homo sapiens\"],\n    \"individualCount\": 44,\n    \"specimenCount\": 33,\n    \"measurementTechnique\": [\"RNA-seq\"]\n  },\n  {\n    \"title\": \"Raw cNF RNAseq Files\",\n    \"creator\": [\"Children's Tumor Foundation\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"description\": \"Raw RNA sequencing FASTQ files from cutaneous neurofibroma samples collected through the CTF Biobank. These represent the original sequencing data for gene expression analysis in NF1 patients.\",\n    \"keywords\": [\"RNA-seq\", \"FASTQ\", \"raw data\", \"cutaneous neurofibroma\", \"NF1\"],\n    \"dataType\": [\"geneExpression\"],\n    \"studyId\": \"syn4984604\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"CTF\"],\n    \"manifestation\": [\"Cutaneous Neurofibroma\"],\n    \"species\": [\"Homo sapiens\"],\n    \"individualCount\": 11,\n    \"specimenCount\": 33,\n    \"measurementTechnique\": [\"RNA-seq\"]\n  },\n  {\n    \"title\": \"Raw cNF RNAseq Files (unmerged)\",\n    \"creator\": [\"Children's Tumor Foundation\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"description\": \"Unmerged raw RNA sequencing FASTQ files from cutaneous neurofibroma samples. These represent the sequencing lane-level data prior to merging for the CTF Biobank NF1 study.\",\n    \"keywords\": [\"RNA-seq\", \"FASTQ\", \"unmerged\", \"raw data\", \"cutaneous neurofibroma\", \"NF1\"],\n    \"dataType\": [\"geneExpression\"],\n    \"studyId\": \"syn4984604\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"CTF\"],\n    \"manifestation\": [\"Cutaneous Neurofibroma\"],\n    \"species\": [\"Homo sapiens\"],\n    \"individualCount\": 11,\n    \"specimenCount\": 33,\n    \"measurementTechnique\": [\"RNA-seq\"]\n  },\n  {\n    \"title\": \"SNP Array Data for Cutaneous Neurofibromas\",\n    \"creator\": [\"Sara Gosline\"],\n    \"contributor\": [\"Children's Tumor Foundation\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"description\": \"SNP array data from cutaneous neurofibroma samples and matched normal samples. These data provide genomic variant information for NF1 patients in the CTF Biobank pilot study.\",\n    \"keywords\": [\"SNP array\", \"genomic variants\", \"cutaneous neurofibroma\", \"NF1\"],\n    \"dataType\": [\"genomicVariants\"],\n    \"studyId\": \"syn4984604\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"CTF\"],\n    \"manifestation\": [\"Cutaneous Neurofibroma\"],\n    \"species\": [\"Homo sapiens\"],\n    \"individualCount\": 11,\n    \"specimenCount\": 48,\n    \"measurementTechnique\": [\"SNP array\"]\n  },\n  {\n    \"title\": \"Sample Information for CTF Biobank cNF Study\",\n    \"creator\": [\"Sara Gosline\"],\n    \"contributor\": [\"Children's Tumor Foundation\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"description\": \"Comprehensive sample information and metadata for the CTF Biobank cutaneous neurofibroma study. Includes sample manifests, experimental protocols, and clinical data forms.\",\n    \"keywords\": [\"sample metadata\", \"clinical data\", \"protocols\", \"cutaneous neurofibroma\", \"NF1\"],\n    \"dataType\": [\"clinical\", \"dataIndex\"],\n    \"studyId\": \"syn4984604\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"CTF\"],\n    \"manifestation\": [\"Cutaneous Neurofibroma\"],\n    \"species\": [\"Homo sapiens\"],\n    \"measurementTechnique\": [\"questionnaire\"]\n  },\n  {\n    \"title\": \"Whole Genome Sequencing Data for Cutaneous Neurofibromas\",\n    \"creator\": [\"Thomas Yu\", \"Sara Gosline\"],\n    \"contributor\": [\"Children's Tumor Foundation\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"description\": \"Whole genome sequencing data from cutaneous neurofibroma samples and matched normal tissues. Includes variant call files (VCF) and mutation annotation files (MAF) for genomic analysis of NF1 patients.\",\n    \"keywords\": [\"WGS\", \"genomic variants\", \"cutaneous neurofibroma\", \"NF1\", \"VCF\"],\n    \"dataType\": [\"genomicVariants\"],\n    \"studyId\": \"syn4984604\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"CTF\"],\n    \"manifestation\": [\"Cutaneous Neurofibroma\"],\n    \"species\": [\"Homo sapiens\"],\n    \"individualCount\": 15,\n    \"specimenCount\": 62,\n    \"measurementTechnique\": [\"whole genome sequencing\"]\n  },\n  {\n    \"title\": \"cNF RNA-seq Quantification Files (Salmon)\",\n    \"creator\": [\"Children's Tumor Foundation\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"description\": \"RNA-seq quantification files generated using Salmon for cutaneous neurofibroma samples. These files provide transcript and gene-level expression quantification derived from the RNA-seq data.\",\n    \"keywords\": [\"RNA-seq\", \"salmon quantification\", \"gene expression\", \"cutaneous neurofibroma\", \"NF1\"],\n    \"dataType\": [\"geneExpression\"],\n    \"studyId\": \"syn4984604\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"CTF\"],\n    \"manifestation\": [\"Cutaneous Neurofibroma\"],\n    \"species\": [\"Homo sapiens\"],\n    \"measurementTechnique\": [\"RNA-seq\"]\n  }\n]\n```"}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":7569,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":2558}}}}
{"custom_id":"syn6633069","result":{"type":"succeeded","message":{"id":"msg_01TMa9HciZY8GwPA8w5NGhCn","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"I'll help you create high-quality dataset metadata for these tables based on the information provided. Here's the completed metadata in JSON format:\n\n```json\n[\n  {\n    \"title\": \"Copy Number Variation from the Columbia University NF1 Glioma Project\",\n    \"creator\": [\"Antonio Iavarone\", \"Fulvio D'Angelo\"],\n    \"contributor\": [\"Columbia University\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"NF1\", \"glioma\", \"copy number variation\", \"low-grade glioma\", \"high-grade glioma\", \"cancer genomics\"],\n    \"dataType\": [\"genomicVariants\", \"CopyNumberVariants\"],\n    \"studyId\": \"syn6633069\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"CTF\"],\n    \"description\": \"Copy number variation data derived from whole exome sequencing of NF1 glioma samples. This dataset contains CNV data from 56 individuals with 59 specimens showing both low-grade and high-grade gliomas.\",\n    \"species\": [\"Homo sapiens\"],\n    \"measurementTechnique\": [\"whole exome sequencing\"],\n    \"manifestation\": [\"Low-Grade Glioma\", \"High-Grade Glioma\"],\n    \"individualCount\": 56,\n    \"specimenCount\": 59,\n    \"subject\": [\"Copy number variation\", \"Neurofibromatosis\", \"Brain cancer\", \"Medical genetics\"]\n  },\n  {\n    \"title\": \"CopyNumberVariation\",\n    \"creator\": [\"Antonio Iavarone\", \"Fulvio D'Angelo\"],\n    \"contributor\": [\"Columbia University\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"NF1\", \"glioma\", \"copy number variation\", \"low-grade glioma\", \"high-grade glioma\", \"cancer genomics\"],\n    \"dataType\": [\"genomicVariants\", \"CopyNumberVariants\"],\n    \"studyId\": \"syn6633069\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"CTF\"],\n    \"description\": \"Copy number variation data from whole exome sequencing of NF1 glioma samples. This dataset contains CNV data from 56 individuals with 59 specimens showing both low-grade and high-grade gliomas.\",\n    \"species\": [\"Homo sapiens\"],\n    \"measurementTechnique\": [\"whole exome sequencing\"],\n    \"manifestation\": [\"Low-Grade Glioma\", \"High-Grade Glioma\"],\n    \"individualCount\": 56,\n    \"specimenCount\": 59,\n    \"subject\": [\"Copy number variation\", \"Neurofibromatosis\", \"Brain cancer\", \"Medical genetics\"]\n  },\n  {\n    \"title\": \"GeneExpression\",\n    \"creator\": [\"Antonio Iavarone\", \"Fulvio D'Angelo\"],\n    \"contributor\": [\"Columbia University\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"NF1\", \"glioma\", \"gene expression\", \"RNA-seq\", \"low-grade glioma\", \"high-grade glioma\", \"transcriptomics\"],\n    \"dataType\": [\"geneExpression\", \"raw counts\"],\n    \"studyId\": \"syn6633069\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"CTF\"],\n    \"description\": \"RNA sequencing data from NF1 glioma samples providing gene expression profiles. This dataset contains expression data from 29 individuals with 32 specimens showing both low-grade and high-grade gliomas.\",\n    \"species\": [\"Homo sapiens\"],\n    \"measurementTechnique\": [\"RNA-seq\"],\n    \"manifestation\": [\"Low-Grade Glioma\", \"High-Grade Glioma\"],\n    \"individualCount\": 29,\n    \"specimenCount\": 32,\n    \"subject\": [\"Gene expression\", \"Neurofibromatosis\", \"Brain cancer\", \"Transcriptomics\"]\n  },\n  {\n    \"title\": \"Methylation\",\n    \"creator\": [\"Antonio Iavarone\", \"Fulvio D'Angelo\"],\n    \"contributor\": [\"Columbia University\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"NF1\", \"glioma\", \"DNA methylation\", \"epigenetics\", \"low-grade glioma\", \"high-grade glioma\"],\n    \"dataType\": [\"chromatinActivity\"],\n    \"studyId\": \"syn6633069\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"CTF\"],\n    \"description\": \"DNA methylation array data from NF1 glioma samples providing epigenetic profiles. This dataset contains methylation data from 31 individuals with 31 specimens showing both low-grade and high-grade gliomas.\",\n    \"species\": [\"Homo sapiens\"],\n    \"measurementTechnique\": [\"methylation array\"],\n    \"manifestation\": [\"Low-Grade Glioma\", \"High-Grade Glioma\"],\n    \"individualCount\": 31,\n    \"specimenCount\": 31,\n    \"subject\": [\"DNA methylation\", \"Epigenetics\", \"Neurofibromatosis\", \"Brain cancer\"]\n  },\n  {\n    \"title\": \"NucleotideVariation\",\n    \"creator\": [\"Antonio Iavarone\", \"Fulvio D'Angelo\"],\n    \"contributor\": [\"Columbia University\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"NF1\", \"glioma\", \"nucleotide variants\", \"mutations\", \"low-grade glioma\", \"high-grade glioma\", \"cancer genomics\"],\n    \"dataType\": [\"genomicVariants\"],\n    \"studyId\": \"syn6633069\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"CTF\"],\n    \"description\": \"Nucleotide variation data from whole exome sequencing of NF1 glioma samples. This dataset contains variant data from 56 individuals with 102 specimens showing both low-grade and high-grade gliomas.\",\n    \"species\": [\"Homo sapiens\"],\n    \"measurementTechnique\": [\"whole exome sequencing\"],\n    \"manifestation\": [\"Low-Grade Glioma\", \"High-Grade Glioma\"],\n    \"individualCount\": 56,\n    \"specimenCount\": 102,\n    \"subject\": [\"Genetic variation\", \"Neurofibromatosis\", \"Brain cancer\", \"Medical genetics\"]\n  },\n  {\n    \"title\": \"WholeGenomeVariants\",\n    \"creator\": [\"Antonio Iavarone\", \"Fulvio D'Angelo\"],\n    \"contributor\": [\"Columbia University\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"NF1\", \"glioma\", \"whole genome sequencing\", \"genomic variants\", \"low-grade glioma\", \"high-grade glioma\", \"cancer genomics\"],\n    \"dataType\": [\"genomicVariants\"],\n    \"studyId\": \"syn6633069\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"CTF\"],\n    \"description\": \"Whole genome sequencing variant data from NF1 glioma samples. This dataset contains genomic variants from 11 individuals with 22 specimens showing both low-grade and high-grade gliomas.\",\n    \"species\": [\"Homo sapiens\"],\n    \"measurementTechnique\": [\"whole genome sequencing\"],\n    \"manifestation\": [\"Low-Grade Glioma\", \"High-Grade Glioma\"],\n    \"individualCount\": 11,\n    \"specimenCount\": 22,\n    \"subject\": [\"Whole genome sequencing\", \"Neurofibromatosis\", \"Brain cancer\", \"Medical genetics\"]\n  }\n]\n```"}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":6470,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":1984}}}}
{"custom_id":"syn26347297","result":{"type":"succeeded","message":{"id":"msg_01Bh4R2ggzBmE2eEj1cKN2EV","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"I'll create high-quality dataset metadata for these tables, following the JSON schema requirements.\n\n```json\n[\n  {\n    \"title\": \"Flow Cytometry Data for Peripheral Nerve Sheath Tumors\",\n    \"creator\": [\"Lindy Zhang\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"MPNST\", \"flow cytometry\", \"peripheral nerve sheath tumor\", \"tumor microenvironment\", \"immune cells\"],\n    \"dataType\": [\"immunoassay\", \"cellularPhysiology\"],\n    \"studyId\": \"syn26347297\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"CTF\"],\n    \"description\": \"Flow cytometry data examining immune cell populations in malignant peripheral nerve sheath tumors (MPNSTs). Part of a study investigating the effects of RAS signaling pathway inhibitors on tumor cells and the tumor immune microenvironment.\",\n    \"contributor\": [\"Christine Pratilas\", \"Nicolas Llosa\"],\n    \"measurementTechnique\": [\"flow cytometry\"],\n    \"manifestation\": [\"Malignant Peripheral Nerve Sheath Tumor (MPNST)\"],\n    \"species\": [\"Homo sapiens\"],\n    \"subject\": [\"Peripheral nerve tumors\", \"Cancer immunology\", \"Signal transduction\", \"Tumor microenvironment\"]\n  },\n  {\n    \"title\": \"Immunohistochemistry Data for Peripheral Nerve Sheath Tumors\",\n    \"creator\": [\"Lindy Zhang\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"MPNST\", \"immunohistochemistry\", \"peripheral nerve sheath tumor\", \"RAS signaling\", \"tumor microenvironment\"],\n    \"dataType\": [\"immunoassay\", \"image\"],\n    \"studyId\": \"syn26347297\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"CTF\"],\n    \"description\": \"Immunohistochemistry data for human peripheral nerve sheath tumors examining protein expression and tissue architecture. Part of a study investigating the effects of RAS signaling pathway inhibitors on tumor cells and the tumor microenvironment.\",\n    \"contributor\": [\"Christine Pratilas\", \"Nicolas Llosa\"],\n    \"measurementTechnique\": [\"immunohistochemistry\"],\n    \"manifestation\": [\"Malignant Peripheral Nerve Sheath Tumor (MPNST)\"],\n    \"species\": [\"Homo sapiens\"],\n    \"subject\": [\"Peripheral nerve tumors\", \"Cancer histopathology\", \"Signal transduction\", \"Tumor microenvironment\"]\n  }\n]\n```"}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":5533,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":659}}}}
{"custom_id":"syn11817821","result":{"type":"succeeded","message":{"id":"msg_01MWhvFmyB2FK7vZXHtxWubz","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"I'll create high-quality dataset metadata for these three tables based on the information provided. I'll follow the schema requirements closely, ensuring all required fields are properly filled and using only the predefined values from enums.\n\n```json\n[\n  {\n    \"title\": \"Exp008_analyzed Data\",\n    \"creator\": [\"Jeffrey Field\", \"Yang Yang\"],\n    \"accessType\": \"Public Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"MPNST\", \"drug screen\", \"cell viability\", \"immunofluorescence\", \"high-throughput screening\"],\n    \"dataType\": [\"drugScreen\", \"image\"],\n    \"studyId\": \"syn11817821\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"CTF\"],\n    \"description\": \"Analyzed data from high-throughput screening of drug sensitivity in MPNST cell lines. Contains normalized data, analysis templates, and IC50 values for cell viability assays.\",\n    \"measurementTechnique\": [\"cell viability assay\", \"immunofluorescence\"],\n    \"manifestation\": [\"Malignant Peripheral Nerve Sheath Tumor (MPNST)\"],\n    \"species\": [\"Homo sapiens\"],\n    \"contributor\": [\"Jeffrey Field\", \"Yang Yang\"]\n  },\n  {\n    \"title\": \"Raw Data and logs\",\n    \"creator\": [\"Jeffrey Field\", \"Yang Yang\"],\n    \"accessType\": \"Public Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"MPNST\", \"drug screen\", \"raw data\", \"high-throughput screening\", \"cell viability\"],\n    \"dataType\": [\"drugScreen\"],\n    \"studyId\": \"syn11817821\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\", \"Neurofibromatosis type 2\"],\n    \"funder\": [\"CTF\"],\n    \"description\": \"Raw data files and logs from high-throughput drug screening experiments across multiple cell lines derived from NF1 and NF2 tumors.\",\n    \"measurementTechnique\": [\"cell viability assay\"],\n    \"manifestation\": [\"Malignant Peripheral Nerve Sheath Tumor (MPNST)\"],\n    \"species\": [\"Homo sapiens\", \"Rattus norvegicus\"],\n    \"contributor\": [\"Jeffrey Field\", \"Yang Yang\"],\n    \"specimenCount\": 27\n  },\n  {\n    \"title\": \"Exome Sequencing\",\n    \"creator\": [\"Jeffrey Field\", \"Robert Allaway\"],\n    \"accessType\": \"Public Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"exome sequencing\", \"genomic variants\", \"MPNST\", \"schwannoma\", \"neurofibromatosis\"],\n    \"dataType\": [\"genomicVariants\"],\n    \"studyId\": \"syn11817821\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\", \"Neurofibromatosis type 2\"],\n    \"funder\": [\"CTF\"],\n    \"description\": \"Whole exome sequencing data from NF1 and NF2 tumor samples including processed variant calls, VCF files, and associated analysis files.\",\n    \"measurementTechnique\": [\"whole exome sequencing\"],\n    \"manifestation\": [\"Malignant Peripheral Nerve Sheath Tumor (MPNST)\", \"Schwannoma\"],\n    \"species\": [\"Homo sapiens\"],\n    \"contributor\": [\"Jeffrey Field\", \"Robert Allaway\"],\n    \"individualCount\": 13\n  }\n]\n```"}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":6501,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":860}}}}
{"custom_id":"syn4939876","result":{"type":"succeeded","message":{"id":"msg_01NJcW59U5uaK7S9Cd9pf7pJ","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"I'll create high-quality metadata for this dataset following the JSON schema requirements.\n\n```json\n[\n  {\n    \"title\": \"Combination Index Validation Studies - Combination Drug Testing Data\",\n    \"creator\": [\"D. Wade Clapp\"],\n    \"contributor\": [\"Heather Daniel\", \"Xindi Guo\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"drug combination\", \"plexiform neurofibroma\", \"cell viability\", \"drug validation\", \"Schwann cells\", \"rapamycin\", \"ganetespib\", \"selumetinib\", \"panobinostat\"],\n    \"dataType\": [\"drugScreen\", \"drugCombinationScreen\"],\n    \"studyId\": \"syn4939876\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"This dataset contains in vitro drug combination testing data validating high-throughput screening results. Experiments tested two prioritized drug combinations (Rapamycin & Ganetespib and Selumetinib & Panobinostat) in primary embryonic Schwann cell lines and murine plexiform-derived cells, comparing different assay methods (Caspase-Glo, CellTiter-Glo, MTT).\",\n    \"manifestation\": [\"Plexiform Neurofibroma\"],\n    \"species\": [\"Mus musculus\"],\n    \"measurementTechnique\": [\"cell viability assay\"],\n    \"subject\": [\"Drug combination therapy\", \"Cell culture\", \"Neurofibromatosis\", \"Preclinical validation\"],\n    \"datePublished\": 2015,\n    \"dataUseModifiers\": [\"General Research Use\"]\n  }\n]\n```"}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":5902,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":431}}}}
{"custom_id":"syn22267330","result":{"type":"succeeded","message":{"id":"msg_01CJiCp7bGdqUyeFmeXESWfN","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"I'll create high-quality dataset metadata for these tables according to the schema and requirements. Here's the resulting JSON:\n\n```json\n[\n  {\n    \"title\": \"Cell Viability Celigo Assays for MPNST\",\n    \"creator\": [\"Laurel Black\", \"James Moon\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"MPNST\", \"cell viability\", \"drug screen\", \"drug combination\", \"Celigo\", \"TFP\"],\n    \"dataType\": [\"image\", \"geneExpression\", \"drugScreen\", \"drugCombinationScreen\"],\n    \"studyId\": \"syn22267330\",\n    \"diseaseFocus\": [\"Multiple\"],\n    \"funder\": [\"CTF\"],\n    \"description\": \"Cell viability assay data for MPNST cell lines treated with various compounds including TFP and Src inhibitors. Includes imaging data from Celigo assays showing treatment effects on cellular proliferation and survival.\",\n    \"species\": [\"Homo sapiens\"],\n    \"measurementTechnique\": [\"cell viability assay\"],\n    \"manifestation\": [\"Malignant Peripheral Nerve Sheath Tumor (MPNST)\"],\n    \"individualCount\": 1,\n    \"contributor\": [\"Laurel Black\", \"James Moon\"]\n  },\n  {\n    \"title\": \"Immunocytochemistry Imaging of MPNST Cells\",\n    \"creator\": [\"Laurel Black\", \"James Moon\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"MPNST\", \"immunocytochemistry\", \"microscopy\", \"ERBB3\", \"imaging\"],\n    \"dataType\": [\"image\"],\n    \"studyId\": \"syn22267330\",\n    \"diseaseFocus\": [\"Multiple\"],\n    \"funder\": [\"CTF\"],\n    \"description\": \"Microscopy images from immunocytochemistry experiments on MPNST cells, with a focus on ERBB3 receptor expression. Includes positive staining and negative controls.\",\n    \"species\": [\"Homo sapiens\"],\n    \"measurementTechnique\": [\"immunocytochemistry\"],\n    \"manifestation\": [\"Malignant Peripheral Nerve Sheath Tumor (MPNST)\"],\n    \"individualCount\": 1,\n    \"contributor\": [\"Laurel Black\", \"James Moon\"]\n  },\n  {\n    \"title\": \"Kinomics Analysis of MPNST Cells\",\n    \"creator\": [\"Laurel Black\", \"James Moon\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"MPNST\", \"kinomics\", \"phosphorylation\", \"signaling pathways\", \"kinase activity\"],\n    \"dataType\": [\"kinomics\"],\n    \"studyId\": \"syn22267330\",\n    \"diseaseFocus\": [\"Multiple\"],\n    \"funder\": [\"CTF\"],\n    \"description\": \"Kinomics data showing kinase activity profiles in MPNST cells, focusing on changes in kinase phosphorylation patterns in response to various treatments and conditions.\",\n    \"species\": [\"Homo sapiens\"],\n    \"measurementTechnique\": [\"immunoassay\"],\n    \"manifestation\": [\"Malignant Peripheral Nerve Sheath Tumor (MPNST)\"],\n    \"individualCount\": 1,\n    \"contributor\": [\"Laurel Black\", \"James Moon\"]\n  },\n  {\n    \"title\": \"Microarray Analysis of NRG1-Beta Regulated Genes in Adult Schwann Cells\",\n    \"creator\": [\"Laurel Black\", \"James Moon\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"Schwann cells\", \"NRG1-Beta\", \"gene expression\", \"microarray\", \"MPNST\"],\n    \"dataType\": [\"geneExpression\"],\n    \"studyId\": \"syn22267330\",\n    \"diseaseFocus\": [\"Multiple\"],\n    \"funder\": [\"CTF\"],\n    \"description\": \"Microarray gene expression data examining the effects of NRG1-Beta stimulation on adult rat Schwann cells, with a focus on identifying genes regulated by this growth factor relevant to MPNST biology.\",\n    \"species\": [\"Rattus norvegicus\"],\n    \"measurementTechnique\": [\"array\"],\n    \"manifestation\": [\"Malignant Peripheral Nerve Sheath Tumor (MPNST)\"],\n    \"individualCount\": 1,\n    \"specimenCount\": 1,\n    \"contributor\": [\"Laurel Black\", \"James Moon\"]\n  }\n]\n```"}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":6821,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":1129}}}}
{"custom_id":"syn31619419","result":{"type":"succeeded","message":{"id":"msg_01ScWN98d1oAmFFC3XTCJk6K","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"I'll create high-quality dataset metadata for each table in this project, following the JSON schema and requirements.\n\n```json\n[\n  {\n    \"title\": \"SFDI Analysis of Cutaneous Neurofibromas\",\n    \"creator\": [\"Wangcun Jia\", \"Junsoo Lee\", \"Christina Parry\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"CC-BY\",\n    \"keywords\": [\"cutaneous neurofibroma\", \"spatial frequency domain imaging\", \"optical coherence tomography\", \"imaging analysis\"],\n    \"dataType\": [\"image\"],\n    \"studyId\": \"syn31619419\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\", \"NIH-NCI\"],\n    \"description\": \"Analysis of cutaneous neurofibromas using spatial frequency domain imaging (SFDI) and optical coherence tomography (OCT). This dataset includes processed images that identify and evaluate cutaneous neurofibromas to support development of optical biomarkers for early detection.\",\n    \"measurementTechnique\": [\"spatial frequency domain imaging\", \"optical coherence tomography\"],\n    \"manifestation\": [\"Cutaneous Neurofibroma\"],\n    \"contributor\": [\"University of California, Irvine\", \"Thomas E. Milner\"],\n    \"dataUseModifiers\": [\"General Research Use\"]\n  },\n  {\n    \"title\": \"Histology Images of Cutaneous Neurofibromas\",\n    \"creator\": [\"Wangcun Jia\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"CC-BY\",\n    \"keywords\": [\"histology\", \"cutaneous neurofibroma\", \"microscopy\", \"NF1\"],\n    \"dataType\": [\"image\"],\n    \"studyId\": \"syn31619419\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\", \"NIH-NCI\"],\n    \"description\": \"Brightfield microscopy histology images of visible and suspected invisible cutaneous neurofibromas and uninvolved skin. These images serve to validate the optical biomarkers identified in the study.\",\n    \"measurementTechnique\": [\"brightfield microscopy\"],\n    \"manifestation\": [\"Cutaneous Neurofibroma\"],\n    \"contributor\": [\"University of California, Irvine\", \"Thomas E. Milner\"],\n    \"dataUseModifiers\": [\"General Research Use\"]\n  },\n  {\n    \"title\": \"OCT Images of Cutaneous Neurofibromas\",\n    \"creator\": [\"Junsoo Lee\", \"Christina Parry\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"CC-BY\",\n    \"keywords\": [\"optical coherence tomography\", \"OCT\", \"cutaneous neurofibroma\", \"tumor imaging\", \"NF1\"],\n    \"dataType\": [\"image\"],\n    \"studyId\": \"syn31619419\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\", \"NIH-NCI\"],\n    \"description\": \"Optical coherence tomography (OCT) images for identification and microstructural analysis of cutaneous neurofibromas. These high-resolution images aim to characterize the tissue properties of the tumors to develop effective laser treatment strategies.\",\n    \"measurementTechnique\": [\"optical coherence tomography\"],\n    \"manifestation\": [\"Cutaneous Neurofibroma\"],\n    \"contributor\": [\"University of California, Irvine\", \"Thomas E. Milner\", \"Wangcun Jia\"],\n    \"dataUseModifiers\": [\"General Research Use\"]\n  },\n  {\n    \"title\": \"Photographic Documentation of Cutaneous Neurofibromas\",\n    \"creator\": [\"Wangcun Jia\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"CC-BY\",\n    \"keywords\": [\"photography\", \"cutaneous neurofibroma\", \"NF1\", \"clinical imaging\"],\n    \"dataType\": [\"image\"],\n    \"studyId\": \"syn31619419\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\", \"NIH-NCI\"],\n    \"description\": \"Photographic documentation of cutaneous neurofibromas for clinical assessment and correlation with other imaging modalities. These images serve as reference for identifying tumor locations and appearance.\",\n    \"measurementTechnique\": [\"photograph\"],\n    \"manifestation\": [\"Cutaneous Neurofibroma\"],\n    \"contributor\": [\"University of California, Irvine\", \"Thomas E. Milner\"],\n    \"dataUseModifiers\": [\"General Research Use\"]\n  },\n  {\n    \"title\": \"SFDI Raw Data for Cutaneous Neurofibroma Analysis\",\n    \"creator\": [\"Wangcun Jia\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"CC-BY\",\n    \"keywords\": [\"spatial frequency domain imaging\", \"SFDI\", \"cutaneous neurofibroma\", \"optical imaging\", \"NF1\"],\n    \"dataType\": [\"image\"],\n    \"studyId\": \"syn31619419\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\", \"NIH-NCI\"],\n    \"description\": \"Raw data from spatial frequency domain imaging (SFDI) for detection and analysis of cutaneous neurofibromas. This dataset includes calibrated reflectance images and position data that contribute to developing optical biomarkers for cutaneous neurofibromas.\",\n    \"measurementTechnique\": [\"spatial frequency domain imaging\"],\n    \"manifestation\": [\"Cutaneous Neurofibroma\"],\n    \"contributor\": [\"University of California, Irvine\", \"Thomas E. Milner\", \"Junsoo Lee\", \"Christina Parry\"],\n    \"dataUseModifiers\": [\"General Research Use\"]\n  }\n]\n```"}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":6475,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":1447}}}}
{"custom_id":"syn4939890","result":{"type":"succeeded","message":{"id":"msg_012LzG2F51wv5V3LPGh9qd3v","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"I'll create high-quality dataset metadata for this table based on the project information provided.\n\n```json\n[\n  {\n    \"title\": \"Gene expression profiling of Schwann cells and macrophages in mouse nerves and neurofibromas\",\n    \"creator\": [\"Jianqiang Wu\", \"Kakajan Komurov\", \"Kwangmn Choi\"],\n    \"description\": \"This dataset contains gene expression profiles of Schwann cells and macrophages isolated from mouse nerves and plexiform neurofibromas. The data was generated to identify molecular networks that mediate intra- and inter-cellular signaling in controlling neurofibroma growth and to characterize gene expression profiles in these cell types.\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"neurofibroma\", \"Schwann cells\", \"macrophages\", \"gene expression\", \"plexiform neurofibroma\", \"NF1\", \"intercellular signaling\", \"inflammation\"],\n    \"dataType\": [\"geneExpression\", \"RawIntensities\", \"NormalizedIntensities\"],\n    \"studyId\": \"syn4939890\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"CTF\"],\n    \"contributor\": [\"Kwangmn Choi\"],\n    \"manifestation\": [\"Plexiform Neurofibroma\"],\n    \"measurementTechnique\": [\"RNA array\"],\n    \"species\": [\"Mus musculus\"],\n    \"subject\": [\"Neurofibromatosis\", \"Gene expression\", \"Cell interaction\", \"Schwann cells\", \"Macrophages\"],\n    \"datePublished\": 1489536000\n  }\n]\n```"}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":6438,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":416}}}}
{"custom_id":"syn7217928","result":{"type":"succeeded","message":{"id":"msg_01Qduij4DWdPcUbA4dBwAD7z","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"I'll create high-quality dataset metadata for these tables based on the provided information.\n\n```json\n[\n  {\n    \"title\": \"Drug screen data\",\n    \"creator\": [\"Ray Mattingly\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"plexiform neurofibroma\", \"drug screening\", \"3D cell culture\", \"preclinical models\", \"cell proliferation\"],\n    \"description\": \"Drug screening data generated using 3D co-culture model systems of plexiform neurofibromas. These models were developed to better recapitulate the in vivo environment for more translational preclinical testing compared to traditional 2D monoculture methods.\",\n    \"studyId\": \"syn7217928\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"contributor\": [\"Anh Nguyet Vu\", \"Ray Mattingly\"],\n    \"dataType\": [\"drugScreen\"],\n    \"manifestation\": [\"Plexiform Neurofibroma\"],\n    \"measurementTechnique\": [\"3D confocal imaging\", \"cell proliferation\"],\n    \"species\": [\"Homo sapiens\"]\n  },\n  {\n    \"title\": \"Drug screens with 3D Plexiform Neurofibroma Model System\",\n    \"creator\": [\"Ray Mattingly\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"plexiform neurofibroma\", \"drug screening\", \"3D culture model\", \"preclinical testing\", \"cell proliferation assay\"],\n    \"description\": \"Results from drug screening experiments using optimized 3D co-culture models of plexiform neurofibroma cells with endothelial cells. These models were developed to investigate the high vascularity of plexiform neurofibromas and test potential therapeutic compounds.\",\n    \"studyId\": \"syn7217928\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"contributor\": [\"Anh Nguyet Vu\", \"Ray Mattingly\"],\n    \"dataType\": [\"drugScreen\"],\n    \"manifestation\": [\"Plexiform Neurofibroma\"],\n    \"measurementTechnique\": [\"3D confocal imaging\", \"cell proliferation\"],\n    \"species\": [\"Homo sapiens\"]\n  }\n]\n```"}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":6648,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":588}}}}
{"custom_id":"syn61696875","result":{"type":"succeeded","message":{"id":"msg_01Eu9wF9nbWbssC6TDnx4Up5","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"Based on the provided information, I'll create high-quality dataset metadata for the Mayo Clinic REDCap database table.\n\n```json\n[\n  {\n    \"title\": \"Mayo Clinic cohort REDCap database of de-identified phenotype and genotype information\",\n    \"creator\": [\"Mayowa Osundiji\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"REDCap\", \"phenotype\", \"genotype\", \"Mayo Clinic\", \"de-identified\", \"electronic health records\"],\n    \"dataType\": [\"clinical\", \"AggregatedData\"],\n    \"studyId\": \"syn61696875\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"CTF\"],\n    \"description\": \"De-identified phenotype and genotype information extracted from Mayo Clinic Rochester electronic health records, compiled into a REDCap database to supplement the Children's Tumor Foundation-Neurofibromatosis Registry. This dataset includes clinical data from patients with NF1.\",\n    \"contributor\": [\"Marlene Girardo\"],\n    \"manifestation\": [\"Malignant Peripheral Nerve Sheath Tumor (MPNST)\"],\n    \"measurementTechnique\": [\"genotyping\", \"clinical data\"],\n    \"species\": [\"Homo sapiens\"],\n    \"individualCount\": 1,\n    \"subject\": [\"Neurofibromatosis\", \"Electronic health records\", \"Disease registries\", \"Clinical data\"]\n  }\n]\n```"}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":5825,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":367}}}}
{"custom_id":"syn2343195","result":{"type":"succeeded","message":{"id":"msg_01GTcznsvVhf9AiTsrUJmMm4","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"I'll create high-quality dataset metadata for each of the tables in this project, following the JSON schema requirements and ensuring accuracy.\n\n```json\n[\n  {\n    \"title\": \"2017 Release - Jumping Library Seq\",\n    \"creator\": [\"Robert Allaway\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"genomic variants\", \"jumping library\", \"structural rearrangement\", \"NF2\"],\n    \"dataType\": [\"genomicVariants\"],\n    \"studyId\": \"syn2343195\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 2\"],\n    \"funder\": [\"CTF\"],\n    \"description\": \"Processed genomic data (bam files) from jumping library sequencing that facilitates detection of chromosomal abnormalities such as pathogenic breakpoints in NF2 tumor models.\",\n    \"measurementTechnique\": [\"jumping library\"],\n    \"species\": [\"Homo sapiens\", \"Mus musculus\"],\n    \"manifestation\": [\"Meningioma\", \"Schwannoma\"],\n    \"individualCount\": 11,\n    \"specimenCount\": 12,\n    \"contributor\": [\"Synodos NF2 Consortium\"]\n  },\n  {\n    \"title\": \"2017 Release - Proteomics_Kinome\",\n    \"creator\": [\"Abhishek Pratap\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"kinomics\", \"proteomics\", \"MIB/MS\", \"NF2\", \"drug treatment\"],\n    \"dataType\": [\"kinomics\"],\n    \"studyId\": \"syn2343195\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 2\"],\n    \"funder\": [\"CTF\"],\n    \"description\": \"Processed kinomics data from MIB/MS (Multiplexed Inhibitor Bead/Mass Spectrometry) analysis of NF2 tumor models after treatment with various small molecule inhibitors.\",\n    \"measurementTechnique\": [\"MIB/MS\"],\n    \"species\": [\"Homo sapiens\", \"Mus musculus\"],\n    \"manifestation\": [\"Schwannoma\", \"Meningioma\"],\n    \"individualCount\": 11,\n    \"specimenCount\": 9,\n    \"contributor\": [\"Synodos NF2 Consortium\"]\n  },\n  {\n    \"title\": \"2019 Release - Animal Studies\",\n    \"creator\": [\"Robert Allaway\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"in vivo\", \"bioluminescence\", \"mouse model\", \"meningioma\", \"tumor volume\"],\n    \"dataType\": [\"Volume\"],\n    \"studyId\": \"syn2343195\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 2\"],\n    \"funder\": [\"CTF\"],\n    \"description\": \"In vivo bioluminescence data from NF2-related meningioma mouse models treated with various small molecule inhibitors.\",\n    \"measurementTechnique\": [\"in vivo bioluminescence\"],\n    \"species\": [\"Mus musculus\", \"Homo sapiens\"],\n    \"manifestation\": [\"Meningioma\"],\n    \"specimenCount\": 2,\n    \"contributor\": [\"Synodos NF2 Consortium\"]\n  },\n  {\n    \"title\": \"2019 Release - High-Throughput Drug Screens\",\n    \"creator\": [\"Robert Allaway\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"drug screen\", \"cell viability\", \"MIPE library\", \"dose response\", \"combination therapy\"],\n    \"dataType\": [\"drugScreen\"],\n    \"studyId\": \"syn2343195\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 2\"],\n    \"funder\": [\"CTF\"],\n    \"description\": \"Cell viability data from high-throughput drug screens testing a panel of 1912 drugs and drug-like molecules in multiple NF2 cell line models of meningioma and schwannoma.\",\n    \"measurementTechnique\": [\"cell viability assay\"],\n    \"species\": [\"Homo sapiens\", \"Mus musculus\"],\n    \"manifestation\": [\"Schwannoma\", \"Meningioma\"],\n    \"individualCount\": 7,\n    \"specimenCount\": 15,\n    \"contributor\": [\"Synodos NF2 Consortium\"]\n  },\n  {\n    \"title\": \"2019 Release - Proteomics_Kinome\",\n    \"creator\": [\"Robert Allaway\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"kinomics\", \"proteomics\", \"MIB/MS\", \"ELISA\", \"NF2\", \"drug treatment\"],\n    \"dataType\": [\"kinomics\", \"immunoassay\"],\n    \"studyId\": \"syn2343195\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 2\"],\n    \"funder\": [\"CTF\"],\n    \"description\": \"Proteomics and kinomics data from MIB/MS and sandwich ELISA assays of NF2 tumor models treated with various single agent and combination drug therapies.\",\n    \"measurementTechnique\": [\"MIB/MS\", \"sandwich ELISA\"],\n    \"species\": [\"Homo sapiens\", \"Mus musculus\"],\n    \"manifestation\": [\"Meningioma\", \"Schwannoma\"],\n    \"individualCount\": 3,\n    \"specimenCount\": 2,\n    \"contributor\": [\"Synodos NF2 Consortium\"]\n  },\n  {\n    \"title\": \"2019 Release - RNASeq\",\n    \"creator\": [\"Serkan Erdin\", \"Robert Allaway\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"RNA-seq\", \"gene expression\", \"transcriptomics\", \"NF2\", \"drug treatment\"],\n    \"dataType\": [\"geneExpression\"],\n    \"studyId\": \"syn2343195\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 2\"],\n    \"funder\": [\"CTF\"],\n    \"description\": \"Raw and processed RNA sequencing data from NF2 tumor models of meningioma and schwannoma treated with various small molecule inhibitors.\",\n    \"measurementTechnique\": [\"RNA-seq\"],\n    \"species\": [\"Homo sapiens\", \"Mus musculus\"],\n    \"manifestation\": [\"Meningioma\", \"Schwannoma\"],\n    \"individualCount\": 8,\n    \"specimenCount\": 109,\n    \"contributor\": [\"Synodos NF2 Consortium\"]\n  },\n  {\n    \"title\": \"2021 - Raw Blot Images\",\n    \"creator\": [\"Abbi Smith\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"raw images\", \"blots\", \"NF2\", \"original data\"],\n    \"dataType\": [\"image\"],\n    \"studyId\": \"syn2343195\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 2\"],\n    \"funder\": [\"CTF\"],\n    \"description\": \"Original unedited blot images from experiments in the Synodos NF2 project.\",\n    \"contributor\": [\"Synodos NF2 Consortium\"]\n  },\n  {\n    \"title\": \"Gene Expression Quantification from RNA-seq\",\n    \"creator\": [\"Robert Allaway\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"RNA-seq\", \"gene expression\", \"quantification\", \"schwannoma\", \"transcript abundance\"],\n    \"dataType\": [\"geneExpression\"],\n    \"studyId\": \"syn2343195\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 2\"],\n    \"funder\": [\"CTF\"],\n    \"description\": \"Gene expression quantification data from RNA-seq experiments on human NF2-related schwannoma samples.\",\n    \"measurementTechnique\": [\"RNA-seq\"],\n    \"species\": [\"Homo sapiens\"],\n    \"manifestation\": [\"Schwannoma\"],\n    \"individualCount\": 2,\n    \"contributor\": [\"Synodos NF2 Consortium\"]\n  },\n  {\n    \"title\": \"NF-OSI RNASeq Reprocessing\",\n    \"creator\": [\"Sara Gosline\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"RNA-seq\", \"gene expression\", \"transcript quantification\", \"meningioma\", \"reprocessed data\"],\n    \"dataType\": [\"geneExpression\"],\n    \"studyId\": \"syn2343195\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 2\"],\n    \"funder\": [\"CTF\"],\n    \"description\": \"Reprocessed RNA-seq data from NF2-related meningioma samples, quantified using modern bioinformatics workflows.\",\n    \"measurementTechnique\": [\"RNA-seq\"],\n    \"species\": [\"Homo sapiens\"],\n    \"manifestation\": [\"Meningioma\"],\n    \"individualCount\": 75,\n    \"specimenCount\": 84,\n    \"contributor\": [\"Synodos NF2 Consortium\"],\n    \"series\": \"NF-OSI Processed Data\"\n  },\n  {\n    \"title\": \"Synodos NF2 Drug Screen - 2017 Release\",\n    \"creator\": [\"Abhishek Pratap\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"drug screen\", \"dose response\", \"compound testing\", \"NF2\", \"cell viability\"],\n    \"dataType\": [\"drugScreen\"],\n    \"studyId\": \"syn2343195\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 2\"],\n    \"funder\": [\"CTF\"],\n    \"description\": \"Raw and processed data from drug screening experiments on NF2 tumor models from the 2017 data release.\",\n    \"manifestation\": [\"Schwannoma\", \"Meningioma\"],\n    \"contributor\": [\"Synodos NF2 Consortium\"]\n  },\n  {\n    \"title\": \"Synodos NF2 Processed RNA-seq - 2017 Release\",\n    \"creator\": [\"Robert Allaway\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"RNA-seq\", \"gene expression\", \"differential expression\", \"NF2\", \"processed data\"],\n    \"dataType\": [\"geneExpression\"],\n    \"studyId\": \"syn2343195\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 2\"],\n    \"funder\": [\"CTF\"],\n    \"description\": \"Processed RNA-seq data including raw counts and differential expression analysis from NF2 tumor models from the 2017 data release.\",\n    \"measurementTechnique\": [\"RNA-seq\"],\n    \"manifestation\": [\"Schwannoma\", \"Meningioma\"],\n    \"contributor\": [\"Synodos NF2 Consortium\"]\n  },\n  {\n    \"title\": \"Synodos NF2 RNA-seq Raw Data - 2017 Release\",\n    \"creator\": [\"Steven Angus\", \"Robert Allaway\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"RNA-seq\", \"raw data\", \"fastq\", \"NF2\", \"transcriptomics\"],\n    \"dataType\": [\"geneExpression\"],\n    \"studyId\": \"syn2343195\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 2\"],\n    \"funder\": [\"CTF\"],\n    \"description\": \"Raw RNA-seq data (fastq files) from NF2 tumor models of meningioma and schwannoma from the 2017 data release.\",\n    \"measurementTechnique\": [\"RNA-seq\"],\n    \"species\": [\"Homo sapiens\", \"Mus musculus\"],\n    \"manifestation\": [\"Schwannoma\", \"Meningioma\"],\n    \"individualCount\": 47,\n    \"specimenCount\": 205,\n    \"contributor\": [\"Synodos NF2 Consortium\"]\n  }\n]\n```"}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":8720,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":3054}}}}
{"custom_id":"syn11374349","result":{"type":"succeeded","message":{"id":"msg_01BhQjKeTUYcuZQjBSJwHXK6","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"I'll create high-quality dataset metadata for these tables according to the JSON schema. Let me analyze the information provided and generate the appropriate metadata entries.\n\n```json\n[\n  {\n    \"title\": \"12 month deliverables\",\n    \"creator\": [\"Gabsang Lee\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"Schwann cells\", \"NF1\", \"immunohistochemistry\", \"flow cytometry\", \"qPCR\"],\n    \"dataType\": [\"image\", \"geneExpression\"],\n    \"studyId\": \"syn11374349\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"Cell cycle, qRT-PCR, karyotyping, and staining data from the NF1-/SMASh hESC model at the 12-month timepoint. Data includes microscopy images and gene expression analysis.\",\n    \"measurementTechnique\": [\"immunohistochemistry\", \"quantitative PCR\", \"flow cytometry\"],\n    \"species\": [\"Homo sapiens\"],\n    \"individualCount\": 1,\n    \"contributor\": [\"Johns Hopkins University\"]\n  },\n  {\n    \"title\": \"18 month deliverables\",\n    \"creator\": [\"Gabsang Lee\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"Schwann cells\", \"NF1\", \"western blot\", \"flow cytometry\", \"Annexin V-PI staining\", \"immunofluorescence\"],\n    \"dataType\": [\"image\"],\n    \"studyId\": \"syn11374349\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"Western blot, flow cytometry, qRT-PCR, and immunostaining data from the NF1-/SMASh hESC model at the 18-month timepoint. Data includes apoptosis assessment using Annexin V-PI staining.\",\n    \"measurementTechnique\": [\"western blot\", \"flow cytometry\", \"quantitative PCR\", \"immunohistochemistry\", \"immunofluorescence\"],\n    \"species\": [\"Homo sapiens\"],\n    \"contributor\": [\"Johns Hopkins University\"]\n  },\n  {\n    \"title\": \"24 month deliverables\",\n    \"creator\": [\"Gabsang Lee\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"Schwann cells\", \"NF1\", \"western blot\", \"qRT-PCR\", \"FACS\", \"immunostaining\"],\n    \"dataType\": [\"geneExpression\", \"immunoassay\"],\n    \"studyId\": \"syn11374349\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"Western blot, qRT-PCR, FACS analysis, and immunostaining data from the NF1-/SMASh hESC model at the 24-month timepoint. Data includes protein expression, gene expression, and cell characterization.\",\n    \"measurementTechnique\": [\"western blot\", \"quantitative PCR\", \"immunofluorescence\", \"immunocytochemistry\"],\n    \"specimenCount\": 1,\n    \"contributor\": [\"Johns Hopkins University\"]\n  },\n  {\n    \"title\": \"30 month deliverables\",\n    \"creator\": [\"Gabsang Lee\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"Schwann cells\", \"NF1\", \"MBP staining\", \"TEM\", \"FACS sorting\", \"RNA-seq\", \"CD49+ SCP cells\"],\n    \"dataType\": [\"immunoassay\", \"image\", \"geneExpression\"],\n    \"studyId\": \"syn11374349\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"MBP staining, TEM imaging, FACS sorting, and RNA-seq data from the NF1-/SMASh hESC model at the 30-month timepoint. Data includes sorting of CD49+ Schwann cell precursors and transcriptomic analysis.\",\n    \"measurementTechnique\": [\"immunocytochemistry\", \"atomic force microscopy\", \"immunofluorescence\", \"RNA-seq\", \"quantitative PCR\"],\n    \"specimenCount\": 1,\n    \"contributor\": [\"Johns Hopkins University\"]\n  },\n  {\n    \"title\": \"36 month deliverables\",\n    \"creator\": [\"Gabsang Lee\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"Schwann cells\", \"NF1\", \"cell proliferation\", \"cell cycle\", \"TEM\", \"RNA-seq\"],\n    \"dataType\": [\"cellularPhysiology\", \"geneExpression\", \"image\", \"immunoassay\"],\n    \"studyId\": \"syn11374349\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"Cell proliferation assay, qRT-PCR, TEM imaging, RNA-seq, and cell cycle analysis data from the NF1-/SMASh hESC model at the 36-month timepoint. Final deliverable data for the complete human Schwann cell model.\",\n    \"measurementTechnique\": [\"cell viability assay\", \"quantitative PCR\", \"atomic force microscopy\", \"RNA-seq\", \"immunofluorescence\"],\n    \"species\": [\"Homo sapiens\"],\n    \"specimenCount\": 16,\n    \"contributor\": [\"Johns Hopkins University\", \"NF Service\"]\n  },\n  {\n    \"title\": \"6 month deliverables\",\n    \"creator\": [\"Gabsang Lee\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"Schwann cells\", \"NF1\", \"donor vector\", \"transfection\", \"sequencing\", \"expansion\"],\n    \"dataType\": [\"genomicVariants\"],\n    \"studyId\": \"syn11374349\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"Construction of donor vector, transfection, sequencing, and expansion data from the initial development of the NF1-/SMASh hESC model at the 6-month timepoint.\",\n    \"measurementTechnique\": [\"Sanger sequencing\"],\n    \"species\": [\"Homo sapiens\"],\n    \"contributor\": [\"Johns Hopkins University\"]\n  },\n  {\n    \"title\": \"Gene Expression Quantification from RNA-seq\",\n    \"creator\": [\"Gabsang Lee\", \"NF Service\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"Schwann cells\", \"NF1\", \"RNA-seq\", \"gene expression\", \"transcript quantification\"],\n    \"dataType\": [\"geneExpression\"],\n    \"studyId\": \"syn11374349\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"Gene and transcript expression quantification data generated from RNA-seq of the NF1-/SMASh hESC model. Contains quantification files (.sf) for gene and transcript expression levels.\",\n    \"measurementTechnique\": [\"RNA-seq\"],\n    \"species\": [\"Homo sapiens\"],\n    \"specimenCount\": 16\n  },\n  {\n    \"title\": \"NFOSI-RNASeq-To-Process-2023-14-03\",\n    \"creator\": [\"Gabsang Lee\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"Schwann cells\", \"NF1\", \"RNA-seq\", \"FASTQ\", \"ES-SSEA4\"],\n    \"dataType\": [\"geneExpression\"],\n    \"studyId\": \"syn11374349\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"Raw RNA-seq data (FASTQ files) from the NF1-/SMASh hESC model, including ES-SSEA4 samples. Files include paired-end reads (R1 and R2) for multiple samples.\",\n    \"measurementTechnique\": [\"RNA-seq\"],\n    \"species\": [\"Homo sapiens\"],\n    \"contributor\": [\"Johns Hopkins University\"]\n  }\n]\n```"}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":7292,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":2136}}}}
{"custom_id":"syn5698493","result":{"type":"succeeded","message":{"id":"msg_01EREVHbXRxnvGuUQo87rmr1","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"I'll create high-quality dataset metadata for these three tables from the Synodos for NF1 - Low Grade Glioma project. Each dataset will conform to the specified JSON schema.\n\n```json\n[\n  {\n    \"title\": \"Synodos LGG Methylation Arrays\",\n    \"creator\": [\"Synodos NF1 LGG Consortium\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"NF1\", \"Low-Grade Glioma\", \"Methylation\", \"Epigenetics\", \"Methylation Array\"],\n    \"dataType\": [\"chromatinActivity\"],\n    \"studyId\": \"syn5698493\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"CTF\"],\n    \"description\": \"Methylation array data from tumor samples of patients with NF1-associated low-grade gliomas. Includes various tumor types such as Pilocytic Astrocytoma, Low-Grade Glioma NOS, and others.\",\n    \"measurementTechnique\": [\"methylation array\"],\n    \"species\": [\"Homo sapiens\"],\n    \"individualCount\": 43,\n    \"specimenCount\": 43,\n    \"manifestation\": [\"Low-Grade Glioma\"],\n    \"contributor\": [\"Synodos NF1 LGG Consortium\"],\n    \"dataUseModifiers\": [\"Health or Medical or Biomedical Research\"]\n  },\n  {\n    \"title\": \"Synodos LGG RNAseq\",\n    \"creator\": [\"Synodos NF1 LGG Consortium\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"NF1\", \"Low-Grade Glioma\", \"RNA-seq\", \"Transcriptomics\", \"Gene Expression\"],\n    \"dataType\": [\"geneExpression\"],\n    \"studyId\": \"syn5698493\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"CTF\"],\n    \"description\": \"RNA sequencing data from tumor samples of patients with NF1-associated low-grade gliomas. Includes various tumor types such as Pilocytic Astrocytoma, Low-Grade Glioma NOS, and others.\",\n    \"measurementTechnique\": [\"RNA-seq\", \"3D microtissue viability\"],\n    \"species\": [\"Homo sapiens\"],\n    \"individualCount\": 23,\n    \"specimenCount\": 23,\n    \"manifestation\": [\"Low-Grade Glioma\"],\n    \"contributor\": [\"Synodos NF1 LGG Consortium\"],\n    \"dataUseModifiers\": [\"Health or Medical or Biomedical Research\"]\n  },\n  {\n    \"title\": \"Synodos LGG Whole Genome Sequencing (bam)\",\n    \"creator\": [\"Synodos NF1 LGG Consortium\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"NF1\", \"Low-Grade Glioma\", \"WGS\", \"Genomics\", \"Whole Genome Sequencing\"],\n    \"dataType\": [\"genomicVariants\"],\n    \"studyId\": \"syn5698493\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"CTF\"],\n    \"description\": \"Whole genome sequencing data (BAM files) from paired tumor and normal samples of patients with NF1-associated low-grade gliomas. Includes various tumor types such as Pilocytic Astrocytoma, Low-Grade Glioma NOS, and others.\",\n    \"measurementTechnique\": [\"whole genome sequencing\"],\n    \"species\": [\"Homo sapiens\"],\n    \"individualCount\": 22,\n    \"specimenCount\": 44,\n    \"manifestation\": [\"Low-Grade Glioma\"],\n    \"contributor\": [\"Synodos NF1 LGG Consortium\"],\n    \"dataUseModifiers\": [\"Health or Medical or Biomedical Research\"]\n  }\n]\n```"}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":6357,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":1013}}}}
{"custom_id":"syn21984813","result":{"type":"succeeded","message":{"id":"msg_01U1BEb4qNaCNrgjkRAEcspb","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"I'll create high-quality metadata for each of the tables in this project. Based on the provided information, I'll generate JSON objects that conform to the schema requirements.\n\n```json\n[\n  {\n    \"title\": \"Animal Tumor Growth Studies\",\n    \"creator\": [\"Angela Hirbe\", \"David Largaespada\"],\n    \"contributor\": [\"Ana Calizo\", \"Himanshi Bhatia\", \"Daniel Schefer\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"tumor growth\", \"PDX\", \"drug screen\", \"MPNST\", \"in vivo\"],\n    \"dataType\": [\"drugScreen\"],\n    \"studyId\": \"syn21984813\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NIH-NCI\", \"NTAP\"],\n    \"manifestation\": [\"Malignant Peripheral Nerve Sheath Tumor (MPNST)\"],\n    \"measurementTechnique\": [\"in vivo tumor growth\"],\n    \"species\": [\"Homo sapiens\"],\n    \"individualCount\": 9,\n    \"description\": \"Data from in vivo tumor growth studies using PDX models to evaluate drug response in NF1-MPNST. Contains measurements of tumor growth under various treatment conditions.\"\n  },\n  {\n    \"title\": \"Batch 1 RNA-seq (Drug Treated Cell Lines)\",\n    \"creator\": [\"Angela Hirbe\", \"David Largaespada\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"RNA-seq\", \"drug treatment\", \"MPNST\", \"gene expression\"],\n    \"dataType\": [\"geneExpression\"],\n    \"studyId\": \"syn21984813\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\", \"NIH-NCI\"],\n    \"manifestation\": [\"Malignant Peripheral Nerve Sheath Tumor (MPNST)\"],\n    \"measurementTechnique\": [\"RNA-seq\"],\n    \"species\": [\"Homo sapiens\"]\n  },\n  {\n    \"title\": \"Cell Growth Data Annotation Files\",\n    \"creator\": [\"Angela Hirbe\", \"David Largaespada\"],\n    \"contributor\": [\"Yang Lyu\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"annotation\", \"cell growth\", \"MPNST\", \"metadata\"],\n    \"dataType\": [\"drugScreen\"],\n    \"studyId\": \"syn21984813\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\", \"NIH-NCI\"],\n    \"manifestation\": [\"Malignant Peripheral Nerve Sheath Tumor (MPNST)\"],\n    \"description\": \"Annotation files for cell growth data experiments, providing metadata for drug screening studies.\"\n  },\n  {\n    \"title\": \"Drug Combo Incucyte\",\n    \"creator\": [\"Angela Hirbe\", \"David Largaespada\"],\n    \"contributor\": [\"Sara Gosline\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"drug combination\", \"incucyte\", \"cell viability\", \"MPNST\"],\n    \"dataType\": [\"drugScreen\"],\n    \"studyId\": \"syn21984813\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\", \"NIH-NCI\"],\n    \"manifestation\": [\"Malignant Peripheral Nerve Sheath Tumor (MPNST)\"],\n    \"measurementTechnique\": [\"cell viability assay\"],\n    \"species\": [\"Homo sapiens\"],\n    \"description\": \"Data from Incucyte studies testing drug combination effects on MPNST cell lines.\"\n  },\n  {\n    \"title\": \"Hirbe_s5180_MGI0731_Batch2_RNAseq\",\n    \"creator\": [\"Angela Hirbe\", \"David Largaespada\"],\n    \"contributor\": [\"Kuangying Yang\", \"Yang Lyu\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"RNA-seq\", \"gene expression\", \"MPNST\", \"PDX\", \"transcriptomics\"],\n    \"dataType\": [\"geneExpression\"],\n    \"studyId\": \"syn21984813\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\", \"NIH-NCI\"],\n    \"manifestation\": [\"Malignant Peripheral Nerve Sheath Tumor (MPNST)\"],\n    \"measurementTechnique\": [\"RNA-seq\"],\n    \"species\": [\"Homo sapiens\"],\n    \"individualCount\": 8,\n    \"specimenCount\": 16,\n    \"description\": \"RNA sequencing data from MPNST patient derived xenografts and primary tumor samples.\"\n  },\n  {\n    \"title\": \"Incucyte Drug Response Data\",\n    \"creator\": [\"Angela Hirbe\", \"David Largaespada\"],\n    \"contributor\": [\"Ana Calizo\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"incucyte\", \"drug response\", \"MPNST\", \"cell viability\", \"drug screening\"],\n    \"dataType\": [\"drugScreen\"],\n    \"studyId\": \"syn21984813\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\", \"NIH-NCI\"],\n    \"manifestation\": [\"Malignant Peripheral Nerve Sheath Tumor (MPNST)\"],\n    \"measurementTechnique\": [\"cell viability assay\"],\n    \"species\": [\"Homo sapiens\"],\n    \"individualCount\": 4,\n    \"description\": \"Cell viability measurements using Incucyte to evaluate drug response in MPNST cell lines, including various MEK inhibitors and trabectedin combinations.\"\n  },\n  {\n    \"title\": \"JH_Samples_WEX_MAF\",\n    \"creator\": [\"Angela Hirbe\", \"David Largaespada\"],\n    \"contributor\": [\"Yang Lyu\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"whole exome sequencing\", \"MAF\", \"somatic variants\", \"MPNST\", \"genomics\"],\n    \"dataType\": [\"genomicVariants\"],\n    \"studyId\": \"syn21984813\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\", \"NIH-NCI\"],\n    \"manifestation\": [\"Malignant Peripheral Nerve Sheath Tumor (MPNST)\"],\n    \"measurementTechnique\": [\"whole exome sequencing\"],\n    \"species\": [\"Homo sapiens\"],\n    \"individualCount\": 6,\n    \"specimenCount\": 6,\n    \"description\": \"Somatic variant data in MAF format from whole exome sequencing of Johns Hopkins MPNST samples.\"\n  },\n  {\n    \"title\": \"MGI_DT-2862929_Batch2_WEX\",\n    \"creator\": [\"Angela Hirbe\", \"David Largaespada\"],\n    \"contributor\": [\"Yang Lyu\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"whole exome sequencing\", \"MPNST\", \"atypical neurofibroma\", \"genomics\", \"fastq\"],\n    \"dataType\": [\"genomicVariants\"],\n    \"studyId\": \"syn21984813\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\", \"NIH-NCI\"],\n    \"manifestation\": [\"Malignant Peripheral Nerve Sheath Tumor (MPNST)\", \"Atypical Neurofibroma\"],\n    \"measurementTechnique\": [\"whole exome sequencing\"],\n    \"species\": [\"Homo sapiens\"],\n    \"individualCount\": 8,\n    \"specimenCount\": 21,\n    \"description\": \"Raw whole exome sequencing FASTQ files from MPNST and atypical neurofibroma samples, including primary tumors and PDX models.\"\n  },\n  {\n    \"title\": \"MGI_DT-2862929_Batch2_WEX_BAM\",\n    \"creator\": [\"Angela Hirbe\", \"David Largaespada\"],\n    \"contributor\": [\"Yang Lyu\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"whole exome sequencing\", \"BAM files\", \"MPNST\", \"atypical neurofibroma\", \"genomics\"],\n    \"dataType\": [\"genomicVariants\"],\n    \"studyId\": \"syn21984813\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\", \"NIH-NCI\"],\n    \"manifestation\": [\"Malignant Peripheral Nerve Sheath Tumor (MPNST)\", \"Atypical Neurofibroma\"],\n    \"measurementTechnique\": [\"whole exome sequencing\"],\n    \"species\": [\"Homo sapiens\"],\n    \"individualCount\": 8,\n    \"specimenCount\": 14,\n    \"description\": \"Processed BAM files from whole exome sequencing of MPNST and atypical neurofibroma samples. Files have undergone trimming, marking duplicates, and base quality score recalibration.\"\n  },\n  {\n    \"title\": \"MGI_DT-2862930_Batch2_WGS\",\n    \"creator\": [\"Angela Hirbe\", \"David Largaespada\"],\n    \"contributor\": [\"Yang Lyu\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"whole genome sequencing\", \"MPNST\", \"atypical neurofibroma\", \"genomics\", \"fastq\"],\n    \"dataType\": [\"genomicVariants\"],\n    \"studyId\": \"syn21984813\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\", \"NIH-NCI\"],\n    \"manifestation\": [\"Malignant Peripheral Nerve Sheath Tumor (MPNST)\", \"Atypical Neurofibroma\"],\n    \"measurementTechnique\": [\"whole genome sequencing\"],\n    \"species\": [\"Homo sapiens\"],\n    \"individualCount\": 8,\n    \"specimenCount\": 22,\n    \"description\": \"Raw whole genome sequencing FASTQ files from MPNST and atypical neurofibroma samples, including primary tumors, recurrent tumors, and PDX models.\"\n  },\n  {\n    \"title\": \"MGI_DT_2862930_Batch2_WGS_BAM\",\n    \"creator\": [\"Angela Hirbe\", \"David Largaespada\"],\n    \"contributor\": [\"Yang Lyu\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"whole genome sequencing\", \"BAM files\", \"MPNST\", \"genomics\"],\n    \"dataType\": [\"genomicVariants\"],\n    \"studyId\": \"syn21984813\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\", \"NIH-NCI\"],\n    \"manifestation\": [\"Malignant Peripheral Nerve Sheath Tumor (MPNST)\"],\n    \"measurementTechnique\": [\"whole genome sequencing\"],\n    \"species\": [\"Homo sapiens\"],\n    \"individualCount\": 8,\n    \"description\": \"Processed BAM files from whole genome sequencing of MPNST samples. Files have undergone trimming, marking duplicates, and base quality score recalibration.\"\n  },\n  {\n    \"title\": \"MGI_WEX_2020_Batch1_BAM\",\n    \"creator\": [\"Angela Hirbe\", \"David Largaespada\"],\n    \"contributor\": [\"Yang Lyu\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"whole exome sequencing\", \"BAM files\", \"MPNST\", \"genomics\"],\n    \"dataType\": [\"genomicVariants\"],\n    \"studyId\": \"syn21984813\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\", \"NIH-NCI\"],\n    \"manifestation\": [\"Malignant Peripheral Nerve Sheath Tumor (MPNST)\"],\n    \"measurementTechnique\": [\"whole exome sequencing\"],\n    \"species\": [\"Homo sapiens\"],\n    \"individualCount\": 8,\n    \"specimenCount\": 27,\n    \"description\": \"Processed BAM files from whole exome sequencing of MPNST samples from batch 1. Files have undergone trimming, marking duplicates, and base quality score recalibration.\"\n  },\n  {\n    \"title\": \"NF-OSI_processing_01242023\",\n    \"creator\": [\"Angela Hirbe\", \"David Largaespada\"],\n    \"contributor\": [\"Yang Lyu\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"processed data\", \"genomics\", \"MPNST\", \"BAM files\"],\n    \"dataType\": [\"genomicVariants\"],\n    \"studyId\": \"syn21984813\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\", \"NIH-NCI\"],\n    \"manifestation\": [\"Malignant Peripheral Nerve Sheath Tumor (MPNST)\"],\n    \"series\": \"NF-OSI Processed Data\",\n    \"yearProcessed\": 2023\n  },\n  {\n    \"title\": \"NFOSI-processing_12192022\",\n    \"creator\": [\"Angela Hirbe\", \"David Largaespada\"],\n    \"contributor\": [\"Yang Lyu\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"processed data\", \"genomics\", \"MPNST\", \"BAM files\"],\n    \"dataType\": [\"genomicVariants\"],\n    \"studyId\": \"syn21984813\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\", \"NIH-NCI\"],\n    \"manifestation\": [\"Malignant Peripheral Nerve Sheath Tumor (MPNST)\"],\n    \"series\": \"NF-OSI Processed Data\",\n    \"yearProcessed\": 2022\n  },\n  {\n    \"title\": \"Proteomics\",\n    \"creator\": [\"Angela Hirbe\", \"David Largaespada\"],\n    \"contributor\": [\"Sara Gosline\", \"Camilo Posso\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"proteomics\", \"phosphoproteomics\", \"MPNST\", \"global proteome\", \"phosphorylation\"],\n    \"dataType\": [\"proteomics\"],\n    \"studyId\": \"syn21984813\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\", \"NIH-NCI\"],\n    \"manifestation\": [\"Malignant Peripheral Nerve Sheath Tumor (MPNST)\"],\n    \"measurementTechnique\": [\"mass spectrometry\"],\n    \"species\": [\"Homo sapiens\"],\n    \"description\": \"Proteomics data from MPNST samples, including global protein expression and phosphoprotein measurements.\"\n  },\n  {\n    \"title\": \"Sample_annotation\",\n    \"creator\": [\"Angela Hirbe\", \"David Largaespada\"],\n    \"contributor\": [\"Yang Lyu\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"annotation\", \"sample metadata\", \"MPNST\", \"PDX\"],\n    \"dataType\": [\"dataIndex\"],\n    \"studyId\": \"syn21984813\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\", \"NIH-NCI\"],\n    \"description\": \"Sample annotation files providing metadata for Washington University PDX samples used in the project.\"\n  },\n  {\n    \"title\": \"Somatic_Varaint_Calls_WEX_2020\",\n    \"creator\": [\"Angela Hirbe\", \"David Largaespada\"],\n    \"contributor\": [\"Yang Lyu\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"somatic variants\", \"whole exome sequencing\", \"MPNST\", \"genomics\", \"PDX\"],\n    \"dataType\": [\"genomicVariants\"],\n    \"studyId\": \"syn21984813\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\", \"NIH-NCI\"],\n    \"manifestation\": [\"Malignant Peripheral Nerve Sheath Tumor (MPNST)\"],\n    \"measurementTechnique\": [\"whole exome sequencing\"],\n    \"species\": [\"Homo sapiens\"],\n    \"individualCount\": 8,\n    \"description\": \"Somatic variant calls in MAF format from whole exome sequencing of MPNST PDX samples from the 2020 batch.\"\n  },\n  {\n    \"title\": \"Updated Somatic Variant Calls\",\n    \"creator\": [\"Angela Hirbe\", \"David Largaespada\"],\n    \"contributor\": [\"Yang Lyu\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"somatic variants\", \"whole exome sequencing\", \"MPNST\", \"genomics\", \"atypical neurofibroma\"],\n    \"dataType\": [\"genomicVariants\"],\n    \"studyId\": \"syn21984813\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\", \"NIH-NCI\"],\n    \"manifestation\": [\"Malignant Peripheral Nerve Sheath Tumor (MPNST)\", \"Atypical Neurofibroma\"],\n    \"measurementTechnique\": [\"whole exome sequencing\"],\n    \"species\": [\"Homo sapiens\"],\n    \"individualCount\": 7,\n    \"specimenCount\": 14,\n    \"description\": \"Updated somatic variant calls in MAF format from whole exome sequencing of MPNST and atypical neurofibroma samples, including primary tumors and PDX models.\"\n  },\n  {\n    \"title\": \"WGS_CNVKIT_MGI2020_2862930\",\n    \"creator\": [\"Angela Hirbe\", \"David Largaespada\"],\n    \"contributor\": [\"Yang Lyu\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"copy number variation\", \"CNV\", \"whole genome sequencing\", \"MPNST\", \"genomics\"],\n    \"dataType\": [\"CopyNumberVariants\"],\n    \"studyId\": \"syn21984813\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\", \"NIH-NCI\"],\n    \"manifestation\": [\"Malignant Peripheral Nerve Sheath Tumor (MPNST)\"],\n    \"measurementTechnique\": [\"whole genome sequencing\"],\n    \"species\": [\"Homo sapiens\"],\n    \"description\": \"Copy number variation data generated using CNVkit from whole genome sequencing of MPNST PDX samples.\"\n  }\n]\n```"}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":11046,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":4952}}}}
{"custom_id":"syn5562324","result":{"type":"succeeded","message":{"id":"msg_017gCcn3A8dFMEH3L6ZMr5xs","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"I'll create high-quality dataset metadata based on the project information provided. Let me analyze the content carefully to ensure accuracy.\n\n```json\n[\n  {\n    \"title\": \"CTF-UCF-Cenix Complete Compound Drug Screen\",\n    \"creator\": [\"Cristina Fernandez-Valle\", \"Cenix Bioscience\"],\n    \"accessType\": \"Open Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"drug screening\", \"compound screening\", \"mouse Schwann cells\", \"NF2\", \"merlin-deficient\", \"high content assay\", \"phenotypic screening\", \"EdU\"],\n    \"dataType\": [\"image\", \"cellularPhysiology\", \"drugScreen\"],\n    \"studyId\": \"syn5562324\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"CTF\"],\n    \"description\": \"Data from phenotypic screening of 95 drug candidates on merlin-deficient and normal mouse Schwann cells. Cells were screened for 48 hours in 8-point dose response format, including EdU incubation to assess DNA replication. Multiple nuclear phenotypes were measured using automated microscopy and image analysis.\",\n    \"contributor\": [\"Children's Tumor Foundation\", \"Cristina Fernandez-Valle\", \"Cenix Bioscience\", \"Abhishek Pratap\"],\n    \"measurementTechnique\": [\"high content screen\", \"cell proliferation\", \"EdU proliferation assay\"],\n    \"species\": [\"Mus musculus\"],\n    \"subject\": [\"Schwann cells\", \"Neurofibromatosis\", \"Drug screening\", \"Phenotypic screening\"]\n  }\n]\n```"}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":5629,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":405}}}}
{"custom_id":"syn22392179","result":{"type":"succeeded","message":{"id":"msg_01Fh7Xk3KFtqaS3QLUmUudpo","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"I'll create high-quality metadata for these tables based on the information provided and conforming to the JSON schema. Here's the result:\n\n```json\n[\n  {\n    \"title\": \"MPNST Cell Line Methylation Arrays\",\n    \"creator\": [\"Bernat Gel Moreno\"],\n    \"accessType\": \"Public Access\",\n    \"license\": \"CC-BY\",\n    \"keywords\": [\"MPNST\", \"Methylation\", \"Cell Line\", \"Epigenomics\"],\n    \"dataType\": [\"chromatinActivity\"],\n    \"studyId\": \"syn22392179\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"Other\"],\n    \"description\": \"Methylation array data from 8 MPNST cell lines used to provide genomic characterization and classification of widely used MPNST cell lines.\",\n    \"species\": [\"Homo sapiens\"],\n    \"measurementTechnique\": [\"methylation array\"],\n    \"individualCount\": 8,\n    \"specimenCount\": 8,\n    \"dataUseModifiers\": [\"General Research Use\"],\n    \"manifestation\": [\"Malignant Peripheral Nerve Sheath Tumor (MPNST)\"]\n  },\n  {\n    \"title\": \"MPNST Cell Line SNP Arrays\",\n    \"creator\": [\"Bernat Gel Moreno\"],\n    \"accessType\": \"Public Access\",\n    \"license\": \"CC-BY\",\n    \"keywords\": [\"MPNST\", \"SNP Array\", \"Cell Line\", \"Genomics\"],\n    \"dataType\": [\"genomicVariants\"],\n    \"studyId\": \"syn22392179\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"Other\"],\n    \"description\": \"SNP array data from 8 MPNST cell lines used to characterize genomic variations and provide insight into potential misdiagnosis of some commonly used MPNST cell lines.\",\n    \"species\": [\"Homo sapiens\"],\n    \"measurementTechnique\": [\"SNP array\"],\n    \"individualCount\": 8,\n    \"specimenCount\": 8,\n    \"dataUseModifiers\": [\"General Research Use\"],\n    \"manifestation\": [\"Malignant Peripheral Nerve Sheath Tumor (MPNST)\"]\n  },\n  {\n    \"title\": \"MPNST Cell Line Whole Exome Sequencing\",\n    \"creator\": [\"Bernat Gel Moreno\"],\n    \"accessType\": \"Public Access\",\n    \"license\": \"CC-BY\",\n    \"keywords\": [\"MPNST\", \"WES\", \"Cell Line\", \"Genomics\", \"Exome\"],\n    \"dataType\": [\"genomicVariants\"],\n    \"studyId\": \"syn22392179\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"Other\"],\n    \"description\": \"Whole exome sequencing data from 8 MPNST cell lines used to characterize genomic variations and analyze mutational status of MPNST-related genes.\",\n    \"species\": [\"Homo sapiens\"],\n    \"measurementTechnique\": [\"whole exome sequencing\"],\n    \"individualCount\": 8,\n    \"specimenCount\": 8,\n    \"dataUseModifiers\": [\"General Research Use\"],\n    \"manifestation\": [\"Malignant Peripheral Nerve Sheath Tumor (MPNST)\"]\n  },\n  {\n    \"title\": \"MPNST Cell Line Whole Genome Sequencing\",\n    \"creator\": [\"Bernat Gel Moreno\"],\n    \"accessType\": \"Public Access\",\n    \"license\": \"CC-BY\",\n    \"keywords\": [\"MPNST\", \"WGS\", \"Cell Line\", \"Genomics\"],\n    \"dataType\": [\"genomicVariants\"],\n    \"studyId\": \"syn22392179\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"Other\"],\n    \"description\": \"Whole genome sequencing data from 8 MPNST cell lines used to provide deep genomic characterization of widely used MPNST cell lines.\",\n    \"species\": [\"Homo sapiens\"],\n    \"measurementTechnique\": [\"whole genome sequencing\"],\n    \"individualCount\": 8,\n    \"specimenCount\": 8,\n    \"dataUseModifiers\": [\"General Research Use\"],\n    \"manifestation\": [\"Malignant Peripheral Nerve Sheath Tumor (MPNST)\"]\n  }\n]\n```"}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":8551,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":1118}}}}
{"custom_id":"syn11672851","result":{"type":"succeeded","message":{"id":"msg_01VWiBAcj4mWpix1KjnJM1Vb","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"I'll create high-quality dataset metadata for the Drug-Target Explorer table according to the JSON schema provided.\n\n```json\n[\n  {\n    \"title\": \"Drug-Target Explorer Database\",\n    \"creator\": [\"Robert Allaway\"],\n    \"accessType\": \"Public Access\",\n    \"license\": \"CC-0\",\n    \"keywords\": [\"drug-target\", \"compound-target interactions\", \"cheminformatics\", \"polypharmacology\", \"oncology\", \"drug discovery\"],\n    \"dataType\": [\"network\", \"dataIndex\"],\n    \"studyId\": \"syn11672851\",\n    \"diseaseFocus\": [\"Multiple\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"A comprehensive database of drug-target interactions compiled from ChEMBL, ChemicalProbes.org, DGIdb, DrugBank, and published literature. Contains over 280,000 molecules with their associated targets, including quantitative binding data when available. Used by the Drug Target Explorer application for exploring chemical-biological interaction space.\",\n    \"contributor\": [\"Sage Bionetworks\"],\n    \"dataUseModifiers\": [\"General Research Use\"],\n    \"datePublished\": 1638316800,\n    \"measurementTechnique\": [\"immunoassay\", \"reporter gene assay\", \"in silico synthesis\"],\n    \"subject\": [\"Drug discovery\", \"Chemical informatics\", \"Oncology\", \"Molecular targets\", \"Polypharmacology\"],\n    \"visualizeDataOn\": [\"https://shiny.synapse.org/users/rallaway/polypharmacology-db/\"],\n    \"yearProcessed\": 2021\n  }\n]\n```"}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":6658,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":389}}}}
{"custom_id":"syn37861830","result":{"type":"succeeded","message":{"id":"msg_01Goa7igDAaWGaDa8Y6Tdhns","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"I'll create high-quality dataset metadata for the table based on the information provided, following the schema requirements carefully.\n\n```json\n[\n  {\n    \"title\": \"IHC Quantification for MPNST Tumor Microenvironment\",\n    \"creator\": [\"Bandarigoda Nipunika Somatilaka\"],\n    \"contributor\": [\"Anh Nguyet Vu\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"MPNST\", \"tumor microenvironment\", \"immunohistochemistry\", \"immune infiltration\", \"NF1\", \"STING pathway\"],\n    \"dataType\": [\"raw counts\", \"image\"],\n    \"studyId\": \"syn37861830\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"CTF\"],\n    \"description\": \"This dataset contains immunohistochemistry (IHC) quantification results from MPNST tumor samples from mouse models, focusing on immune cell infiltration and tumor microenvironment characteristics. The data supports research into reprogramming the tumor microenvironment to target NF1 malignancies.\",\n    \"measurementTechnique\": [\"immunohistochemistry\"],\n    \"manifestation\": [\"Malignant Peripheral Nerve Sheath Tumor (MPNST)\"],\n    \"species\": [\"Mus musculus\"],\n    \"subject\": [\"Tumor microenvironment\", \"Immune infiltration\", \"STING pathway activation\", \"Cancer immunotherapy\"],\n    \"dataUseModifiers\": [\"General Research Use\"]\n  }\n]\n```"}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":6100,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":391}}}}
{"custom_id":"syn4939874","result":{"type":"succeeded","message":{"id":"msg_01GGtZbXtEdXbbX88WgNDeKK","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"Based on the provided information, I'll create dataset metadata for the three tables in this project.\n\n```json\n[\n  {\n    \"title\": \"NFOSI-WES-To-Process-2024-03\",\n    \"creator\": [\"Sara Gosline\", \"Xindi Guo\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"whole exome sequencing\", \"pNF\", \"cell lines\"],\n    \"dataType\": [\"genomicVariants\"],\n    \"studyId\": \"syn4939874\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"Whole exome sequencing data from plexiform neurofibroma cell lines for processing.\",\n    \"manifestation\": [\"Plexiform Neurofibroma\"],\n    \"measurementTechnique\": [\"whole exome sequencing\"],\n    \"species\": [\"Homo sapiens\"],\n    \"dataUseModifiers\": [\"General Research Use\"]\n  },\n  {\n    \"title\": \"Selected pNF cell line Kallisto output\",\n    \"creator\": [\"Sara Gosline\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"kallisto\", \"RNA-seq\", \"transcriptomics\", \"pNF\", \"cell lines\"],\n    \"dataType\": [\"geneExpression\"],\n    \"studyId\": \"syn4939874\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"Kallisto quantified gene expression data processed from RNA-seq of plexiform neurofibroma cell lines.\",\n    \"manifestation\": [\"Plexiform Neurofibroma\"],\n    \"measurementTechnique\": [\"RNA-seq\"],\n    \"species\": [\"Homo sapiens\"],\n    \"dataUseModifiers\": [\"General Research Use\"]\n  },\n  {\n    \"title\": \"pNF Cell Line RNA-seq (NFOSIprocessing-2022-04-18)\",\n    \"creator\": [\"Peggy Wallace\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"RNA-seq\", \"transcriptomics\", \"pNF\", \"cell lines\", \"plexiform neurofibroma\"],\n    \"dataType\": [\"geneExpression\"],\n    \"studyId\": \"syn4939874\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"RNA sequencing data from 11 plexiform neurofibroma cell lines developed as part of the Cell Culture initiative.\",\n    \"manifestation\": [\"Plexiform Neurofibroma\"],\n    \"measurementTechnique\": [\"RNA-seq\"],\n    \"species\": [\"Homo sapiens\"],\n    \"individualCount\": 11,\n    \"specimenCount\": 11,\n    \"dataUseModifiers\": [\"General Research Use\"]\n  }\n]\n```"}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":6402,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":749}}}}
{"custom_id":"syn8016650","result":{"type":"succeeded","message":{"id":"msg_01Mi7kjkNzNCZvNz1UCK7T1s","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"I'll create high-quality dataset metadata for each of the tables in this project, following the JSON schema requirements carefully.\n\n```json\n[\n  {\n    \"title\": \"ATP hydrolysis rate\",\n    \"creator\": [\"Andrea Rasola\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"ATP hydrolysis\", \"ATPase activity\", \"NF1\"],\n    \"dataType\": [\"proteomics\"],\n    \"studyId\": \"syn8016650\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"contributor\": [\"Giorgio Colombo\"],\n    \"description\": \"Dataset containing measurements of ATP hydrolysis rates in human NF1 samples, part of a study investigating the role of TRAP1 in plexiform neurofibroma metabolism.\",\n    \"measurementTechnique\": [\"ATPase activity assay\"],\n    \"species\": [\"Homo sapiens\"],\n    \"subject\": [\"Neurofibromatosis\", \"Energy metabolism\", \"ATP hydrolysis\"]\n  },\n  {\n    \"title\": \"Calcium Retention Capacity\",\n    \"creator\": [\"Andrea Rasola\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"calcium retention\", \"mitochondria\", \"NF1\"],\n    \"dataType\": [\"cellularPhysiology\"],\n    \"studyId\": \"syn8016650\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"contributor\": [\"Giorgio Colombo\"],\n    \"description\": \"Dataset measuring calcium retention capacity in human NF1 samples, investigating mitochondrial function and TRAP1 activity in plexiform neurofibroma.\",\n    \"measurementTechnique\": [\"calcium retention capacity assay\"],\n    \"species\": [\"Homo sapiens\"],\n    \"subject\": [\"Neurofibromatosis\", \"Calcium metabolism\", \"Mitochondrial function\"]\n  },\n  {\n    \"title\": \"NADH dehydrogenase activity\",\n    \"creator\": [\"Andrea Rasola\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"NADH dehydrogenase\", \"complex I\", \"mitochondrial function\"],\n    \"dataType\": [\"proteomics\", \"cellularPhysiology\"],\n    \"studyId\": \"syn8016650\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"contributor\": [\"Giorgio Colombo\"],\n    \"description\": \"Dataset containing measurements of NADH dehydrogenase (Complex I) activity, investigating mitochondrial function in the context of TRAP1 regulation.\",\n    \"subject\": [\"Neurofibromatosis\", \"Energy metabolism\", \"Electron transport chain\"]\n  },\n  {\n    \"title\": \"Oxygen Consumption Rate and Extracellular Acidification Rate\",\n    \"creator\": [\"Andrea Rasola\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"oxygen consumption\", \"ECAR\", \"OCR\", \"metabolic profiling\", \"Seahorse assay\"],\n    \"dataType\": [\"cellularPhysiology\", \"metabolomics\"],\n    \"studyId\": \"syn8016650\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"contributor\": [\"Giorgio Colombo\"],\n    \"description\": \"Dataset measuring oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) in human and zebrafish samples, investigating metabolic adaptations in NF1.\",\n    \"measurementTechnique\": [\"oxygen consumption assay\"],\n    \"species\": [\"Homo sapiens\", \"Danio rerio\"],\n    \"subject\": [\"Neurofibromatosis\", \"Cellular respiration\", \"Metabolic profiling\"]\n  },\n  {\n    \"title\": \"Sorbitol Dehydrogenase Activity\",\n    \"creator\": [\"Andrea Rasola\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"SDH activity\", \"sorbitol dehydrogenase\", \"TRAP1 inhibitors\", \"metabolic enzymes\"],\n    \"dataType\": [\"proteomics\", \"cellularPhysiology\"],\n    \"studyId\": \"syn8016650\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"contributor\": [\"Giorgio Colombo\"],\n    \"description\": \"Dataset measuring sorbitol dehydrogenase activity in mouse, human, and zebrafish samples with various TRAP1 inhibitors, studying metabolic adaptations in NF1 and MPNST.\",\n    \"measurementTechnique\": [\"sorbitol dehydrogenase activity level assay\"],\n    \"species\": [\"Mus musculus\", \"Homo sapiens\", \"Danio rerio\"],\n    \"manifestation\": [\"Plexiform Neurofibroma\", \"Malignant Peripheral Nerve Sheath Tumor (MPNST)\"],\n    \"subject\": [\"Neurofibromatosis\", \"Enzyme activity\", \"Metabolic enzymes\"]\n  },\n  {\n    \"title\": \"SDS and Blue Native PAGE\",\n    \"creator\": [\"Andrea Rasola\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"SDS-PAGE\", \"blue native PAGE\", \"gel filtration\", \"protein purification\", \"TRAP1\"],\n    \"dataType\": [\"proteomics\"],\n    \"studyId\": \"syn8016650\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"contributor\": [\"Giorgio Colombo\"],\n    \"description\": \"Dataset containing protein analyses using SDS-PAGE, blue native PAGE, immunoprecipitation, and gel filtration chromatography to study TRAP1 in human NF1 samples.\",\n    \"measurementTechnique\": [\"blue native PAGE\", \"gel filtration chromatography\"],\n    \"species\": [\"Homo sapiens\"],\n    \"subject\": [\"Neurofibromatosis\", \"Protein analysis\", \"Chaperone proteins\"]\n  },\n  {\n    \"title\": \"Split GFP Analysis\",\n    \"creator\": [\"Andrea Rasola\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"split GFP\", \"protein-protein interaction\", \"TRAP1\", \"mouse models\"],\n    \"dataType\": [\"proteomics\"],\n    \"studyId\": \"syn8016650\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"contributor\": [\"Giorgio Colombo\"],\n    \"description\": \"Dataset containing split GFP analyses to study protein-protein interactions in mouse samples, investigating TRAP1 interacting partners.\",\n    \"measurementTechnique\": [\"Split GFP\"],\n    \"species\": [\"Mus musculus\"],\n    \"subject\": [\"Neurofibromatosis\", \"Protein-protein interactions\", \"Fluorescence techniques\"]\n  },\n  {\n    \"title\": \"TRAP1-HSP90 ATPase Activity\",\n    \"creator\": [\"Andrea Rasola\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"TRAP1\", \"HSP90\", \"ATPase activity\", \"drug screening\", \"inhibitors\"],\n    \"dataType\": [\"proteomics\"],\n    \"studyId\": \"syn8016650\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"contributor\": [\"Giorgio Colombo\"],\n    \"description\": \"Dataset measuring ATPase activity of TRAP1 and HSP90 in the presence of various inhibitors, including dose-response curves for drug screening.\",\n    \"measurementTechnique\": [\"ATPase activity assay\"],\n    \"subject\": [\"Neurofibromatosis\", \"Drug screening\", \"Enzyme inhibition\", \"Chaperone proteins\"]\n  },\n  {\n    \"title\": \"Cell Proliferation Analysis\",\n    \"creator\": [\"Andrea Rasola\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"cell proliferation\", \"TRAP1 inhibitors\", \"NF1\", \"compound screening\"],\n    \"dataType\": [\"cellularPhysiology\"],\n    \"studyId\": \"syn8016650\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"contributor\": [\"Giorgio Colombo\"],\n    \"description\": \"Dataset measuring cell proliferation in mouse NF1 models treated with various TRAP1 inhibitors, evaluating their potential anti-neoplastic effects.\",\n    \"measurementTechnique\": [\"cell proliferation\"],\n    \"species\": [\"Mus musculus\"],\n    \"manifestation\": [\"Plexiform Neurofibroma\"],\n    \"subject\": [\"Neurofibromatosis\", \"Cell proliferation\", \"Drug effects\"]\n  },\n  {\n    \"title\": \"Cell Viability Analysis\",\n    \"creator\": [\"Andrea Rasola\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"cell viability\", \"TRAP1 inhibitors\", \"NF1\", \"compound screening\", \"hypoxia\"],\n    \"dataType\": [\"cellularPhysiology\"],\n    \"studyId\": \"syn8016650\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"contributor\": [\"Giorgio Colombo\"],\n    \"description\": \"Dataset measuring cell viability in mouse NF1 models treated with various TRAP1 inhibitors under different conditions, including normoxia and hypoxia.\",\n    \"measurementTechnique\": [\"cell viability assay\"],\n    \"species\": [\"Mus musculus\"],\n    \"manifestation\": [\"Plexiform Neurofibroma\"],\n    \"subject\": [\"Neurofibromatosis\", \"Cell viability\", \"Drug effects\", \"Hypoxia\"]\n  },\n  {\n    \"title\": \"TRAP1 Inhibitor Compound List\",\n    \"creator\": [\"Andrea Rasola\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"TRAP1 inhibitors\", \"compound structures\", \"Honokiol\", \"drug design\"],\n    \"dataType\": [\"AggregatedData\"],\n    \"studyId\": \"syn8016650\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"contributor\": [\"Giorgio Colombo\"],\n    \"description\": \"Dataset containing structures and information about TRAP1 inhibitors used in the study, including Honokiol bis-dichloroacetate (HDCA).\",\n    \"subject\": [\"Neurofibromatosis\", \"Chemical compounds\", \"Drug design\"]\n  },\n  {\n    \"title\": \"Fluorescence Microscopy Images\",\n    \"creator\": [\"Andrea Rasola\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"fluorescence microscopy\", \"imaging\", \"mouse models\"],\n    \"dataType\": [\"image\"],\n    \"studyId\": \"syn8016650\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"contributor\": [\"Giorgio Colombo\"],\n    \"description\": \"Dataset containing fluorescence microscopy images from mouse samples, including stacks and Z-sections, used to study cellular and tissue features.\",\n    \"measurementTechnique\": [\"confocal microscopy\"],\n    \"species\": [\"Mus musculus\"],\n    \"subject\": [\"Neurofibromatosis\", \"Microscopy\", \"Cell imaging\"]\n  },\n  {\n    \"title\": \"Immunohistochemistry Images\",\n    \"creator\": [\"Andrea Rasola\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"immunohistochemistry\", \"histology\", \"tissue analysis\"],\n    \"dataType\": [\"image\"],\n    \"studyId\": \"syn8016650\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"contributor\": [\"Giorgio Colombo\"],\n    \"description\": \"Dataset containing immunohistochemistry images at various magnifications (20x, 40x) showing tissue sections with fluorescent labeling.\",\n    \"measurementTechnique\": [\"immunohistochemistry\"],\n    \"subject\": [\"Neurofibromatosis\", \"Histology\", \"Tissue analysis\"]\n  },\n  {\n    \"title\": \"In Vitro Protein Interaction Analysis\",\n    \"creator\": [\"Andrea Rasola\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"in vitro interaction\", \"protein binding\", \"TRAP1\", \"Biacore\"],\n    \"dataType\": [\"proteomics\"],\n    \"studyId\": \"syn8016650\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"contributor\": [\"Giorgio Colombo\"],\n    \"description\": \"Dataset containing Biacore analysis of in vitro protein interactions with human TRAP1, investigating binding partners and interaction dynamics.\",\n    \"species\": [\"Homo sapiens\"],\n    \"subject\": [\"Neurofibromatosis\", \"Protein interactions\", \"Binding kinetics\"]\n  },\n  {\n    \"title\": \"In Vitro Tumorigenesis Assays\",\n    \"creator\": [\"Andrea Rasola\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"in vitro tumorigenesis\", \"focus forming\", \"Matrigel\", \"TRAP1 inhibitors\"],\n    \"dataType\": [\"cellularPhysiology\"],\n    \"studyId\": \"syn8016650\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"contributor\": [\"Giorgio Colombo\"],\n    \"description\": \"Dataset measuring in vitro tumorigenesis in mouse models of NF1 and MPNST using focus forming and Matrigel-based assays, with dose-dependent effects of TRAP1 inhibitors.\",\n    \"measurementTechnique\": [\"focus forming assay\", \"Matrigel-based tumorigenesis assay\"],\n    \"species\": [\"Mus musculus\"],\n    \"manifestation\": [\"Plexiform Neurofibroma\", \"Malignant Peripheral Nerve Sheath Tumor (MPNST)\"],\n    \"subject\": [\"Neurofibromatosis\", \"Tumorigenesis\", \"Drug effects\"]\n  },\n  {\n    \"title\": \"In Vivo Tumorigenesis Assays\",\n    \"creator\": [\"Andrea Rasola\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"in vivo tumorigenesis\", \"mouse models\", \"MPNST\", \"TRAP1\"],\n    \"dataType\": [\"cellularPhysiology\"],\n    \"studyId\": \"syn8016650\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"contributor\": [\"Giorgio Colombo\"],\n    \"description\": \"Dataset measuring in vivo tumorigenesis in mouse models of MPNST, investigating the effects of TRAP1 and related factors on tumor growth.\",\n    \"measurementTechnique\": [\"in vivo tumor growth\"],\n    \"species\": [\"Mus musculus\"],\n    \"manifestation\": [\"Malignant Peripheral Nerve Sheath Tumor (MPNST)\"],\n    \"subject\": [\"Neurofibromatosis\", \"Tumor growth\", \"Animal models\"]\n  },\n  {\n    \"title\": \"Mass Spectrometry Data\",\n    \"creator\": [\"Andrea Rasola\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"mass spectrometry\", \"NAD+/NADH\", \"metabolites\", \"NF1\"],\n    \"dataType\": [\"metabolomics\", \"proteomics\"],\n    \"studyId\": \"syn8016650\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"contributor\": [\"Giorgio Colombo\"],\n    \"description\": \"Dataset containing mass spectrometry analyses of metabolites including NAD+/NADH ratios in human NF1 samples, investigating metabolic adaptations.\",\n    \"measurementTechnique\": [\"mass spectrometry\"],\n    \"species\": [\"Homo sapiens\"],\n    \"subject\": [\"Neurofibromatosis\", \"Metabolomics\", \"NAD metabolism\"]\n  },\n  {\n    \"title\": \"Mitochondrial ROS Measurements\",\n    \"creator\": [\"Andrea Rasola\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"reactive oxygen species\", \"ROS\", \"mitochondria\", \"Honokiol\", \"oxidative stress\"],\n    \"dataType\": [\"cellularPhysiology\"],\n    \"studyId\": \"syn8016650\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"contributor\": [\"Giorgio Colombo\"],\n    \"description\": \"Dataset measuring reactive oxygen species (ROS) levels in mouse NF1 models, including the effects of Honokiol treatment on mitochondrial oxidative stress.\",\n    \"measurementTechnique\": [\"reactive oxygen species assay\"],\n    \"species\": [\"Mus musculus\"],\n    \"manifestation\": [\"Plexiform Neurofibroma\"],\n    \"subject\": [\"Neurofibromatosis\", \"Oxidative stress\", \"Mitochondrial function\"]\n  }\n]\n```"}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":8959,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":4478}}}}
{"custom_id":"syn5610418","result":{"type":"succeeded","message":{"id":"msg_01HevsmkaVcPM2eZzNRMecy4","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"I'll create the dataset metadata for the table you provided following the schema requirements.\n\n```json\n[\n  {\n    \"title\": \"Synodos NF1 Patient WES Data (GSE145064)\",\n    \"creator\": [\"CTF Synodos for NF1\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"Neurofibromatosis type 1\", \"RNA-seq\", \"gene expression\", \"patient-derived samples\"],\n    \"dataType\": [\"geneExpression\"],\n    \"studyId\": \"syn5610418\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"CTF\"],\n    \"description\": \"This dataset contains RNA-seq data from patient-derived samples related to Neurofibromatosis type 1. It includes data from both Plexiform Neurofibroma and Malignant Peripheral Nerve Sheath Tumor specimens.\",\n    \"contributor\": [\"Iowa\", \"Sanford\", \"Exemplar Genetics\"],\n    \"measurementTechnique\": [\"RNA-seq\"],\n    \"manifestation\": [\"Plexiform Neurofibroma\", \"Malignant Peripheral Nerve Sheath Tumor\"],\n    \"species\": [\"Homo sapiens\"],\n    \"individualCount\": 15,\n    \"specimenCount\": 46,\n    \"subject\": [\"Neurofibromatosis\", \"Gene expression\", \"Genomics\", \"Rare diseases\"]\n  }\n]\n```"}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":5653,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":366}}}}
{"custom_id":"syn8016599","result":{"type":"succeeded","message":{"id":"msg_014uxeeXjcuTYb7HQnGzUUHW","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"I'll create high-quality dataset metadata for these tables according to the schema and ensure the output meets all requirements.\n\n```json\n[\n  {\n    \"title\": \"Kinome Data from NF1-deficient Schwann Cells\",\n    \"creator\": [\"James Walker\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"NF1\", \"Schwann cells\", \"Kinome\", \"plexiform neurofibroma\", \"signaling\", \"MIB/MS\"],\n    \"dataType\": [\"kinomics\"],\n    \"studyId\": \"syn8016599\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"Kinome profiling data from NF1-deficient Schwann cells using Multiplexed Inhibitor Beads and Mass Spectrometry (MIB/MS) analysis. Part of a project investigating signaling networks in NF1-deficient Schwann cells and plexiform neurofibromas.\",\n    \"contributor\": [\"Stephanie Bouley\"],\n    \"measurementTechnique\": [\"MIB/MS\"],\n    \"species\": [\"Homo sapiens\"],\n    \"dataUseModifiers\": [\"General Research Use\"],\n    \"manifestation\": [\"Plexiform Neurofibroma\"]\n  },\n  {\n    \"title\": \"RNA-Seq Data To Process from NF1 Study\",\n    \"creator\": [\"James Walker\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"NF1\", \"RNA-Seq\", \"gene expression\", \"Schwann cells\", \"plexiform neurofibroma\"],\n    \"dataType\": [\"geneExpression\"],\n    \"studyId\": \"syn8016599\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"Raw RNA sequencing data from the study of NF1-deficient Schwann cells. This dataset contains raw fastq files pending processing to investigate gene expression patterns related to NF1 deficiency.\",\n    \"contributor\": [\"Stephanie Bouley\"],\n    \"measurementTechnique\": [\"RNA-seq\"],\n    \"species\": [\"Homo sapiens\"],\n    \"dataUseModifiers\": [\"General Research Use\"],\n    \"manifestation\": [\"Plexiform Neurofibroma\"]\n  },\n  {\n    \"title\": \"Proteomics Data from NF1-deficient Schwann Cells\",\n    \"creator\": [\"James Walker\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"NF1\", \"proteomics\", \"phosphoproteome\", \"Schwann cells\", \"TMT\", \"plexiform neurofibroma\"],\n    \"dataType\": [\"proteomics\"],\n    \"studyId\": \"syn8016599\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"Proteomics and phosphoproteomics data from NF1-deficient Schwann cells using TMT quantitation. This dataset includes both total proteome and normalized phosphoproteome data to identify misregulated phospho-targets in NF1-deficient cells.\",\n    \"contributor\": [\"Stephanie Bouley\"],\n    \"measurementTechnique\": [\"TMT quantitation\"],\n    \"species\": [\"Homo sapiens\"],\n    \"dataUseModifiers\": [\"General Research Use\"],\n    \"manifestation\": [\"Plexiform Neurofibroma\"]\n  },\n  {\n    \"title\": \"RNA-Seq Raw Data from NF1-deficient Schwann Cells\",\n    \"creator\": [\"James Walker\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"NF1\", \"RNA-Seq\", \"gene expression\", \"Schwann cells\", \"plexiform neurofibroma\", \"raw data\"],\n    \"dataType\": [\"geneExpression\"],\n    \"studyId\": \"syn8016599\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"Raw RNA sequencing data from NF1-deficient Schwann cells. This dataset contains the original fastq files used for transcriptome profiling to complement proteomics and kinome analyses of NF1-regulated signaling pathways.\",\n    \"contributor\": [\"Stephanie Bouley\"],\n    \"measurementTechnique\": [\"RNA-seq\"],\n    \"species\": [\"Homo sapiens\"],\n    \"dataUseModifiers\": [\"General Research Use\"],\n    \"manifestation\": [\"Plexiform Neurofibroma\"]\n  }\n]\n```"}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":7413,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":1170}}}}
{"custom_id":"syn4939910","result":{"type":"succeeded","message":{"id":"msg_01GfgChTjEGxAy6bwLEU5D2d","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"# Dataset Metadata JSON\n\n```json\n[\n  {\n    \"title\": \"Copy Number Variant - CNVkit\",\n    \"creator\": [\"Matthew R. Steensma\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"Copy Number Variants\", \"CNVkit\", \"NF1\", \"peripheral nerve sheath tumors\"],\n    \"dataType\": [\"CopyNumberVariants\"],\n    \"studyId\": \"syn4939910\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"Copy number variant data generated using CNVkit from samples from a Neurofibromatosis type 1 study focused on peripheral nerve sheath tumors.\",\n    \"measurementTechnique\": [\"whole genome sequencing\"]\n  },\n  {\n    \"title\": \"Germline Genomic Variants - DeepVariant Pipeline\",\n    \"creator\": [\"Matthew R. Steensma\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"DeepVariant\", \"Germline Variants\", \"NF1\", \"whole genome sequencing\"],\n    \"dataType\": [\"GermlineVariants\"],\n    \"studyId\": \"syn4939910\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"Germline genomic variants identified using the DeepVariant pipeline from whole genome sequencing data of NF1 patients.\",\n    \"measurementTechnique\": [\"whole genome sequencing\"],\n    \"species\": [\"Homo sapiens\"],\n    \"individualCount\": 9\n  },\n  {\n    \"title\": \"Germline Genomic Variants - FreeBayes Pipeline\",\n    \"creator\": [\"Matthew R. Steensma\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"FreeBayes\", \"Germline Variants\", \"NF1\", \"whole genome sequencing\"],\n    \"dataType\": [\"GermlineVariants\"],\n    \"studyId\": \"syn4939910\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"Germline genomic variants identified using the FreeBayes pipeline from whole genome sequencing data of NF1 patients.\",\n    \"measurementTechnique\": [\"whole genome sequencing\"],\n    \"species\": [\"Homo sapiens\"],\n    \"individualCount\": 9\n  },\n  {\n    \"title\": \"Germline Genomic Variants - Mutect2 Pipeline\",\n    \"creator\": [\"Matthew R. Steensma\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"Mutect2\", \"Germline Variants\", \"NF1\", \"whole genome sequencing\"],\n    \"dataType\": [\"GermlineVariants\"],\n    \"studyId\": \"syn4939910\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"Germline genomic variants identified using the Mutect2 pipeline from whole genome sequencing data of NF1 patients.\",\n    \"measurementTechnique\": [\"whole genome sequencing\"],\n    \"species\": [\"Homo sapiens\"],\n    \"individualCount\": 9\n  },\n  {\n    \"title\": \"Germline Genomic Variants - Strelka Pipeline\",\n    \"creator\": [\"Matthew R. Steensma\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"Strelka\", \"Germline Variants\", \"NF1\", \"whole genome sequencing\"],\n    \"dataType\": [\"GermlineVariants\"],\n    \"studyId\": \"syn4939910\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"Germline genomic variants identified using the Strelka pipeline from whole genome sequencing data of NF1 patients.\",\n    \"measurementTechnique\": [\"whole genome sequencing\"],\n    \"species\": [\"Homo sapiens\"],\n    \"individualCount\": 9\n  },\n  {\n    \"title\": \"Metadata for DNA Methylation Analysis\",\n    \"creator\": [\"Matthew R. Steensma\", \"Benjamin Johnson\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"methylation\", \"epigenetics\", \"NF1\", \"Cutaneous Neurofibroma\"],\n    \"dataType\": [\"chromatinActivity\"],\n    \"studyId\": \"syn4939910\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"Metadata associated with DNA methylation array analysis comparing cutaneous neurofibromas with other types of neurofibromas.\",\n    \"measurementTechnique\": [\"methylation array\"],\n    \"manifestation\": [\"Cutaneous Neurofibroma\"]\n  },\n  {\n    \"title\": \"RNASeq Fastq Files for Processing\",\n    \"creator\": [\"Matthew R. Steensma\", \"Steven Angus\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"RNA-seq\", \"gene expression\", \"NF1\", \"peripheral nerve sheath tumors\"],\n    \"dataType\": [\"geneExpression\"],\n    \"studyId\": \"syn4939910\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"Raw RNA sequencing data (fastq files) from NF1 patients for processing and analysis.\"\n  },\n  {\n    \"title\": \"Whole Genome Sequencing of NF1 Samples\",\n    \"creator\": [\"Matthew R. Steensma\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"whole genome sequencing\", \"NF1\", \"Plexiform Neurofibroma\", \"genomic variants\"],\n    \"dataType\": [\"genomicVariants\"],\n    \"studyId\": \"syn4939910\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"Raw whole genome sequencing data from patients with Neurofibromatosis type 1 and plexiform neurofibromas.\",\n    \"measurementTechnique\": [\"whole genome sequencing\"],\n    \"species\": [\"Homo sapiens\"],\n    \"individualCount\": 9,\n    \"manifestation\": [\"Plexiform Neurofibroma\"]\n  },\n  {\n    \"title\": \"Processed DNA Methylation Beta Matrix\",\n    \"creator\": [\"Matthew R. Steensma\", \"Benjamin Johnson\", \"Sara Gosline\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"methylation\", \"beta values\", \"NF1\", \"epigenetics\", \"Cutaneous Neurofibroma\", \"Plexiform Neurofibroma\"],\n    \"dataType\": [\"chromatinActivity\"],\n    \"studyId\": \"syn4939910\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"Processed DNA methylation beta value matrix comparing Cutaneous Neurofibromas (CNF) and Plexiform Neurofibromas (PNF) in NF1 patients.\",\n    \"measurementTechnique\": [\"methylation array\"],\n    \"manifestation\": [\"Cutaneous Neurofibroma\", \"Plexiform Neurofibroma\"]\n  },\n  {\n    \"title\": \"Raw DNA Methylation IDAT Files for CNF and PNF\",\n    \"creator\": [\"Matthew R. Steensma\", \"Benjamin Johnson\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"IDAT\", \"methylation\", \"EPIC array\", \"NF1\", \"Cutaneous Neurofibroma\"],\n    \"dataType\": [\"chromatinActivity\"],\n    \"studyId\": \"syn4939910\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"Raw IDAT files from methylation EPIC array analysis of Cutaneous Neurofibromas (CNF) and Plexiform Neurofibromas (PNF) in NF1 patients.\",\n    \"measurementTechnique\": [\"methylation array\"],\n    \"species\": [\"Homo sapiens\"],\n    \"individualCount\": 38,\n    \"specimenCount\": 60,\n    \"manifestation\": [\"Cutaneous Neurofibroma\"]\n  },\n  {\n    \"title\": \"Van Andel - RNAseq and Whole Exome Sequencing\",\n    \"creator\": [\"Matthew R. Steensma\", \"Steven Angus\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"RNA-seq\", \"whole exome sequencing\", \"NF1\", \"gene expression\", \"Plexiform Neurofibroma\"],\n    \"dataType\": [\"geneExpression\", \"genomicVariants\"],\n    \"studyId\": \"syn4939910\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"RNA sequencing and whole exome sequencing data from NF1 patients with plexiform neurofibromas from the Van Andel Research Institute.\",\n    \"measurementTechnique\": [\"RNA-seq\", \"whole genome sequencing\"],\n    \"species\": [\"Homo sapiens\"],\n    \"individualCount\": 9,\n    \"specimenCount\": 11,\n    \"manifestation\": [\"Plexiform Neurofibroma\"]\n  },\n  {\n    \"title\": \"Whole Exome Sequencing of Mouse NF1 MPNST Models\",\n    \"creator\": [\"Matthew R. Steensma\", \"Megan Bowman\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"mouse model\", \"whole exome sequencing\", \"NF1\", \"MPNST\", \"preclinical\"],\n    \"dataType\": [\"genomicVariants\"],\n    \"studyId\": \"syn4939910\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"Whole exome sequencing data from mouse models of NF1-associated Malignant Peripheral Nerve Sheath Tumors (MPNSTs), including the MET-overexpression model.\",\n    \"measurementTechnique\": [\"whole exome sequencing\"],\n    \"species\": [\"Mus musculus\"],\n    \"individualCount\": 2,\n    \"specimenCount\": 7,\n    \"manifestation\": [\"Malignant Peripheral Nerve Sheath Tumor (MPNST)\"]\n  }\n]\n```"}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":8982,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":2787}}}}
{"custom_id":"syn11374353","result":{"type":"succeeded","message":{"id":"msg_01UNWk9P1Y8CeM6gJLrYSZ5e","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"I'll create high-quality dataset metadata for each table in this project, following the specified JSON schema and requirements.\n\n```json\n[\n  {\n    \"title\": \"12 month deliverables - Whole Exome Sequencing\",\n    \"creator\": [\"Eduard Serra\", \"Bernat Gel Moreno\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"Neurofibromatosis type 1\", \"cutaneous neurofibroma\", \"Schwann cells\", \"fibroblasts\", \"whole exome sequencing\"],\n    \"dataType\": [\"genomicVariants\"],\n    \"studyId\": \"syn11374353\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"Whole exome sequencing data from cutaneous neurofibroma (cNF) samples, including fibroblasts and Schwann cells derived from 5 individuals with NF1. This data is part of a study examining the interactions between Schwann cells and fibroblasts in cNF development.\",\n    \"contributor\": [\"Bernat Gel Moreno\"],\n    \"dataUseModifiers\": [\"Health or Medical or Biomedical Research\"],\n    \"measurementTechnique\": [\"whole exome sequencing\"],\n    \"manifestation\": [\"Cutaneous Neurofibroma\"],\n    \"species\": [\"Homo sapiens\"],\n    \"individualCount\": 5,\n    \"specimenCount\": 10\n  },\n  {\n    \"title\": \"18 month deliverables - RNA Sequencing\",\n    \"creator\": [\"Eduard Serra\", \"Bernat Gel Moreno\", \"Christina Parry\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"Neurofibromatosis type 1\", \"cutaneous neurofibroma\", \"RNA-seq\", \"gene expression\", \"Schwann cells\", \"fibroblasts\", \"co-culture\"],\n    \"dataType\": [\"geneExpression\"],\n    \"studyId\": \"syn11374353\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"RNA sequencing data from cutaneous neurofibroma (cNF) samples, including isolated fibroblasts, Schwann cells, and co-cultures of these cells from 13 individuals with NF1. This data aims to identify expression signatures due to heterotypic cell interactions.\",\n    \"contributor\": [\"Bernat Gel Moreno\", \"Christina Parry\"],\n    \"dataUseModifiers\": [\"Health or Medical or Biomedical Research\"],\n    \"measurementTechnique\": [\"RNA-seq\"],\n    \"manifestation\": [\"Cutaneous Neurofibroma\"],\n    \"species\": [\"Homo sapiens\"],\n    \"individualCount\": 13,\n    \"specimenCount\": 28\n  },\n  {\n    \"title\": \"24 month deliverables - Co-culture Analysis\",\n    \"creator\": [\"Eduard Serra\", \"Bernat Gel Moreno\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"Neurofibromatosis type 1\", \"cutaneous neurofibroma\", \"co-culture\", \"Schwann cells\", \"fibroblasts\", \"cell interactions\"],\n    \"dataType\": [\"AggregatedData\"],\n    \"studyId\": \"syn11374353\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"Co-culture analysis data exploring the interactions between Schwann cells and fibroblasts derived from cutaneous neurofibromas. This data includes various combinations of co-cultures aimed at understanding signaling pathways specific to SC-FB interactions.\",\n    \"contributor\": [\"Bernat Gel Moreno\"],\n    \"dataUseModifiers\": [\"Health or Medical or Biomedical Research\"],\n    \"manifestation\": [\"Cutaneous Neurofibroma\"]\n  },\n  {\n    \"title\": \"36 month deliverables - Functional Assays\",\n    \"creator\": [\"Eduard Serra\", \"Bernat Gel Moreno\", \"Helena Mazuelas\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"Neurofibromatosis type 1\", \"cutaneous neurofibroma\", \"functional assays\", \"Luminex\", \"EdU\", \"cell proliferation\"],\n    \"dataType\": [\"clinical\"],\n    \"studyId\": \"syn11374353\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"Functional assay data testing the impact of disrupting specific signaling pathways between Schwann cells and fibroblasts. Includes proliferation assays (ClickiT-EdU) and cytokine profiling (Luminex) from co-cultures and single cell cultures.\",\n    \"contributor\": [\"Bernat Gel Moreno\", \"Helena Mazuelas\"],\n    \"dataUseModifiers\": [\"Health or Medical or Biomedical Research\"],\n    \"manifestation\": [\"Cutaneous Neurofibroma\"]\n  },\n  {\n    \"title\": \"6 month deliverables - Mutation Analysis\",\n    \"creator\": [\"Eduard Serra\", \"Bernat Gel Moreno\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"Neurofibromatosis type 1\", \"cutaneous neurofibroma\", \"mutation analysis\", \"genetic variation\"],\n    \"dataType\": [\"genomicVariants\"],\n    \"studyId\": \"syn11374353\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"Mutation analysis data from cutaneous neurofibroma samples, focusing on genetic variations present in gene coding regions of neurofibroma donors. This analysis helps identify which differently expressed genes belong to specific cell types.\",\n    \"contributor\": [\"Bernat Gel Moreno\"],\n    \"dataUseModifiers\": [\"Health or Medical or Biomedical Research\"],\n    \"manifestation\": [\"Cutaneous Neurofibroma\"]\n  },\n  {\n    \"title\": \"Gene Expression Quantification from RNA-seq\",\n    \"creator\": [\"Eduard Serra\", \"NF Service\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"Neurofibromatosis type 1\", \"cutaneous neurofibroma\", \"RNA-seq\", \"gene expression quantification\", \"transcript abundance\"],\n    \"dataType\": [\"geneExpression\"],\n    \"studyId\": \"syn11374353\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"Gene expression quantification data derived from RNA-seq of cutaneous neurofibroma samples, including isolated cell types and co-cultures. Contains transcript abundance estimates in Salmon format (sf files).\",\n    \"contributor\": [\"NF Service\"],\n    \"dataUseModifiers\": [\"Health or Medical or Biomedical Research\"],\n    \"measurementTechnique\": [\"RNA-seq\"],\n    \"manifestation\": [\"Cutaneous Neurofibroma\"],\n    \"species\": [\"Homo sapiens\"],\n    \"individualCount\": 13,\n    \"specimenCount\": 28\n  },\n  {\n    \"title\": \"NF-OSI-processed-data\",\n    \"creator\": [\"Eduard Serra\", \"NF Service\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"Neurofibromatosis type 1\", \"cutaneous neurofibroma\", \"RNA-seq\", \"processed data\", \"aligned reads\", \"gene expression\"],\n    \"dataType\": [\"geneExpression\", \"AlignedReads\"],\n    \"studyId\": \"syn11374353\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"contributor\": [\"NF Service\"],\n    \"dataUseModifiers\": [\"Health or Medical or Biomedical Research\"],\n    \"measurementTechnique\": [\"RNA-seq\"],\n    \"manifestation\": [\"Cutaneous Neurofibroma\"],\n    \"species\": [\"Homo sapiens\"],\n    \"individualCount\": 13,\n    \"specimenCount\": 28,\n    \"description\": \"NF-OSI processed RNA-seq data from cutaneous neurofibroma samples, including quality control reports, aligned reads, and transcript quantification. This processed data supports the analysis of gene expression profiles in cNF tissues, fibroblasts, Schwann cells, and co-cultures.\",\n    \"series\": \"NF-OSI Processed Data\",\n    \"yearProcessed\": 2023\n  },\n  {\n    \"title\": \"NFOSI-RNASeq-To-Process-2023-14-03\",\n    \"creator\": [\"Eduard Serra\", \"Bernat Gel Moreno\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"Neurofibromatosis type 1\", \"cutaneous neurofibroma\", \"RNA-seq\", \"raw data\"],\n    \"dataType\": [\"geneExpression\"],\n    \"studyId\": \"syn11374353\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"Raw RNA-seq data files submitted for processing by NF-OSI. Contains fastq files from cutaneous neurofibroma samples, including fibroblasts, Schwann cells, and co-cultures.\",\n    \"contributor\": [\"Bernat Gel Moreno\"],\n    \"dataUseModifiers\": [\"Health or Medical or Biomedical Research\"],\n    \"measurementTechnique\": [\"RNA-seq\"],\n    \"manifestation\": [\"Cutaneous Neurofibroma\"],\n    \"species\": [\"Homo sapiens\"],\n    \"specimenCount\": 28\n  },\n  {\n    \"title\": \"NFOSI-WES-To-Process-2024-03\",\n    \"creator\": [\"Eduard Serra\", \"Bernat Gel Moreno\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"Neurofibromatosis type 1\", \"cutaneous neurofibroma\", \"whole exome sequencing\", \"raw data\"],\n    \"dataType\": [\"genomicVariants\"],\n    \"studyId\": \"syn11374353\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"Raw whole exome sequencing data files submitted for processing by NF-OSI. Contains fastq files from cutaneous neurofibroma samples, focusing on fibroblasts and Schwann cells to identify genetic variation.\",\n    \"contributor\": [\"Bernat Gel Moreno\"],\n    \"dataUseModifiers\": [\"Health or Medical or Biomedical Research\"],\n    \"measurementTechnique\": [\"whole exome sequencing\"],\n    \"manifestation\": [\"Cutaneous Neurofibroma\"],\n    \"species\": [\"Homo sapiens\"]\n  }\n]\n```"}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":7569,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":2763}}}}
{"custom_id":"syn21650484","result":{"type":"succeeded","message":{"id":"msg_015Zz3KwXizewH6XMqGRpsVL","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"I'll create high-quality dataset metadata for this table according to the JSON schema and the information provided. Let me carefully ensure all required fields are included and that values match the schema's specifications.\n\n```json\n[\n  {\n    \"title\": \"Bulk RNA Sequencing Donor RGCs\",\n    \"creator\": [\"Michael Young\", \"Petr Baranov\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"RNA-seq\", \"retinal ganglion cells\", \"RGC transplantation\", \"exome sequencing\"],\n    \"dataType\": [\"AlignedReads\", \"geneExpression\", \"raw counts\"],\n    \"studyId\": \"syn21650484\",\n    \"diseaseFocus\": [\"Multiple\"],\n    \"funder\": [\"GFF\"],\n    \"description\": \"Bulk RNA sequencing data from donor retinal ganglion cells (RGCs) used in transplantation studies. Part of research to improve the success of RGC transplantation using mouse cells combined with tissue engineering strategies.\",\n    \"contributor\": [\"Julia Oswald\", \"Christina Parry\"],\n    \"measurementTechnique\": [\"targeted exome sequencing\", \"RNA-seq\"],\n    \"species\": [\"Mus musculus\"],\n    \"specimenCount\": 2,\n    \"subject\": [\"Retinal ganglion cells\", \"Cell transplantation\", \"Vision research\", \"Stem cells\"],\n    \"datePublished\": 2020\n  }\n]\n```"}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":5863,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":356}}}}
{"custom_id":"syn7231973","result":{"type":"succeeded","message":{"id":"msg_01KFpZYNaiaCZ82ZQAyMtYGF","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"I'll create high-quality dataset metadata for these tables according to the JSON schema provided. Here's the structured metadata:\n\n```json\n[\n  {\n    \"title\": \"Exome Sequencing Data of Plexiform Neurofibroma Samples\",\n    \"creator\": [\"Eduard Serra\", \"Bernat Gel Moreno\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"Exome\", \"NF1\", \"Plexiform Neurofibroma\", \"Genetics\", \"Genome Sequencing\"],\n    \"dataType\": [\"genomicVariants\"],\n    \"studyId\": \"syn7231973\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"contributor\": [\"Bernat Gel Moreno\"],\n    \"description\": \"Whole exome sequencing data from plexiform neurofibroma samples and derived iPS cells. This dataset contains raw sequencing files (FASTQ) and alignment index files (BAI) from tumor samples and induced pluripotent stem cells derived from NF1+/- and NF1-/- cells.\",\n    \"measurementTechnique\": [\"whole exome sequencing\"],\n    \"species\": [\"Homo sapiens\"],\n    \"individualCount\": 9,\n    \"specimenCount\": 35,\n    \"manifestation\": [\"Plexiform Neurofibroma\"]\n  },\n  {\n    \"title\": \"SNP Array Analysis of Plexiform Neurofibroma Samples\",\n    \"creator\": [\"Eduard Serra\", \"Bernat Gel Moreno\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"SNP array\", \"NF1\", \"Plexiform Neurofibroma\", \"Genetics\", \"Genomic Variants\"],\n    \"dataType\": [\"genomicVariants\"],\n    \"studyId\": \"syn7231973\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"contributor\": [\"Bernat Gel Moreno\"],\n    \"description\": \"SNP array data from plexiform neurofibroma samples. This dataset contains text files with single nucleotide polymorphism information to explore genomic variation within plexiform neurofibromas.\",\n    \"measurementTechnique\": [\"SNP array\"],\n    \"species\": [\"Homo sapiens\"],\n    \"individualCount\": 23,\n    \"specimenCount\": 40,\n    \"manifestation\": [\"Plexiform Neurofibroma\"]\n  }\n]\n```"}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":6247,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":642}}}}
{"custom_id":"syn23651229","result":{"type":"succeeded","message":{"id":"msg_01Y13QYTLTz7QQKNXoWtafXg","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"I'll create high-quality dataset metadata for each of the tables in this project. I'll ensure all fields conform to the JSON schema requirements, using only predefined values for enumerated fields.\n\n```json\n[\n  {\n    \"title\": \"Copy Number Variant - CNVkit\",\n    \"creator\": [\"Jack Shern\", \"Angela Hirbe\", \"Aadel Chaudhuri\"],\n    \"contributor\": [\"R. Taylor Sundby\", \"Jeff Szymanski\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"NF1\", \"MPNST\", \"Plexiform Neurofibroma\", \"cfDNA\", \"ultra-low-pass sequencing\", \"copy number variants\"],\n    \"dataType\": [\"CopyNumberVariants\", \"genomicVariants\"],\n    \"studyId\": \"syn23651229\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NIH-NCI\", \"Other\"],\n    \"description\": \"Copy number variant analysis of ultra-low-pass whole genome sequencing data from plasma cell-free DNA of NF1 patients with plexiform neurofibroma and malignant peripheral nerve sheath tumors, analyzed using CNVkit.\",\n    \"species\": [\"Homo sapiens\"],\n    \"individualCount\": 59,\n    \"specimenCount\": 117,\n    \"measurementTechnique\": [\"whole genome sequencing\"],\n    \"manifestation\": [\"Plexiform Neurofibroma\", \"Malignant Peripheral Nerve Sheath Tumor\"],\n    \"dataUseModifiers\": [\"General Research Use\"]\n  },\n  {\n    \"title\": \"Germline Genomic Variants - DeepVariant Pipeline\",\n    \"creator\": [\"Jack Shern\", \"Angela Hirbe\", \"Aadel Chaudhuri\"],\n    \"contributor\": [\"R. Taylor Sundby\", \"Jeff Szymanski\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"NF1\", \"MPNST\", \"Plexiform Neurofibroma\", \"cfDNA\", \"ultra-low-pass sequencing\", \"DeepVariant\", \"germline variants\"],\n    \"dataType\": [\"GermlineVariants\", \"genomicVariants\"],\n    \"studyId\": \"syn23651229\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NIH-NCI\", \"Other\"],\n    \"description\": \"Germline genomic variants called using the DeepVariant pipeline from ultra-low-pass whole genome sequencing data of plasma cell-free DNA from NF1 patients with plexiform neurofibroma and malignant peripheral nerve sheath tumors.\",\n    \"species\": [\"Homo sapiens\"],\n    \"individualCount\": 59,\n    \"specimenCount\": 117,\n    \"measurementTechnique\": [\"whole genome sequencing\"],\n    \"manifestation\": [\"Plexiform Neurofibroma\", \"Malignant Peripheral Nerve Sheath Tumor\"],\n    \"dataUseModifiers\": [\"General Research Use\"]\n  },\n  {\n    \"title\": \"Germline Genomic Variants - FreeBayes Pipeline\",\n    \"creator\": [\"Jack Shern\", \"Angela Hirbe\", \"Aadel Chaudhuri\"],\n    \"contributor\": [\"R. Taylor Sundby\", \"Jeff Szymanski\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"NF1\", \"MPNST\", \"Plexiform Neurofibroma\", \"cfDNA\", \"ultra-low-pass sequencing\", \"FreeBayes\", \"germline variants\"],\n    \"dataType\": [\"GermlineVariants\", \"genomicVariants\"],\n    \"studyId\": \"syn23651229\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NIH-NCI\", \"Other\"],\n    \"description\": \"Germline genomic variants called using the FreeBayes pipeline from ultra-low-pass whole genome sequencing data of plasma cell-free DNA from NF1 patients with plexiform neurofibroma and malignant peripheral nerve sheath tumors.\",\n    \"species\": [\"Homo sapiens\"],\n    \"individualCount\": 59,\n    \"specimenCount\": 117,\n    \"measurementTechnique\": [\"whole genome sequencing\"],\n    \"manifestation\": [\"Plexiform Neurofibroma\", \"Malignant Peripheral Nerve Sheath Tumor\"],\n    \"dataUseModifiers\": [\"General Research Use\"]\n  },\n  {\n    \"title\": \"Germline Genomic Variants - Mutect2 Pipeline\",\n    \"creator\": [\"Jack Shern\", \"Angela Hirbe\", \"Aadel Chaudhuri\"],\n    \"contributor\": [\"R. Taylor Sundby\", \"Jeff Szymanski\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"NF1\", \"MPNST\", \"Plexiform Neurofibroma\", \"cfDNA\", \"ultra-low-pass sequencing\", \"Mutect2\", \"germline variants\"],\n    \"dataType\": [\"GermlineVariants\", \"genomicVariants\"],\n    \"studyId\": \"syn23651229\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NIH-NCI\", \"Other\"],\n    \"description\": \"Germline genomic variants called using the Mutect2 pipeline from ultra-low-pass whole genome sequencing data of plasma cell-free DNA from NF1 patients with plexiform neurofibroma and malignant peripheral nerve sheath tumors.\",\n    \"species\": [\"Homo sapiens\"],\n    \"individualCount\": 42,\n    \"specimenCount\": 90,\n    \"measurementTechnique\": [\"whole genome sequencing\"],\n    \"manifestation\": [\"Plexiform Neurofibroma\", \"Malignant Peripheral Nerve Sheath Tumor\"],\n    \"dataUseModifiers\": [\"General Research Use\"]\n  },\n  {\n    \"title\": \"Germline Genomic Variants - Strelka Pipeline\",\n    \"creator\": [\"Jack Shern\", \"Angela Hirbe\", \"Aadel Chaudhuri\"],\n    \"contributor\": [\"R. Taylor Sundby\", \"Jeff Szymanski\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"NF1\", \"MPNST\", \"Plexiform Neurofibroma\", \"cfDNA\", \"ultra-low-pass sequencing\", \"Strelka\", \"germline variants\"],\n    \"dataType\": [\"GermlineVariants\", \"genomicVariants\"],\n    \"studyId\": \"syn23651229\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NIH-NCI\", \"Other\"],\n    \"description\": \"Germline genomic variants called using the Strelka pipeline from ultra-low-pass whole genome sequencing data of plasma cell-free DNA from NF1 patients with plexiform neurofibroma and malignant peripheral nerve sheath tumors.\",\n    \"species\": [\"Homo sapiens\"],\n    \"individualCount\": 59,\n    \"specimenCount\": 117,\n    \"measurementTechnique\": [\"whole genome sequencing\"],\n    \"manifestation\": [\"Plexiform Neurofibroma\", \"Malignant Peripheral Nerve Sheath Tumor\"],\n    \"dataUseModifiers\": [\"General Research Use\"]\n  },\n  {\n    \"title\": \"NFOSIprocessing-2022-26-04\",\n    \"creator\": [\"Jack Shern\", \"Angela Hirbe\", \"Aadel Chaudhuri\"],\n    \"contributor\": [\"R. Taylor Sundby\", \"Jeff Szymanski\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"NF1\", \"MPNST\", \"Plexiform Neurofibroma\", \"cfDNA\", \"ultra-low-pass sequencing\", \"processed data\"],\n    \"dataType\": [\"AlignedReads\", \"genomicVariants\"],\n    \"studyId\": \"syn23651229\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NIH-NCI\", \"Other\"],\n    \"description\": \"Processed bam files from ultra-low-pass whole genome sequencing data of plasma cell-free DNA from NF1 patients with plexiform neurofibroma and malignant peripheral nerve sheath tumors.\",\n    \"species\": [\"Homo sapiens\"],\n    \"individualCount\": 59,\n    \"specimenCount\": 117,\n    \"measurementTechnique\": [\"whole genome sequencing\"],\n    \"manifestation\": [\"Plexiform Neurofibroma\", \"Malignant Peripheral Nerve Sheath Tumor\"],\n    \"dataUseModifiers\": [\"General Research Use\"],\n    \"series\": \"NF-OSI Processed Data\",\n    \"yearProcessed\": 2022\n  },\n  {\n    \"title\": \"ULP Whole Genome Sequencing\",\n    \"creator\": [\"Jack Shern\", \"Angela Hirbe\", \"Aadel Chaudhuri\"],\n    \"contributor\": [\"R. Taylor Sundby\", \"Jeff Szymanski\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"NF1\", \"MPNST\", \"Plexiform Neurofibroma\", \"cfDNA\", \"ultra-low-pass sequencing\"],\n    \"dataType\": [\"genomicVariants\", \"clinical\", \"AlignedReads\"],\n    \"studyId\": \"syn23651229\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NIH-NCI\", \"Other\"],\n    \"description\": \"Ultra-low-pass whole genome sequencing data and clinical metadata from plasma cell-free DNA of NF1 patients with plexiform neurofibroma and malignant peripheral nerve sheath tumors.\",\n    \"species\": [\"Homo sapiens\"],\n    \"individualCount\": 59,\n    \"specimenCount\": 117,\n    \"measurementTechnique\": [\"whole genome sequencing\"],\n    \"manifestation\": [\"Plexiform Neurofibroma\", \"Malignant Peripheral Nerve Sheath Tumor\"],\n    \"dataUseModifiers\": [\"General Research Use\"]\n  }\n]\n```"}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":7137,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":2603}}}}
{"custom_id":"syn52740594","result":{"type":"succeeded","message":{"id":"msg_01Qi3v33HftFCfXXMSGkW1yi","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"I'll create high-quality dataset metadata for the Minnesota CCHMC Recombinetics Team Data table according to the JSON schema provided.\n\n```json\n[\n  {\n    \"title\": \"Minnesota CCHMC Recombinetics Team Data\",\n    \"creator\": [\"Sue Rathe\", \"Jon Hawkinson\", \"Kyle Williams\", \"Mike Mason\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"NF1\", \"preclinical\", \"Synodos\", \"pig model\", \"MRI\", \"RNA-seq\", \"drug screening\"],\n    \"dataType\": [\"image\", \"geneExpression\", \"drugScreen\"],\n    \"studyId\": \"syn52740594\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"CTF\"],\n    \"description\": \"Data from the Minnesota, CCHMC and Recombinetics team part of the Synodos NF1 preclinical models initiative. Includes MRI imaging, RNA-seq data, and drug screening results from pig models and human cell lines.\",\n    \"contributor\": [\"Robert Allaway\", \"Nasim Sanati\", \"Sara Gosline\"],\n    \"manifestation\": [\"Plexiform Neurofibroma\", \"Malignant Peripheral Nerve Sheath Tumor\"],\n    \"measurementTechnique\": [\"conventional MRI\", \"RNA-seq\", \"cell viability assay\"],\n    \"species\": [\"Sus scrofa\", \"Homo sapiens\"],\n    \"individualCount\": 20,\n    \"specimenCount\": 21,\n    \"dataUseModifiers\": [\"General Research Use\"]\n  }\n]\n```"}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":5663,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":406}}}}
{"custom_id":"syn18904024","result":{"type":"succeeded","message":{"id":"msg_01AX2rfTMZWE9TGMRsqmesQu","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"# Dataset Metadata Creation\n\nBased on the provided information, I'll create high-quality dataset metadata that conforms to the specified JSON schema.\n\n```json\n[\n  {\n    \"title\": \"Optical Dopamine Monitoring with dLight1 in NF1 Model Mice\",\n    \"creator\": [\"J. Elliott Robinson\", \"Gerard M. Coughlin\", \"Acacia M. Hori\", \"Elisha D. Mackey\", \"Jounhong Ryan Cho\", \"Zeynep Turan\", \"Tommaso Patriarchi\", \"Lin Tian\", \"Viviana Gradinaru\"],\n    \"contributor\": [\"California Institute of Technology\", \"University of California, Davis\"],\n    \"description\": \"Dataset examining dopaminergic neurotransmission in the ventral striatum of NF1 mice during motivated behavior using dLight1 optical dopamine sensors. Includes behavioral assays, electrophysiology, immunofluorescence, and morphological analyses revealing reduced spontaneous dopaminergic neurotransmission and stimulus-dependent responses in NF1 mice.\",\n    \"keywords\": [\"dopamine\", \"neurofibromatosis type 1\", \"ventral striatum\", \"dLight1\", \"neurotransmission\", \"ventral tegmental area\", \"mouse model\"],\n    \"accessType\": \"Controlled Access\",\n    \"dataType\": [\"behavior process\", \"electrophysiology\", \"immunoassay\", \"proteomics\"],\n    \"measurementTechnique\": [\"contextual conditioning behavior assay\", \"in vivo bioluminescence\", \"whole-cell patch clamp\", \"immunofluorescence\", \"HPLC\", \"active avoidance learning behavior assay\", \"novelty response behavior assay\"],\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"CTF\", \"NIH-NCI\"],\n    \"license\": \"UNKNOWN\",\n    \"species\": [\"Mus musculus\"],\n    \"studyId\": \"syn18904024\",\n    \"subject\": [\"Neurodevelopmental disorders\", \"Dopaminergic pathways\", \"Neural circuits\", \"Behavioral neuroscience\"]\n  }\n]\n```\n\nThis metadata captures the key aspects of the dataset including:\n- Complete creator list from the author list\n- Appropriate disease focus, species, and measurement techniques from the enumerated lists\n- Descriptive keywords related to the research focus\n- Comprehensive data types based on the project information\n- Relevant subject terms for cataloging\n- Proper attribution of funding sources\n\nThe metadata complies with all required fields according to the JSON schema and uses only permitted values from the enumerated lists where applicable."}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":5913,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":623}}}}
{"custom_id":"syn22267284","result":{"type":"succeeded","message":{"id":"msg_01E8VhexDPvW18Bq6Hq3Gq8W","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"I'll create high-quality dataset metadata for these three tables based on the provided information, following the JSON schema requirements carefully.\n\n```json\n[\n  {\n    \"title\": \"20201125-ipNF0.23 and ipnF05.5 O-glycosylation\",\n    \"creator\": [\"Kevin Bruemmer\", \"Anh Nguyet Vu\"],\n    \"contributor\": [\"Stanford University\"],\n    \"accessType\": \"Controlled Access\",\n    \"description\": \"O-glycosylation profiling in ipNF0.23 and ipNF05.5 cells via mass spectrometry. This dataset contains O-glycan analysis for neurofibromatosis type 1 (NF1) cell lines.\",\n    \"measurementTechnique\": [\"mass spectrometry\"],\n    \"species\": [\"Homo sapiens\"],\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"CTF\"],\n    \"dataType\": [\"proteomics\"],\n    \"keywords\": [\"glycosylation\", \"O-glycan\", \"proteomics\", \"NF1\", \"Schwann cells\", \"post-translational modifications\"],\n    \"studyId\": \"syn22267284\",\n    \"specimenCount\": 2,\n    \"license\": \"UNKNOWN\"\n  },\n  {\n    \"title\": \"NF1 Proteomics\",\n    \"creator\": [\"Kevin Bruemmer\", \"Anh Nguyet Vu\"],\n    \"contributor\": [\"Stanford University\"],\n    \"accessType\": \"Controlled Access\",\n    \"description\": \"Mass spectrometry-based proteomics data for NF1 cell lines examining protein expression and post-translational modifications. Contains raw mass spectrometry files from various experimental conditions including azide-labeled treatments.\",\n    \"measurementTechnique\": [\"mass spectrometry\"],\n    \"species\": [\"Homo sapiens\"],\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"CTF\"],\n    \"dataType\": [\"proteomics\"],\n    \"keywords\": [\"proteomics\", \"mass spectrometry\", \"NF1\", \"post-translational modifications\", \"azide labeling\"],\n    \"studyId\": \"syn22267284\",\n    \"specimenCount\": 2,\n    \"license\": \"UNKNOWN\"\n  },\n  {\n    \"title\": \"Neurofibromin Immunoprecipitation 20201123\",\n    \"creator\": [\"Kevin Bruemmer\", \"Anh Nguyet Vu\"],\n    \"contributor\": [\"Stanford University\"],\n    \"accessType\": \"Controlled Access\",\n    \"description\": \"Immunoprecipitation and mass spectrometry analysis of neurofibromin protein and its interacting partners. Contains peptide and protein identification data from neurofibromin pulldown experiments.\",\n    \"measurementTechnique\": [\"mass spectrometry\"],\n    \"species\": [\"Homo sapiens\"],\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"CTF\"],\n    \"dataType\": [\"proteomics\"],\n    \"keywords\": [\"neurofibromin\", \"immunoprecipitation\", \"proteomics\", \"protein-protein interactions\", \"NF1\"],\n    \"studyId\": \"syn22267284\",\n    \"specimenCount\": 1,\n    \"license\": \"UNKNOWN\"\n  }\n]\n```"}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":6274,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":826}}}}
{"custom_id":"syn4939878","result":{"type":"succeeded","message":{"id":"msg_017rU4ieDXXWCvHpJCmPN4ZF","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"I'll create comprehensive metadata for the dataset according to the schema requirements. Let me analyze the information provided:\n\n```json\n[\n  {\n    \"title\": \"Pediatric Quality of Life Inventory NF1 Module Survey Data\",\n    \"creator\": [\n      \"Nancy Swigonski\",\n      \"Kavitha Nutakki\"\n    ],\n    \"contributor\": [\n      \"Sara Gosline\"\n    ],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\n      \"quality of life\",\n      \"patient reported outcomes\",\n      \"pediatric\",\n      \"PedsQL\",\n      \"survey\"\n    ],\n    \"dataType\": [\n      \"surveyData\",\n      \"clinical\"\n    ],\n    \"studyId\": \"syn4939878\",\n    \"diseaseFocus\": [\n      \"Neurofibromatosis type 1\"\n    ],\n    \"funder\": [\n      \"NTAP\"\n    ],\n    \"manifestation\": [\n      \"Plexiform Neurofibroma\",\n      \"Quality of Life\"\n    ],\n    \"measurementTechnique\": [\n      \"questionnaire\"\n    ],\n    \"species\": [\n      \"Homo sapiens\"\n    ],\n    \"description\": \"This dataset contains patient-reported outcome survey data collected using the Pediatric Quality of Life Inventory (PedsQL) NF1 Module. The survey measures health-related quality of life in pediatric patients with NF1 ages 5-25 and includes both child self-report and parent proxy-report versions.\",\n    \"dataUseModifiers\": [\n      \"Health or Medical or Biomedical Research\"\n    ],\n    \"subject\": [\n      \"Quality of Life Assessment\",\n      \"Pediatric Neurofibromatosis\",\n      \"Patient Reported Outcomes\"\n    ]\n  }\n]\n```\n\nThis metadata accurately captures the dataset based on the provided information. I've included all required fields plus appropriate optional fields:\n\n1. Completed all required fields (title, creator, accessType, license, keywords, dataType, studyId, diseaseFocus, funder)\n2. Added specific disease and manifestation information based on the project description\n3. Included relevant measurement techniques (questionnaire)\n4. Added appropriate keywords reflecting the patient-reported outcomes focus\n5. Created a concise but informative description that summarizes the dataset's content and purpose\n6. Selected appropriate dataUseModifiers aligned with health/medical research\n7. Included species information (Homo sapiens)\n8. Added subject terms aligned with the dataset's focus\n\nAll values for enum fields (accessType, license, dataType, diseaseFocus, funder, manifestation, measurementTechnique, species) were selected from the predefined lists in the schema."}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":6049,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":661}}}}
{"custom_id":"syn11681835","result":{"type":"succeeded","message":{"id":"msg_01DCo4AEVqM5apAfvPRLYYz7","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"I'll create high-quality dataset metadata for these tables according to the schema provided.\n\n```json\n[\n  {\n    \"title\": \"NF-OSI Processed RNA-Seq Quality Control Data\",\n    \"creator\": [\"NF Service\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"MPNST\", \"RNA-Seq\", \"FastQC\", \"quality control\", \"NF1\"],\n    \"dataType\": [\"geneExpression\"],\n    \"studyId\": \"syn11681835\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"Quality control results from NF-OSI processed RNA-Seq data from MPNST samples. Includes FastQC reports for the sequencing data.\",\n    \"dataUseModifiers\": [\"General Research Use\"],\n    \"manifestation\": [\"Malignant Peripheral Nerve Sheath Tumor (MPNST)\"],\n    \"measurementTechnique\": [\"RNA-seq\"],\n    \"species\": [\"Homo sapiens\"],\n    \"contributor\": [\"Ping Chi\"],\n    \"series\": \"NF-OSI Processed Data\",\n    \"yearProcessed\": 2023\n  },\n  {\n    \"title\": \"RNA-Seq Data from MPNST Samples for NF-OSI Processing\",\n    \"creator\": [\"Christina Parry\", \"Ping Chi\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"MPNST\", \"RNA-Seq\", \"single-cell RNA-seq\", \"NF1\", \"transcriptomics\"],\n    \"dataType\": [\"geneExpression\"],\n    \"studyId\": \"syn11681835\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"Raw RNA sequencing data from 41 Malignant Peripheral Nerve Sheath Tumor (MPNST) samples submitted for NF-OSI processing. Includes both bulk RNA-seq and single-cell RNA-seq data.\",\n    \"individualCount\": 41,\n    \"specimenCount\": 41,\n    \"dataUseModifiers\": [\"General Research Use\"],\n    \"manifestation\": [\"Malignant Peripheral Nerve Sheath Tumor (MPNST)\"],\n    \"measurementTechnique\": [\"RNA-seq\", \"single-cell RNA-seq\"],\n    \"species\": [\"Homo sapiens\"],\n    \"contributor\": [\"Ping Chi\", \"Memorial Sloan Kettering Cancer Center\"]\n  }\n]\n```"}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":7165,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":649}}}}
{"custom_id":"syn26238842","result":{"type":"succeeded","message":{"id":"msg_01SemZyYVagh5iL2BSVRbCaG","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"I'll create high-quality dataset metadata for the table in this project according to the JSON schema provided.\n\n```json\n[\n  {\n    \"title\": \"Trial Run HscWT and Hsc45 Proteomics\",\n    \"creator\": [\"Maria C. Franco\", \"Isabelle E. Logan\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"proteomics\", \"phosphoproteomics\", \"NF2\", \"Hsp90\", \"schwannoma\"],\n    \"dataType\": [\"proteomics\"],\n    \"studyId\": \"syn26238842\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"CTF\"],\n    \"description\": \"Proteomics and phosphoproteomics data from experiments investigating the role of heat shock protein 90 (Hsp90) in NF2 schwannoma cells. Part of research examining how tyrosine nitrated proteins support tumor cell survival in neurofibromatosis.\",\n    \"contributor\": [\"Oregon State University\", \"University of Central Florida\"],\n    \"measurementTechnique\": [\"mass spectrometry\"],\n    \"species\": [\"Homo sapiens\"],\n    \"manifestation\": [\"Schwannoma\"],\n    \"dataUseModifiers\": [\"General Research Use\"],\n    \"subject\": [\"Neurofibromatosis\", \"Proteomics\", \"Cancer biology\", \"Heat shock proteins\"]\n  }\n]\n```"}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":5877,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":352}}}}
{"custom_id":"syn11374354","result":{"type":"succeeded","message":{"id":"msg_01PnQCxfVW7m7r4R4emo3DG3","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"I'll create high-quality dataset metadata for each of the 8 tables according to the JSON schema requirements.\n\n```json\n[\n  {\n    \"title\": \"Cutaneous Neurofibroma Immunohistochemistry - 12 months deliverable\",\n    \"creator\": [\"Alice Soragni\"],\n    \"description\": \"Immunohistochemistry images from cutaneous neurofibroma specimens including staining for markers such as S100, CD34, and CD56 at different magnifications (20X, 40X).\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"cutaneous neurofibroma\", \"immunohistochemistry\", \"S100\", \"CD34\", \"CD56\", \"microscopy\"],\n    \"dataType\": [\"image\"],\n    \"studyId\": \"syn11374354\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"dataUseModifiers\": [\"General Research Use\"],\n    \"individualCount\": 9,\n    \"specimenCount\": 76,\n    \"species\": [\"Homo sapiens\"],\n    \"manifestation\": [\"Cutaneous Neurofibroma\"],\n    \"measurementTechnique\": [\"immunohistochemistry\"]\n  },\n  {\n    \"title\": \"Cutaneous Neurofibroma Immunohistochemistry Protocols - 6 month deliverables\",\n    \"creator\": [\"Alice Soragni\"],\n    \"description\": \"Protocols and documentation for immunohistochemistry staining of cutaneous neurofibroma samples, including methods for CD56, SOX10, SOX2, NGFR, and S100 markers.\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"cutaneous neurofibroma\", \"immunohistochemistry\", \"protocol\", \"staining\", \"S100\", \"CD56\", \"SOX10\", \"SOX2\", \"NGFR\"],\n    \"dataType\": [\"image\"],\n    \"studyId\": \"syn11374354\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"dataUseModifiers\": [\"General Research Use\"],\n    \"individualCount\": 1,\n    \"specimenCount\": 2,\n    \"species\": [\"Homo sapiens\"],\n    \"manifestation\": [\"Cutaneous Neurofibroma\"],\n    \"measurementTechnique\": [\"immunohistochemistry\"]\n  },\n  {\n    \"title\": \"Aligned reads from RNA-seq of cutaneous neurofibroma organoid model\",\n    \"creator\": [\"Alice Soragni\"],\n    \"description\": \"Aligned BAM files from RNA-sequencing of cutaneous neurofibroma organoid models, including corresponding index files (.bai).\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"cutaneous neurofibroma\", \"RNA-seq\", \"organoid\", \"aligned reads\", \"BAM\"],\n    \"dataType\": [\"AlignedReads\", \"dataIndex\"],\n    \"studyId\": \"syn11374354\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"dataUseModifiers\": [\"General Research Use\"],\n    \"individualCount\": 5,\n    \"specimenCount\": 54,\n    \"species\": [\"Homo sapiens\"],\n    \"manifestation\": [\"Cutaneous Neurofibroma\"],\n    \"measurementTechnique\": [\"RNA-seq\"]\n  },\n  {\n    \"title\": \"Gene expression quantification of cutaneous neurofibroma organoid model\",\n    \"creator\": [\"Alice Soragni\"],\n    \"description\": \"Quantified gene expression data derived from RNA-sequencing of cutaneous neurofibroma organoid models in Salmon format (.sf files).\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"cutaneous neurofibroma\", \"RNA-seq\", \"organoid\", \"gene expression\", \"quantification\", \"Salmon\"],\n    \"dataType\": [\"geneExpression\"],\n    \"studyId\": \"syn11374354\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"dataUseModifiers\": [\"General Research Use\"],\n    \"individualCount\": 5,\n    \"specimenCount\": 55,\n    \"species\": [\"Homo sapiens\"],\n    \"manifestation\": [\"Cutaneous Neurofibroma\"],\n    \"measurementTechnique\": [\"RNA-seq\"]\n  },\n  {\n    \"title\": \"NF Organoid Bisulfite-seq\",\n    \"creator\": [\"Alice Soragni\"],\n    \"description\": \"Reduced representation bisulfite sequencing (RRBS) data from cutaneous neurofibroma organoid models to assess DNA methylation patterns.\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"cutaneous neurofibroma\", \"organoid\", \"bisulfite sequencing\", \"DNA methylation\", \"epigenetics\"],\n    \"dataType\": [\"chromatinActivity\"],\n    \"studyId\": \"syn11374354\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"dataUseModifiers\": [\"General Research Use\"],\n    \"individualCount\": 5,\n    \"specimenCount\": 55,\n    \"species\": [\"Homo sapiens\"],\n    \"manifestation\": [\"Cutaneous Neurofibroma\"],\n    \"measurementTechnique\": [\"bisulfite sequencing\"]\n  },\n  {\n    \"title\": \"NF Organoid RNA-seq\",\n    \"creator\": [\"Alice Soragni\"],\n    \"description\": \"Raw RNA sequencing data (FASTQ files) from cutaneous neurofibroma organoid models to characterize gene expression profiles.\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"cutaneous neurofibroma\", \"RNA-seq\", \"organoid\", \"transcriptomics\", \"gene expression\"],\n    \"dataType\": [\"geneExpression\"],\n    \"studyId\": \"syn11374354\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"dataUseModifiers\": [\"General Research Use\"],\n    \"individualCount\": 5,\n    \"specimenCount\": 57,\n    \"species\": [\"Homo sapiens\"],\n    \"manifestation\": [\"Cutaneous Neurofibroma\"],\n    \"measurementTechnique\": [\"RNA-seq\"]\n  },\n  {\n    \"title\": \"NFOSI-RNASeq-To-Process-2023-14-03\",\n    \"creator\": [\"Alice Soragni\"],\n    \"description\": \"Raw RNA sequencing data (FASTQ files) from cutaneous neurofibroma organoid models scheduled for processing on March 14, 2023.\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"cutaneous neurofibroma\", \"RNA-seq\", \"organoid\", \"transcriptomics\", \"gene expression\"],\n    \"dataType\": [\"geneExpression\"],\n    \"studyId\": \"syn11374354\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"dataUseModifiers\": [\"General Research Use\"],\n    \"individualCount\": 5,\n    \"specimenCount\": 57,\n    \"species\": [\"Homo sapiens\"],\n    \"manifestation\": [\"Cutaneous Neurofibroma\"],\n    \"measurementTechnique\": [\"RNA-seq\"]\n  },\n  {\n    \"title\": \"RNASeq - Failed QC\",\n    \"creator\": [\"Alice Soragni\", \"Sara Gosline\"],\n    \"description\": \"RNA sequencing data from cutaneous neurofibroma samples that did not pass quality control standards. Contains both raw FASTQ files and Salmon quantification files.\",\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"cutaneous neurofibroma\", \"RNA-seq\", \"failed QC\", \"quality control\", \"gene expression\"],\n    \"dataType\": [\"geneExpression\"],\n    \"studyId\": \"syn11374354\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"dataUseModifiers\": [\"General Research Use\"],\n    \"individualCount\": 2,\n    \"specimenCount\": 6,\n    \"species\": [\"Homo sapiens\"],\n    \"manifestation\": [\"Cutaneous Neurofibroma\"],\n    \"measurementTechnique\": [\"RNA-seq\"]\n  }\n]\n```"}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":7686,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":2186}}}}
{"custom_id":"syn28545963","result":{"type":"succeeded","message":{"id":"msg_01FNsjqQsFuXFBVQjUnndeXM","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"I'll create high-quality dataset metadata for the two tables from the Schwannomatosis Open Research Collaborative (SORC) project according to the JSON schema provided.\n\n```json\n[\n  {\n    \"title\": \"Viral Counts (CTAT-VIF)\",\n    \"creator\": [\"Robert Allaway\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"schwannomatosis\", \"viral detection\", \"tumor samples\", \"CTAT-VIF\"],\n    \"dataType\": [\"genomicFeatures\"],\n    \"studyId\": \"syn28545963\",\n    \"diseaseFocus\": [\"Schwannomatosis-NOS\"],\n    \"funder\": [\"CTF\"],\n    \"description\": \"Viral read count data generated using the CTAT-VIF (Comprehensive Transcriptome Analysis Toolkit-Virus Integration Finder) pipeline, which detects potential viral DNA signatures in schwannomatosis tumor samples.\",\n    \"measurementTechnique\": [\"RNA-seq\"],\n    \"species\": [\"Homo sapiens\"],\n    \"subject\": [\"Schwannomatosis\", \"Viral genomics\", \"Tumor samples\", \"Virus detection\"],\n    \"contributor\": [\"Schwannomatosis Open Research Collaborative\"],\n    \"datePublished\": 2022,\n    \"manifestation\": [\"Schwannoma\"]\n  },\n  {\n    \"title\": \"Whole Exome Sequencing Data (WES)\",\n    \"creator\": [\"Schwannomatosis Open Research Collaborative\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"schwannomatosis\", \"exome sequencing\", \"genomic variants\", \"tumor analysis\"],\n    \"dataType\": [\"genomicVariants\", \"SomaticVariants\", \"GermlineVariants\"],\n    \"studyId\": \"syn28545963\",\n    \"diseaseFocus\": [\"SMARCB1-related schwannomatosis\", \"LZTR1-related schwannomatosis\", \"22q-related schwannomatosis\", \"Schwannomatosis-NOS\", \"NF2-related schwannomatosis\"],\n    \"funder\": [\"CTF\"],\n    \"description\": \"Whole exome sequencing data from schwannomatosis patients, reprocessed using standardized nf-core pipelines. This dataset contains genomic variant information that may help identify coding variants contributing to disease etiology and heterogeneity in schwannomatosis.\",\n    \"measurementTechnique\": [\"whole exome sequencing\"],\n    \"species\": [\"Homo sapiens\"],\n    \"subject\": [\"Schwannomatosis\", \"Genomics\", \"Exome sequencing\", \"Rare genetic disorders\"],\n    \"contributor\": [\"Synodos for Schwannomatosis initiative\"]\n  }\n]\n```"}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":7072,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":666}}}}
{"custom_id":"syn4939892","result":{"type":"succeeded","message":{"id":"msg_01JsJzrpuzmD14Kv5bgsZ1JV","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"I'll create high-quality dataset metadata for this table that conforms to the JSON schema. Let me analyze the information provided.\n\n```json\n[\n  {\n    \"title\": \"Gene Expression for Identification of Neurofibroma Growth and Drug Resistance Pathways\",\n    \"creator\": [\"Nancy Ratner\"],\n    \"contributor\": [\"Kwangmn Choi\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"RNA-seq\", \"Gene Expression\", \"Neurofibroma\", \"Drug Resistance\", \"PD0325901\", \"MEK inhibitor\"],\n    \"dataType\": [\"geneExpression\", \"raw counts\"],\n    \"description\": \"RNA-seq gene expression data from mouse models comparing neurofibroma growth rates and response/resistance to MEK inhibitor therapy (PD0325901). This dataset includes differential expression analysis outputs from multiple tools (DESeq2, edgeR, Voom) comparing control vs. treated samples and responders vs. non-responders.\",\n    \"studyId\": \"syn4939892\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"measurementTechnique\": [\"RNA-seq\"],\n    \"manifestation\": [\"Plexiform Neurofibroma\"],\n    \"species\": [\"Mus musculus\"],\n    \"individualCount\": 2,\n    \"specimenCount\": 2,\n    \"subject\": [\"Neurofibromatosis\", \"Drug resistance\", \"Gene expression profiling\", \"Tumor biomarkers\"]\n  }\n]\n```"}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":6247,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":388}}}}
{"custom_id":"syn51133946","result":{"type":"succeeded","message":{"id":"msg_01EdbqydX24HCvnPAA2Nj1Xf","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"I'll create the metadata for the DHART SPORE Project 3 Phase 1 dataset. Here's the properly formatted JSON:\n\n```json\n[\n  {\n    \"title\": \"ADVL1521 Omic Data Repository\",\n    \"creator\": [\"Kevin Shannon\", \"Mignon Loh\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"juvenile myelomonocytic leukemia\", \"JMML\", \"MEK inhibitor\", \"trametinib\", \"single-cell RNA-seq\"],\n    \"dataType\": [\"geneExpression\"],\n    \"studyId\": \"syn51133946\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NIH-NCI\"],\n    \"description\": \"Single-cell RNA sequencing data from the ADVL1521 clinical trial evaluating the MEK inhibitor trametinib in children with juvenile myelomonocytic leukemia (JMML). Data includes pre- and post-treatment samples.\",\n    \"measurementTechnique\": [\"single-cell RNA-seq\"],\n    \"species\": [\"Homo sapiens\"],\n    \"individualCount\": 7,\n    \"specimenCount\": 14,\n    \"manifestation\": [\"Juvenile Myelomonocytic Leukemia (JMML)\"],\n    \"contributor\": [\"University of California, San Francisco\"],\n    \"subject\": [\"Juvenile myelomonocytic leukemia\", \"Ras signaling\", \"MEK inhibition\", \"Trametinib\"],\n    \"dataUseModifiers\": [\"Health or Medical or Biomedical Research\"]\n  }\n]\n```"}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":6000,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":413}}}}
{"custom_id":"syn4939918","result":{"type":"succeeded","message":{"id":"msg_01LwMpLS4ikAnrX1hdaRk3E5","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"I'll create high-quality dataset metadata for the tables in this project. Based on the information provided, I'll ensure all fields conform to the schema requirements.\n\n```json\n[\n  {\n    \"title\": \"Gene Expression Quantification from RNA-seq\",\n    \"creator\": [\"Edu Serra\", \"NF Service\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"RNA-seq\", \"gene expression\", \"iPSC\", \"plexiform neurofibroma\", \"NF1\", \"quantification\"],\n    \"dataType\": [\"geneExpression\"],\n    \"studyId\": \"syn4939918\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"Gene expression quantification data derived from RNA-seq analysis of NF1(+/-) and NF1(-/-) induced pluripotent stem cells (iPSCs). These cells were generated from plexiform neurofibroma samples to study cell differentiation and lineage commitment.\",\n    \"specimenCount\": 27,\n    \"individualCount\": 4,\n    \"species\": [\"Homo sapiens\"],\n    \"manifestation\": [\"Plexiform Neurofibroma\"],\n    \"dataUseModifiers\": [\"General Research Use\"]\n  },\n  {\n    \"title\": \"Methylation Array Data from PNF-derived iPSCs\",\n    \"creator\": [\"Edu Serra\", \"Bernat Gel Moreno\", \"Kaitlin Throgmorton\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"methylation\", \"epigenetics\", \"iPSC\", \"plexiform neurofibroma\", \"NF1\", \"chromatin activity\"],\n    \"dataType\": [\"chromatinActivity\"],\n    \"studyId\": \"syn4939918\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"Methylation array data from plexiform neurofibroma-derived induced pluripotent stem cells (iPSCs) with varying NF1 genotypes. Part of a study characterizing the methylome of cells in the Neural Crest-Schwann cell lineage.\",\n    \"measurementTechnique\": [\"methylation array\"],\n    \"species\": [\"Homo sapiens\"],\n    \"manifestation\": [\"Plexiform Neurofibroma\"],\n    \"dataUseModifiers\": [\"General Research Use\"]\n  },\n  {\n    \"title\": \"NFOSI-RNASeq Raw Data for Processing\",\n    \"creator\": [\"Edu Serra\", \"Bernat Gel Moreno\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"RNA-seq\", \"raw data\", \"iPSC\", \"plexiform neurofibroma\", \"NF1\", \"neural crest\"],\n    \"dataType\": [\"geneExpression\"],\n    \"studyId\": \"syn4939918\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"Raw RNA-Seq data (FASTQ files) from NF1(+/-) and NF1(-/-) induced pluripotent stem cells (iPSCs) derived from plexiform neurofibroma samples. This dataset contains raw sequencing files prepared for processing.\",\n    \"specimenCount\": 27,\n    \"individualCount\": 4,\n    \"species\": [\"Homo sapiens\"],\n    \"manifestation\": [\"Plexiform Neurofibroma\"],\n    \"dataUseModifiers\": [\"General Research Use\"]\n  },\n  {\n    \"title\": \"RNA-seq Data from PNF-derived iPSCs\",\n    \"creator\": [\"Edu Serra\", \"Bernat Gel Moreno\", \"Christina Parry\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"RNA-seq\", \"transcriptome\", \"iPSC\", \"plexiform neurofibroma\", \"NF1\", \"neural crest\"],\n    \"dataType\": [\"geneExpression\"],\n    \"studyId\": \"syn4939918\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"RNA-seq data from plexiform neurofibroma-derived induced pluripotent stem cells (iPSCs) with varying NF1 genotypes. Part of a study characterizing the transcriptome of cells in the Neural Crest-Schwann cell lineage.\",\n    \"measurementTechnique\": [\"RNA-seq\"],\n    \"specimenCount\": 27,\n    \"individualCount\": 4,\n    \"species\": [\"Homo sapiens\"],\n    \"manifestation\": [\"Plexiform Neurofibroma\"],\n    \"dataUseModifiers\": [\"General Research Use\"]\n  },\n  {\n    \"title\": \"SNP Array Data from PNF-derived iPSCs\",\n    \"creator\": [\"Edu Serra\", \"Bernat Gel Moreno\", \"Kaitlin Throgmorton\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"SNP array\", \"genomic variants\", \"iPSC\", \"plexiform neurofibroma\", \"NF1\", \"genetic characterization\"],\n    \"dataType\": [\"genomicVariants\"],\n    \"studyId\": \"syn4939918\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"SNP array data from plexiform neurofibroma-derived induced pluripotent stem cells (iPSCs) with varying NF1 genotypes. Part of a study characterizing the genomic profile of cells in the Neural Crest-Schwann cell lineage.\",\n    \"measurementTechnique\": [\"SNP array\"],\n    \"species\": [\"Homo sapiens\"],\n    \"manifestation\": [\"Plexiform Neurofibroma\"],\n    \"dataUseModifiers\": [\"General Research Use\"]\n  }\n]\n```"}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":6862,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":1513}}}}
{"custom_id":"syn7239560","result":{"type":"succeeded","message":{"id":"msg_01N9L3GV9X5ypma3p3G7edGF","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"I'll create metadata for this table based on the provided information and conforming to the JSON schema.\n\n```json\n[\n  {\n    \"title\": \"Compound Annotations from Evotec Drug Target Research\",\n    \"creator\": [\"Tim James\", \"Robert Allaway\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"drug discovery\", \"compound structures\", \"compound annotations\", \"drug targets\", \"chemical properties\"],\n    \"dataType\": [\"drugScreen\", \"network\"],\n    \"studyId\": \"syn7239560\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"CTF\"],\n    \"description\": \"This dataset contains compound annotations from the Evotec Drug-Target discovery research, including supplier-provided structures and unique structure properties. The data includes structure files, chemical properties, and activity information for compounds being investigated as potential drug targets.\",\n    \"contributor\": [\"Evotec\"],\n    \"datePublished\": 2022,\n    \"dataUseModifiers\": [\"General Research Use\"],\n    \"includedInDataCatalog\": \"https://www.synapse.org/DataCatalog:0\"\n  }\n]\n```"}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":5435,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":291}}}}
{"custom_id":"syn4939906","result":{"type":"succeeded","message":{"id":"msg_018tWSGBC4dSMQW7rkbkuWdC","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"I'll create high-quality dataset metadata for these three tables according to the schema provided.\n\n```json\n[\n  {\n    \"title\": \"10x10 Combination Screens of pNF Cell Lines\",\n    \"creator\": [\"Marc Ferrer\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"plexiform neurofibroma\", \"drug combination\", \"cell viability\", \"synergy\", \"screening\"],\n    \"dataType\": [\"drugCombinationScreen\"],\n    \"studyId\": \"syn4939906\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"This dataset contains results from 10x10 drug combination screens performed on plexiform neurofibroma cell lines. The screens tested synergistic effects of prioritized compound combinations identified from previous 6x6 screens, with the goal of identifying optimal therapeutic combinations for plexiform neurofibromas.\",\n    \"species\": [\"Homo sapiens\"],\n    \"individualCount\": 4,\n    \"specimenCount\": 4,\n    \"measurementTechnique\": [\"cell viability assay\"],\n    \"manifestation\": [\"Plexiform Neurofibroma\"],\n    \"contributor\": [\"NCATS\"],\n    \"subject\": [\"Drug screening\", \"Neurofibromatosis\", \"Drug combinations\", \"Cell culture\"],\n    \"dataUseModifiers\": [\"Health or Medical or Biomedical Research\"]\n  },\n  {\n    \"title\": \"6x6 Combination Screens of pNF Cell Lines\",\n    \"creator\": [\"Marc Ferrer\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"plexiform neurofibroma\", \"drug combination\", \"cell viability\", \"synergy\", \"screening\"],\n    \"dataType\": [\"drugCombinationScreen\"],\n    \"studyId\": \"syn4939906\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"This dataset contains results from 6x6 drug combination screens of plexiform neurofibroma cell lines. The screens tested 780 combinations of the top 40 compounds identified from initial single agent screening, with the goal of identifying synergistic drug combinations for further investigation.\",\n    \"species\": [\"Homo sapiens\"],\n    \"individualCount\": 6,\n    \"specimenCount\": 6,\n    \"measurementTechnique\": [\"cell viability assay\"],\n    \"manifestation\": [\"Plexiform Neurofibroma\"],\n    \"contributor\": [\"NCATS\"],\n    \"subject\": [\"Drug screening\", \"Neurofibromatosis\", \"Drug combinations\", \"Cell culture\"],\n    \"dataUseModifiers\": [\"Health or Medical or Biomedical Research\"]\n  },\n  {\n    \"title\": \"Single Agent Screens of pNF Cell Lines\",\n    \"creator\": [\"Marc Ferrer\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"plexiform neurofibroma\", \"MIPE library\", \"cell viability\", \"drug screening\", \"NF1\"],\n    \"dataType\": [\"drugScreen\"],\n    \"studyId\": \"syn4939906\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"This dataset contains results from single agent screens of the MIPE 4.0 library of approximately 1912 small molecules against 9 different cell lines (5 NF1 nullizygous, 1 carrier, 2 normal, and 1 control). The data includes single agent viability results for each cell line to identify top hits with highest potency and efficacy.\",\n    \"species\": [\"Homo sapiens\", \"Mus musculus\"],\n    \"individualCount\": 11,\n    \"specimenCount\": 11,\n    \"measurementTechnique\": [\"cell viability assay\"],\n    \"manifestation\": [\"Plexiform Neurofibroma\"],\n    \"contributor\": [\"NCATS\"],\n    \"subject\": [\"Drug screening\", \"Neurofibromatosis\", \"Cell culture\"],\n    \"dataUseModifiers\": [\"Health or Medical or Biomedical Research\"]\n  }\n]\n```"}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":6629,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":1055}}}}
{"custom_id":"syn53185180","result":{"type":"succeeded","message":{"id":"msg_01VVotp2ehpCXd8JvRcL54Cc","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"I'll create high-quality dataset metadata for the table in this project following the JSON schema.\n\n```json\n[\n  {\n    \"title\": \"Colony Forming Assays for NF1 MPNST Cell Lines\",\n    \"creator\": [\"Raymond Mattingly\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"MPNST\", \"colony formation\", \"FTI\", \"lovastatin\", \"NF1\", \"cell proliferation\", \"drug combination\"],\n    \"dataType\": [\"cellularPhysiology\"],\n    \"studyId\": \"syn53185180\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"GFF\"],\n    \"description\": \"Colony formation assay data from NF1 MPNST cell lines treated with farnesyltransferase inhibitors (FTI) and lovastatin combinations. This dataset includes assay results from multiple cell lines including S462TY, rat Schwann cells, and ST88-14.\",\n    \"manifestation\": [\"Malignant Peripheral Nerve Sheath Tumor (MPNST)\"],\n    \"measurementTechnique\": [\"cell proliferation\"],\n    \"species\": [\"Homo sapiens\", \"Rattus norvegicus\"],\n    \"contributor\": [\"Robert Allaway\"],\n    \"subject\": [\"NF1 MPNST\", \"drug screening\", \"RAS pathway inhibition\", \"cancer therapeutic approaches\"]\n  }\n]\n```"}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":5599,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":361}}}}
{"custom_id":"syn20608511","result":{"type":"succeeded","message":{"id":"msg_01MDJqXpSY6XMJESBiecjRF7","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"I'll create high-quality metadata for the Whole Body MRI of NF Patients dataset according to the schema requirements.\n\n```json\n[\n  {\n    \"title\": \"Whole Body MRI of NF Patients\",\n    \"creator\": [\"Wenli Cai\", \"Gordon Harris\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"MRI\", \"Neurofibromatosis\", \"Whole-body imaging\", \"STIR\", \"T1\"],\n    \"dataType\": [\"image\"],\n    \"studyId\": \"syn20608511\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\", \"NF2-related schwannomatosis\", \"Multiple\"],\n    \"funder\": [\"CTF\"],\n    \"contributor\": [\"Robert Allaway\", \"Jineta Banerjee\"],\n    \"description\": \"Whole-body MRI data from 48 NF1, NF2, and schwannomatosis patients, including STIR and T1 modalities. Dataset includes 96 image stacks (two per patient) and associated clinical metadata about tumor burden and location, supporting research on tumor characterization and disease progression.\",\n    \"measurementTechnique\": [\"conventional MRI\"],\n    \"species\": [\"Homo sapiens\"],\n    \"individualCount\": 48,\n    \"specimenCount\": 48,\n    \"subject\": [\"Neurofibromatosis\", \"Diagnostic imaging\", \"Tumor burden\", \"Magnetic resonance imaging\"]\n  }\n]\n```"}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":5799,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":370}}}}
{"custom_id":"syn51133914","result":{"type":"succeeded","message":{"id":"msg_01H7vAG4EuQFHjUrttEpKzPN","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"I'll create high-quality dataset metadata for the two tables according to the JSON schema. Here's the valid JSON output:\n\n```json\n[\n  {\n    \"title\": \"Histopathology - Human PN, ANNUBP and MPNST Specimens\",\n    \"creator\": [\"D. Wade Clapp\", \"Jaishri Blakeley\", \"Brigitte Widemann\", \"Lu Le\"],\n    \"contributor\": [\"Steven Rhodes\", \"Andrew Horvai\", \"Elliot Stieglitz\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"histopathology\", \"plexiform neurofibroma\", \"ANNUBP\", \"MPNST\", \"microscopy\", \"tumor specimens\"],\n    \"dataType\": [\"image\"],\n    \"studyId\": \"syn51133914\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NIH-NCI\"],\n    \"description\": \"This dataset contains histopathology images of human plexiform neurofibroma (PN), aneurysmal bone cyst (ANNUBP), and malignant peripheral nerve sheath tumor (MPNST) specimens from NF1 patients. Data includes brightfield microscopy images in SVS format with accompanying metadata.\",\n    \"individualCount\": 30,\n    \"specimenCount\": 61,\n    \"species\": [\"Homo sapiens\"],\n    \"manifestation\": [\"Plexiform Neurofibroma\", \"Malignant Peripheral Nerve Sheath Tumor\", \"Aneurysmal Bone Cyst (ANNUBP)\"],\n    \"measurementTechnique\": [\"brightfield microscopy\"],\n    \"dataUseModifiers\": [\"General Research Use\"],\n    \"subject\": [\"Neurofibromatosis\", \"Histopathology\", \"Tumor specimens\", \"Medical imaging\"]\n  },\n  {\n    \"title\": \"Van Andel - Kinome\",\n    \"creator\": [\"D. Wade Clapp\", \"Jaishri Blakeley\", \"Brigitte Widemann\", \"Lu Le\"],\n    \"contributor\": [\"Steven Angus\", \"Sara Gosline\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"kinome\", \"proteomics\", \"NF1\", \"kinase activity\"],\n    \"dataType\": [\"kinomics\"],\n    \"studyId\": \"syn51133914\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NIH-NCI\"],\n    \"description\": \"This dataset contains kinome profiling data collected from NF1 specimens as part of the DHART SPORE Project 1. The dataset includes kinome analysis results stored in Excel spreadsheets and CSV files, characterizing kinase activity patterns in NF1-associated tumors.\",\n    \"individualCount\": 16,\n    \"dataUseModifiers\": [\"General Research Use\"],\n    \"subject\": [\"Neurofibromatosis\", \"Kinome profiling\", \"Proteomics\", \"Signal transduction\"]\n  }\n]\n```"}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":6195,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":760}}}}
{"custom_id":"syn22268639","result":{"type":"succeeded","message":{"id":"msg_01XcyRPpkWrnaoBpigAwycx1","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"I'll create the high-quality dataset metadata for this table according to the specified JSON schema.\n\n```json\n[\n  {\n    \"title\": \"P2RY14 and NF1\",\n    \"creator\": [\"Jennifer Patritti Cram\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"P2RY14\", \"NF1\", \"purinergic signaling\", \"neurofibroma\", \"western blot\"],\n    \"dataType\": [\"immunoassay\"],\n    \"studyId\": \"syn22268639\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"CTF\"],\n    \"description\": \"Western blot data examining the role of purinergic signaling via P2RY14 receptor on tumor formation in a mouse model of Neurofibromatosis Type 1. Includes protein expression data from neurofibroma tissues and signaling pathway analysis.\",\n    \"species\": [\"Homo sapiens\", \"Mus musculus\"],\n    \"contributor\": [\"Cincinnati Medical Center\"],\n    \"measurementTechnique\": [\"western blot\"],\n    \"manifestation\": [\"Plexiform Neurofibroma\"],\n    \"dataUseModifiers\": [\"General Research Use\"],\n    \"subject\": [\"Neurofibromatosis\", \"Purinerigic signaling\", \"Tumor formation\", \"P2RY14 receptor\"]\n  }\n]\n```"}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":6822,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":353}}}}
{"custom_id":"syn32128792","result":{"type":"succeeded","message":{"id":"msg_01RB5KMopJ4r7LrFKstsPCHG","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"I'll create high-quality dataset metadata for these three tables following the schema requirements.\n\n```json\n[\n  {\n    \"title\": \"MPNST EGA Raw RNA-Seq Data\",\n    \"creator\": [\"David Miller\", \"Katherine Piculell\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"MPNST\", \"NF1\", \"RNA-seq\", \"fastq\", \"GeM Consortium\"],\n    \"dataType\": [\"geneExpression\"],\n    \"studyId\": \"syn32128792\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\", \"Multiple\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"Raw RNA sequencing data (fastq files) from the Genomics of MPNST (GeM) Consortium multi-omic study of malignant peripheral nerve sheath tumors. Data includes samples from 79 individuals, including both NF1-related and sporadic MPNST cases. Data must be accessed through EGA.\",\n    \"contributor\": [\"NFRI - Genomics of MPNST (GeM) Consortium\", \"Boston Children's Hospital\"],\n    \"individualCount\": 79,\n    \"specimenCount\": 139,\n    \"manifestation\": [\"Malignant Peripheral Nerve Sheath Tumor (MPNST)\"],\n    \"measurementTechnique\": [\"RNA-seq\"],\n    \"species\": [\"Homo sapiens\"],\n    \"conditionsOfAccess\": \"Data must be requested and accessed through the European Genome-phenome Archive (EGA), dataset EGAD00001008608.\",\n    \"visualizeDataOn\": [\"https://ega-archive.org/datasets/EGAD00001008608/\"]\n  },\n  {\n    \"title\": \"MPNST RNA-Seq Gene Quantifications\",\n    \"creator\": [\"David Miller\", \"Katherine Piculell\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"MPNST\", \"NF1\", \"RNA-seq\", \"gene quantification\", \"GeM Consortium\"],\n    \"dataType\": [\"geneExpression\"],\n    \"studyId\": \"syn32128792\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\", \"Multiple\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"Processed gene-level quantifications (quant.genes.sf files) from RNA-seq data of the Genomics of MPNST (GeM) Consortium study. These are gene-level transcript abundance estimates from 139 specimens across 79 individuals, including NF1-related and sporadic MPNST samples. Data must be accessed through EGA.\",\n    \"contributor\": [\"NFRI - Genomics of MPNST (GeM) Consortium\", \"Boston Children's Hospital\"],\n    \"individualCount\": 79,\n    \"specimenCount\": 139,\n    \"manifestation\": [\"Malignant Peripheral Nerve Sheath Tumor (MPNST)\"],\n    \"measurementTechnique\": [\"RNA-seq\"],\n    \"species\": [\"Homo sapiens\"],\n    \"conditionsOfAccess\": \"Data must be requested and accessed through the European Genome-phenome Archive (EGA), dataset EGAD00001008608.\",\n    \"visualizeDataOn\": [\"https://ega-archive.org/datasets/EGAD00001008608/\"]\n  },\n  {\n    \"title\": \"MPNST RNA-Seq Transcript Quantifications\",\n    \"creator\": [\"David Miller\", \"Katherine Piculell\", \"Robert Allaway\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"MPNST\", \"NF1\", \"RNA-seq\", \"transcript quantification\", \"GeM Consortium\"],\n    \"dataType\": [\"geneExpression\"],\n    \"studyId\": \"syn32128792\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\", \"Multiple\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"Processed transcript-level quantifications (quant.sf files) from RNA-seq data of the Genomics of MPNST (GeM) Consortium study. These are transcript-level abundance estimates from 139 specimens across 79 individuals, including NF1-related and sporadic MPNST samples. Data must be accessed through EGA.\",\n    \"contributor\": [\"NFRI - Genomics of MPNST (GeM) Consortium\", \"Boston Children's Hospital\"],\n    \"individualCount\": 79,\n    \"specimenCount\": 139,\n    \"manifestation\": [\"Malignant Peripheral Nerve Sheath Tumor (MPNST)\"],\n    \"measurementTechnique\": [\"RNA-seq\"],\n    \"species\": [\"Homo sapiens\"],\n    \"conditionsOfAccess\": \"Data must be requested and accessed through the European Genome-phenome Archive (EGA), dataset EGAD00001008608.\",\n    \"visualizeDataOn\": [\"https://ega-archive.org/datasets/EGAD00001008608/\"]\n  }\n]\n```"}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":6039,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":1256}}}}
{"custom_id":"syn22268689","result":{"type":"succeeded","message":{"id":"msg_01DGQUx2gNTRE2gqPQvAJpAj","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"I'll create high-quality dataset metadata for the two tables in this project, following the schema requirements carefully.\n\n```json\n[\n  {\n    \"title\": \"Proteomics characterization of LZTR1 function\",\n    \"creator\": [\"Aram Ko\", \"James Moon\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"LZTR1\", \"proteomics\", \"mass spectrometry\", \"TMT quantitation\", \"schwannomatosis\", \"ubiquitin ligase\"],\n    \"dataType\": [\"proteomics\"],\n    \"studyId\": \"syn22268689\",\n    \"diseaseFocus\": [\"LZTR1-related schwannomatosis\"],\n    \"funder\": [\"CTF\"],\n    \"description\": \"Mass spectrometry and TMT quantitation proteomics data from LZTR1 studies, including DiGly proteomics and immunoprecipitation. This dataset helps elucidate the substrates and cellular functions of LZTR1, which is implicated in schwannomatosis and other tumors.\",\n    \"contributor\": [\"Aram Ko\", \"James Moon\"],\n    \"dataUseModifiers\": [\"General Research Use\"],\n    \"measurementTechnique\": [\"mass spectrometry\", \"TMT quantitation\"],\n    \"species\": [\"Mus musculus\", \"Homo sapiens\"],\n    \"specimenCount\": 1\n  },\n  {\n    \"title\": \"LZTR1 in vitro viability assay data\",\n    \"creator\": [\"Aram Ko\", \"James Moon\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"LZTR1\", \"viability assay\", \"drug combination\", \"schwannomatosis\", \"in vitro\"],\n    \"dataType\": [\"drugCombinationScreen\"],\n    \"studyId\": \"syn22268689\",\n    \"diseaseFocus\": [\"LZTR1-related schwannomatosis\"],\n    \"funder\": [\"CTF\"],\n    \"description\": \"Cell viability assay data examining the effects of drug combinations on cellular viability in the context of LZTR1 studies. Part of research characterizing the functional role of LZTR1 in schwannomatosis.\",\n    \"contributor\": [\"Aram Ko\", \"James Moon\"],\n    \"dataUseModifiers\": [\"General Research Use\"],\n    \"measurementTechnique\": [\"cell viability assay\"],\n    \"species\": [\"Mus musculus\"]\n  }\n]\n```"}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":6588,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":613}}}}
{"custom_id":"syn11374345","result":{"type":"succeeded","message":{"id":"msg_01QVGwi9LxvWwji2PJS2eeHx","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"I'll create high-quality dataset metadata for the four tables according to the schema. Here's the structured JSON:\n\n```json\n[\n  {\n    \"title\": \"12 month deliverables - NF1 iPSC Study\",\n    \"creator\": [\"Corina Anastasaki\", \"David H. Gutmann\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"iPSC\", \"Neurofibromatosis type 1\", \"gene expression\", \"immunofluorescence\"],\n    \"dataType\": [\"image\", \"geneExpression\"],\n    \"studyId\": \"syn11374345\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"This dataset contains gene expression data and immunofluorescence images collected at the 12-month milestone of a study examining how peripheral sensory neurons affect NF1-deficient Schwann cell growth through mitogen production. Includes progress reports and experimental results on patient-derived human iPSCs.\",\n    \"contributor\": [\"Corina Anastasaki\"],\n    \"measurementTechnique\": [\"immunofluorescence\", \"quantitative PCR\"],\n    \"species\": [\"Homo sapiens\"],\n    \"subject\": [\"Neurofibromatosis\", \"iPSC\", \"Schwann cells\", \"Gene expression\"]\n  },\n  {\n    \"title\": \"18 month deliverables - NF1 iPSC Sensory Neuron Study - Jan 2020\",\n    \"creator\": [\"Corina Anastasaki\", \"Christina Parry\", \"David H. Gutmann\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"iPSC\", \"Neurofibromatosis type 1\", \"sensory neurons\", \"gene expression\", \"BRN3A\", \"NF200\"],\n    \"dataType\": [\"image\", \"geneExpression\"],\n    \"studyId\": \"syn11374345\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"This dataset contains gene expression data and immunocytochemistry images collected at the 18-month milestone from January 2020. Includes characterization of sensory neuron markers like BRN3A, NF200, Peripherin, and TRK receptors in patient-derived iPSCs with NF1 mutations.\",\n    \"contributor\": [\"Corina Anastasaki\", \"Christina Parry\"],\n    \"measurementTechnique\": [\"immunocytochemistry\", \"quantitative PCR\"],\n    \"species\": [\"Homo sapiens\"],\n    \"subject\": [\"Neurofibromatosis\", \"Sensory neurons\", \"iPSC\", \"Gene expression\"]\n  },\n  {\n    \"title\": \"30 month deliverables - NF1 iPSC Sensory Neuron/Schwann Cell Study - December 2020\",\n    \"creator\": [\"Corina Anastasaki\", \"David H. Gutmann\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"iPSC\", \"Neurofibromatosis type 1\", \"electrophysiology\", \"MEA\", \"Schwann cells\", \"DRG\", \"cell proliferation\"],\n    \"dataType\": [\"electrophysiology\", \"image\", \"raw counts\"],\n    \"studyId\": \"syn11374345\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"This dataset contains electrophysiology recordings, image data, and cell proliferation measurements collected at the 30-month milestone from December 2020. Includes multi-electrode array (MEA) sensory data examining burst frequency, mean firing, and network burst measurements, plus DRG-NSC proliferation data.\",\n    \"contributor\": [\"Corina Anastasaki\"],\n    \"measurementTechnique\": [\"local field potential recording\", \"array\", \"cell proliferation\", \"cell count\", \"western blot\", \"immunocytochemistry\", \"immunohistochemistry\"],\n    \"species\": [\"Homo sapiens\", \"Mus musculus\"],\n    \"subject\": [\"Neurofibromatosis\", \"Sensory neurons\", \"Electrophysiology\", \"Schwann cells\", \"Cell proliferation\"]\n  },\n  {\n    \"title\": \"6 month deliverables - NF1 iPSC Initial Characterization\",\n    \"creator\": [\"Corina Anastasaki\", \"David H. Gutmann\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"iPSC\", \"Neurofibromatosis type 1\", \"Schwann cells\", \"immunocytochemistry\", \"western blot\"],\n    \"dataType\": [\"image\"],\n    \"studyId\": \"syn11374345\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"This dataset contains initial characterization data collected at the 6-month milestone for the NF1 iPSC study. Includes immunocytochemistry images of Schwann cell markers, western blot data, and progress reports documenting early findings in the study of patient-derived iPSCs with NF1 mutations.\",\n    \"contributor\": [\"Corina Anastasaki\"],\n    \"measurementTechnique\": [\"immunocytochemistry\", \"western blot\", \"quantitative PCR\"],\n    \"species\": [\"Homo sapiens\"],\n    \"specimenCount\": 2,\n    \"subject\": [\"Neurofibromatosis\", \"iPSC\", \"Schwann cells\", \"Immunocytochemistry\"]\n  }\n]\n```"}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":6671,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":1415}}}}
{"custom_id":"syn9727752","result":{"type":"succeeded","message":{"id":"msg_01XmsJ8h5bgwyBt1YrWdxM6z","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"I'll create high-quality dataset metadata for each table in the Synodos Schwannomatosis Data Portal project according to the schema requirements.\n\n```json\n[\n  {\n    \"title\": \"Deep Variant Tumor Calls\",\n    \"creator\": [\"Synodos for Schwannomatosis Consortium\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"schwannomatosis\", \"tumor\", \"variant calls\", \"deep variant\"],\n    \"dataType\": [\"genomicVariants\"],\n    \"studyId\": \"syn9727752\",\n    \"diseaseFocus\": [\"Schwannomatosis-NOS\"],\n    \"funder\": [\"CTF\"]\n  },\n  {\n    \"title\": \"Methylation\",\n    \"creator\": [\"Sheila Mansouri\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"schwannomatosis\", \"methylation\", \"epigenomics\", \"schwannoma\"],\n    \"dataType\": [\"chromatinActivity\"],\n    \"studyId\": \"syn9727752\",\n    \"diseaseFocus\": [\"Schwannomatosis-NOS\"],\n    \"funder\": [\"CTF\"],\n    \"description\": \"Methylation array data from schwannomatosis patients' tumor samples.\",\n    \"measurementTechnique\": [\"methylation array\"],\n    \"species\": [\"Homo sapiens\"],\n    \"individualCount\": 45,\n    \"specimenCount\": 91\n  },\n  {\n    \"title\": \"RNAseq\",\n    \"creator\": [\"Robert Allaway\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"schwannomatosis\", \"RNA-seq\", \"gene expression\", \"schwannoma\"],\n    \"dataType\": [\"geneExpression\"],\n    \"studyId\": \"syn9727752\",\n    \"diseaseFocus\": [\"Schwannomatosis-NOS\"],\n    \"funder\": [\"CTF\"],\n    \"description\": \"RNA-seq data from schwannomatosis patients' tumor samples.\",\n    \"measurementTechnique\": [\"RNA-seq\"],\n    \"species\": [\"Homo sapiens\"],\n    \"individualCount\": 14,\n    \"specimenCount\": 24\n  },\n  {\n    \"title\": \"SWNTS_processing_2020-05-13\",\n    \"creator\": [\"Synodos for Schwannomatosis Consortium\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"schwannomatosis\", \"data processing\", \"computational analysis\"],\n    \"dataType\": [\"AggregatedData\"],\n    \"studyId\": \"syn9727752\",\n    \"diseaseFocus\": [\"Schwannomatosis-NOS\"],\n    \"funder\": [\"CTF\"]\n  },\n  {\n    \"title\": \"Schwannomatosis RNA-seq Raw Data (NF-OSI Merged fastq)\",\n    \"creator\": [\"Synodos for Schwannomatosis Consortium\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"schwannomatosis\", \"RNA-seq\", \"gene expression\", \"schwannoma\", \"merged fastq\"],\n    \"dataType\": [\"geneExpression\"],\n    \"studyId\": \"syn9727752\",\n    \"diseaseFocus\": [\"Schwannomatosis-NOS\"],\n    \"funder\": [\"CTF\"],\n    \"description\": \"Merged fastq files from RNA-seq data of schwannomatosis patients.\",\n    \"measurementTechnique\": [\"RNA-seq\"],\n    \"species\": [\"Homo sapiens\"],\n    \"individualCount\": 14,\n    \"specimenCount\": 24\n  },\n  {\n    \"title\": \"Schwannomatosis RNA-seq Raw Data (Unmerged, Original fastq)\",\n    \"creator\": [\"Synodos for Schwannomatosis Consortium\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"schwannomatosis\", \"RNA-seq\", \"gene expression\", \"schwannoma\", \"unmerged fastq\"],\n    \"dataType\": [\"geneExpression\"],\n    \"studyId\": \"syn9727752\",\n    \"diseaseFocus\": [\"Schwannomatosis-NOS\"],\n    \"funder\": [\"CTF\"]\n  },\n  {\n    \"title\": \"Schwannomatosis RNA-seq quant.sf files\",\n    \"creator\": [\"Synodos for Schwannomatosis Consortium\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"schwannomatosis\", \"RNA-seq\", \"gene expression\", \"schwannoma\", \"quantification\"],\n    \"dataType\": [\"geneExpression\"],\n    \"studyId\": \"syn9727752\",\n    \"diseaseFocus\": [\"Schwannomatosis-NOS\"],\n    \"funder\": [\"CTF\"],\n    \"description\": \"Salmon quantification output files from RNA-seq data of schwannomatosis patients.\",\n    \"measurementTechnique\": [\"RNA-seq\"],\n    \"species\": [\"Homo sapiens\"],\n    \"individualCount\": 14,\n    \"specimenCount\": 22\n  },\n  {\n    \"title\": \"Somatic Mutations\",\n    \"creator\": [\"Synodos for Schwannomatosis Consortium\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"schwannomatosis\", \"somatic mutations\", \"genomic variants\", \"schwannoma\"],\n    \"dataType\": [\"SomaticVariants\"],\n    \"studyId\": \"syn9727752\",\n    \"diseaseFocus\": [\"Schwannomatosis-NOS\"],\n    \"funder\": [\"CTF\"]\n  },\n  {\n    \"title\": \"Somatic Variants - Strelka - WES\",\n    \"creator\": [\"Sasha Scott\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"schwannomatosis\", \"somatic variants\", \"Strelka\", \"whole exome sequencing\", \"schwannoma\"],\n    \"dataType\": [\"SomaticVariants\"],\n    \"studyId\": \"syn9727752\",\n    \"diseaseFocus\": [\"Schwannomatosis-NOS\"],\n    \"funder\": [\"CTF\"],\n    \"description\": \"Somatic variants called with Strelka from whole exome sequencing data of schwannomatosis patients.\",\n    \"measurementTechnique\": [\"whole exome sequencing\"],\n    \"species\": [\"Homo sapiens\"],\n    \"specimenCount\": 40\n  },\n  {\n    \"title\": \"Whole genome sequencing\",\n    \"creator\": [\"Robert Allaway\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"schwannomatosis\", \"whole genome sequencing\", \"genomic variants\", \"schwannoma\"],\n    \"dataType\": [\"genomicVariants\"],\n    \"studyId\": \"syn9727752\",\n    \"diseaseFocus\": [\"Schwannomatosis-NOS\"],\n    \"funder\": [\"CTF\"],\n    \"description\": \"Whole genome sequencing data from schwannomatosis patients' tumor and blood samples.\",\n    \"measurementTechnique\": [\"whole genome sequencing\"],\n    \"species\": [\"Homo sapiens\"],\n    \"individualCount\": 8,\n    \"specimenCount\": 18\n  },\n  {\n    \"title\": \"whole exome sequencing\",\n    \"creator\": [\"Fulvio D'Angelo\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"schwannomatosis\", \"whole exome sequencing\", \"genomic variants\", \"schwannoma\"],\n    \"dataType\": [\"genomicVariants\"],\n    \"studyId\": \"syn9727752\",\n    \"diseaseFocus\": [\"Schwannomatosis-NOS\"],\n    \"funder\": [\"CTF\"],\n    \"description\": \"Whole exome sequencing data from schwannomatosis patients' tumor and blood samples.\",\n    \"measurementTechnique\": [\"whole exome sequencing\"],\n    \"species\": [\"Homo sapiens\"],\n    \"individualCount\": 38,\n    \"specimenCount\": 91\n  }\n]\n```"}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":7869,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":2036}}}}
{"custom_id":"syn4939916","result":{"type":"succeeded","message":{"id":"msg_01PuvTG7ifUnCfJnysLdA7PV","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"I'll create high-quality dataset metadata for the table based on the provided information, following the JSON schema requirements.\n\n```json\n[\n  {\n    \"title\": \"Screening of Plexiform Neurofibroma Models in 96-well Format\",\n    \"description\": \"Data from cell viability assays comparing drug sensitivity in 2D and 3D plexiform neurofibroma cell culture models. The study examines whether cells grown in 3D matrices exhibit drug responses that better predict clinical effectiveness compared to traditional 2D cultures.\",\n    \"creator\": [\"Raymond Mattingly\"],\n    \"contributor\": [\"Markiesha Baines\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"plexiform neurofibroma\", \"drug screening\", \"3D cell culture\", \"cell viability\", \"drug sensitivity\"],\n    \"dataType\": [\"drugScreen\"],\n    \"studyId\": \"syn4939916\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"manifestation\": [\"Plexiform Neurofibroma\"],\n    \"measurementTechnique\": [\"cell viability assay\"],\n    \"species\": [\"Homo sapiens\"]\n  }\n]\n```"}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":6014,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":306}}}}
{"custom_id":"syn11374333","result":{"type":"succeeded","message":{"id":"msg_01E6H5x5kV5ei8w1gkjghAkF","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"I'll create high-quality dataset metadata for these tables following the JSON schema requirements.\n\n```json\n[\n  {\n    \"title\": \"12 month deliverables\",\n    \"creator\": [\"Lu Le\", \"Robert Allaway\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"immunofluorescence\", \"cutaneous neurofibroma\", \"microscopy images\"],\n    \"dataType\": [\"image\"],\n    \"studyId\": \"syn11374333\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"Microscopy images showing immunofluorescence analysis of cutaneous neurofibroma tissue samples from the Le lab's research on NF1 biology and models.\",\n    \"measurementTechnique\": [\"immunofluorescence\"],\n    \"specimenCount\": 1,\n    \"manifestation\": [\"Cutaneous Neurofibroma\"]\n  },\n  {\n    \"title\": \"18 month deliverables\",\n    \"creator\": [\"Lu Le\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"immunofluorescence\", \"microscopy\", \"neurofibroma\"],\n    \"dataType\": [\"image\"],\n    \"studyId\": \"syn11374333\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"Microscopy images from immunofluorescence analysis of neurofibroma samples as part of the 18-month deliverables for the Le lab's research on NF1 biology and models.\",\n    \"measurementTechnique\": [\"immunofluorescence\"]\n  },\n  {\n    \"title\": \"24 month deliverables\",\n    \"creator\": [\"Lu Le\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"neurofibroma\", \"microscopy\", \"gene expression\", \"immunohistochemistry\", \"western blot\"],\n    \"dataType\": [\"geneExpression\", \"image\"],\n    \"studyId\": \"syn11374333\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"Collection of microscopy images and gene expression data from analysis of neurofibroma tissues using multiple techniques including immunofluorescence, brightfield microscopy, and quantitative PCR.\",\n    \"measurementTechnique\": [\"immunofluorescence\", \"brightfield microscopy\", \"immunohistochemistry\", \"quantitative PCR\", \"immunocytochemistry\", \"western blot\"],\n    \"manifestation\": [\"Cutaneous Neurofibroma\", \"Plexiform Neurofibroma\"]\n  },\n  {\n    \"title\": \"36 month deliverables\",\n    \"creator\": [\"Renee McKay\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"neurofibroma\", \"immunohistochemistry\", \"mouse model\", \"human samples\", \"microscopy\"],\n    \"dataType\": [\"geneExpression\", \"image\"],\n    \"studyId\": \"syn11374333\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"Microscopy and genomic data from neurofibroma analysis, including images from reporter gene assays, immunohistochemistry, and cell counting experiments using both mouse models and human samples.\",\n    \"measurementTechnique\": [\"immunohistochemistry\", \"reporter gene assay\", \"brightfield microscopy\", \"immunofluorescence\", \"cell count\", \"whole exome sequencing\"],\n    \"species\": [\"Mus musculus\", \"Homo sapiens\"],\n    \"manifestation\": [\"Cutaneous Neurofibroma\", \"Plexiform Neurofibroma\"]\n  },\n  {\n    \"title\": \"6 month deliverables\",\n    \"creator\": [\"Lu Le\", \"Robert Allaway\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"neurofibroma\", \"immunofluorescence\", \"NF1\", \"microscopy\"],\n    \"dataType\": [\"image\"],\n    \"studyId\": \"syn11374333\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"Early microscopy images showing immunofluorescence analysis of neurofibroma tissue samples as part of the 6-month deliverables for the Le lab's research on NF1 biology and models.\",\n    \"measurementTechnique\": [\"immunofluorescence\"],\n    \"specimenCount\": 1\n  }\n]\n```"}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":6902,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":1176}}}}
{"custom_id":"syn21650493","result":{"type":"succeeded","message":{"id":"msg_01JACoR7tWphBZGKT7pU8ELg","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"I'll create detailed dataset metadata for each table in the project based on the provided information, following the JSON schema requirements.\n\n```json\n[\n  {\n    \"title\": \"AAV Ascl1 v YapS5A EdU\",\n    \"creator\": [\"Daniel Goldman\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"EdU\", \"Ascl1\", \"YapS5A\", \"immunofluorescence\", \"retina regeneration\"],\n    \"dataType\": [\"raw counts\"],\n    \"studyId\": \"syn21650493\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"GFF\"],\n    \"measurementTechnique\": [\"immunofluorescence\"],\n    \"species\": [\"Mus musculus\"],\n    \"description\": \"Immunofluorescence data comparing AAV-delivered Ascl1 versus YapS5A with EdU labeling in mouse retina. Part of a study on retina regeneration mechanisms for potential application to NF1-related optic nerve tumors and resulting blindness.\"\n  },\n  {\n    \"title\": \"AAV Ascl1 v YapS5A EdU image\",\n    \"creator\": [\"Daniel Goldman\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"EdU\", \"Ascl1\", \"YapS5A\", \"immunofluorescence\", \"imaging\", \"retina regeneration\"],\n    \"dataType\": [\"immunoassay\", \"image\"],\n    \"studyId\": \"syn21650493\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"GFF\"],\n    \"measurementTechnique\": [\"immunofluorescence\"],\n    \"species\": [\"Mus musculus\"],\n    \"description\": \"Microscopy images from immunofluorescence experiments comparing AAV-delivered Ascl1 versus YapS5A with EdU labeling in mouse retina, supporting research on retinal regeneration potential.\"\n  },\n  {\n    \"title\": \"ATACseq Ascl1a lin28a OE v control uninj Muller glia\",\n    \"creator\": [\"Daniel Goldman\", \"Christina Parry\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"ATAC-seq\", \"Ascl1a\", \"lin28a\", \"Muller glia\", \"chromatin accessibility\", \"retina regeneration\"],\n    \"dataType\": [\"chromatinActivity\"],\n    \"studyId\": \"syn21650493\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"GFF\"],\n    \"measurementTechnique\": [\"ATAC-seq\"],\n    \"species\": [\"Danio rerio\"],\n    \"individualCount\": 4,\n    \"specimenCount\": 5,\n    \"description\": \"ATAC-seq data comparing chromatin accessibility in zebrafish Muller glia with Ascl1a and lin28a overexpression versus uninjected controls, investigating mechanisms of retinal regeneration.\"\n  },\n  {\n    \"title\": \"ATACseq DAPT v DMSO\",\n    \"creator\": [\"Daniel Goldman\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"ATAC-seq\", \"DAPT\", \"DMSO\", \"chromatin accessibility\", \"Notch inhibition\", \"retina regeneration\"],\n    \"dataType\": [\"raw counts\"],\n    \"studyId\": \"syn21650493\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"GFF\"],\n    \"measurementTechnique\": [\"ATAC-seq\"],\n    \"species\": [\"Danio rerio\"],\n    \"individualCount\": 1,\n    \"specimenCount\": 1,\n    \"description\": \"ATAC-seq data comparing chromatin accessibility in zebrafish treated with DAPT (Notch inhibitor) versus DMSO control, investigating regulatory mechanisms in retinal regeneration.\"\n  },\n  {\n    \"title\": \"ATACseq inj v uninj\",\n    \"creator\": [\"Daniel Goldman\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"ATAC-seq\", \"injury\", \"chromatin accessibility\", \"retina regeneration\"],\n    \"dataType\": [\"raw counts\"],\n    \"studyId\": \"syn21650493\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"GFF\"],\n    \"measurementTechnique\": [\"ATAC-seq\"],\n    \"species\": [\"Danio rerio\"],\n    \"individualCount\": 1,\n    \"specimenCount\": 1,\n    \"description\": \"ATAC-seq data comparing chromatin accessibility changes in injured versus uninjured zebrafish retina at 4 days post-injury, investigating regulatory mechanisms during retinal regeneration.\"\n  },\n  {\n    \"title\": \"Cxcl18b injury dep gene exp\",\n    \"creator\": [\"Daniel Goldman\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"Cxcl18b\", \"qPCR\", \"gene expression\", \"chemokine\", \"injury response\", \"retina regeneration\"],\n    \"dataType\": [\"geneExpression\"],\n    \"studyId\": \"syn21650493\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"GFF\"],\n    \"measurementTechnique\": [\"quantitative PCR\"],\n    \"species\": [\"Danio rerio\"],\n    \"description\": \"Quantitative PCR data measuring the injury-dependent expression of Cxcl18b in zebrafish retina, exploring chemokine signaling in retinal regeneration.\"\n  },\n  {\n    \"title\": \"Cxcl18b knockdown EdU\",\n    \"creator\": [\"Daniel Goldman\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"Cxcl18b\", \"knockdown\", \"EdU\", \"proliferation\", \"retina regeneration\"],\n    \"dataType\": [\"immunoassay\"],\n    \"studyId\": \"syn21650493\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"GFF\"],\n    \"species\": [\"Danio rerio\"],\n    \"description\": \"EdU incorporation data following Cxcl18b knockdown in zebrafish retina, investigating the role of this chemokine in cell proliferation during retinal regeneration.\"\n  },\n  {\n    \"title\": \"Drug screen\",\n    \"creator\": [\"Daniel Goldman\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"drug screen\", \"small molecules\", \"retina regeneration\", \"therapeutic candidates\"],\n    \"dataType\": [\"drugScreen\"],\n    \"studyId\": \"syn21650493\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"GFF\"],\n    \"species\": [\"Danio rerio\"],\n    \"individualCount\": 1,\n    \"description\": \"Drug screening data to identify small molecules that promote retinal regeneration in zebrafish, with potential therapeutic applications for NF1-related vision loss.\"\n  },\n  {\n    \"title\": \"Flt1 knockdown and mutant EdU injury data\",\n    \"creator\": [\"Daniel Goldman\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"Flt1\", \"VEGF receptor\", \"knockdown\", \"mutant\", \"EdU\", \"injury\", \"proliferation\", \"retina regeneration\"],\n    \"dataType\": [\"immunoassay\"],\n    \"studyId\": \"syn21650493\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"GFF\"],\n    \"measurementTechnique\": [\"immunofluorescence\"],\n    \"species\": [\"Danio rerio\"],\n    \"description\": \"EdU incorporation data comparing proliferation responses in Flt1 knockdown and mutant zebrafish retinas following injury, investigating VEGF signaling in retinal regeneration.\"\n  },\n  {\n    \"title\": \"Images NF1 knockdown\",\n    \"creator\": [\"Daniel Goldman\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"NF1\", \"knockdown\", \"morpholino\", \"immunofluorescence\", \"imaging\", \"retina regeneration\"],\n    \"dataType\": [\"image\"],\n    \"studyId\": \"syn21650493\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"GFF\"],\n    \"measurementTechnique\": [\"immunofluorescence\"],\n    \"individualCount\": 1,\n    \"specimenCount\": 1,\n    \"description\": \"Microscopy images comparing NF1 morpholino knockdown versus control morpholino in zebrafish retina, investigating the direct role of neurofibromin in retinal regeneration.\"\n  },\n  {\n    \"title\": \"Myc\",\n    \"creator\": [\"Daniel Goldman\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"Myc\", \"Mycb\", \"Mych\", \"gene expression\", \"knockdown\", \"TUNEL\", \"apoptosis\", \"proliferation\", \"retina regeneration\"],\n    \"dataType\": [\"geneExpression\", \"cellularPhysiology\"],\n    \"studyId\": \"syn21650493\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"GFF\"],\n    \"measurementTechnique\": [\"quantitative PCR\", \"immunofluorescence\"],\n    \"species\": [\"Danio rerio\"],\n    \"description\": \"Data on Myc family gene expression, effects of Mycb and Mych knockdown, and apoptosis/proliferation analysis using EdU and TUNEL in zebrafish retina regeneration models.\"\n  },\n  {\n    \"title\": \"NF1 qPCR and MO knockdown\",\n    \"creator\": [\"Daniel Goldman\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"NF1\", \"neurofibromin\", \"qPCR\", \"morpholino\", \"knockdown\", \"Ascl1a\", \"retina regeneration\"],\n    \"dataType\": [\"geneExpression\"],\n    \"studyId\": \"syn21650493\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"GFF\"],\n    \"measurementTechnique\": [\"quantitative PCR\"],\n    \"species\": [\"Danio rerio\"],\n    \"individualCount\": 1,\n    \"specimenCount\": 1,\n    \"description\": \"Quantitative PCR data measuring NF1 expression and effects of morpholino-mediated NF1 knockdown on regeneration-associated genes like Ascl1a in zebrafish retina.\"\n  },\n  {\n    \"title\": \"RNAseq Ascl1a-Lin28a v control\",\n    \"creator\": [\"Daniel Goldman\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"RNA-seq\", \"Ascl1a\", \"Lin28a\", \"gene expression\", \"transcriptome\", \"retina regeneration\"],\n    \"dataType\": [\"geneExpression\"],\n    \"studyId\": \"syn21650493\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"GFF\"],\n    \"measurementTechnique\": [\"RNA-seq\"],\n    \"species\": [\"Danio rerio\"],\n    \"individualCount\": 1,\n    \"specimenCount\": 1,\n    \"description\": \"RNA sequencing data comparing gene expression profiles in zebrafish retina with Ascl1a and Lin28a manipulation versus controls, investigating key regulators of retinal regeneration.\"\n  },\n  {\n    \"title\": \"RNAseq DAPT v DMSO MG\",\n    \"creator\": [\"Daniel Goldman\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"RNA-seq\", \"DAPT\", \"Notch inhibition\", \"DMSO\", \"Muller glia\", \"gene expression\", \"retina regeneration\"],\n    \"dataType\": [\"geneExpression\"],\n    \"studyId\": \"syn21650493\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"GFF\"],\n    \"measurementTechnique\": [\"RNA-seq\"],\n    \"species\": [\"Danio rerio\"],\n    \"description\": \"RNA sequencing data comparing gene expression profiles in zebrafish Muller glia treated with DAPT (Notch inhibitor) versus DMSO control, investigating Notch signaling in retinal regeneration.\"\n  },\n  {\n    \"title\": \"RNAseq inj v uninj MG\",\n    \"creator\": [\"Daniel Goldman\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"RNA-seq\", \"injury\", \"Muller glia\", \"gene expression\", \"retina regeneration\"],\n    \"dataType\": [\"geneExpression\"],\n    \"studyId\": \"syn21650493\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"GFF\"],\n    \"measurementTechnique\": [\"RNA-seq\"],\n    \"species\": [\"Danio rerio\"],\n    \"description\": \"RNA sequencing data comparing gene expression profiles in Muller glia from injured versus uninjured zebrafish retina, investigating transcriptional changes during regeneration.\"\n  },\n  {\n    \"title\": \"RNAseq uninj v inj retina non-Muller glia\",\n    \"creator\": [\"Daniel Goldman\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"RNA-seq\", \"injury\", \"non-Muller glia\", \"gene expression\", \"retina regeneration\"],\n    \"dataType\": [\"geneExpression\"],\n    \"studyId\": \"syn21650493\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"GFF\"],\n    \"measurementTechnique\": [\"RNA-seq\"],\n    \"species\": [\"Danio rerio\"],\n    \"description\": \"RNA sequencing data comparing gene expression profiles in non-Muller glial cells from uninjured versus injured zebrafish retina, investigating cell type-specific responses during regeneration.\"\n  },\n  {\n    \"title\": \"Vegf signaling component gene expression\",\n    \"creator\": [\"Daniel Goldman\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"VEGF\", \"signaling\", \"qPCR\", \"gene expression\", \"angiogenesis\", \"retina regeneration\"],\n    \"dataType\": [\"geneExpression\"],\n    \"studyId\": \"syn21650493\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"GFF\"],\n    \"measurementTechnique\": [\"quantitative PCR\"],\n    \"species\": [\"Danio rerio\"],\n    \"description\": \"Quantitative PCR data measuring expression of VEGF signaling pathway components in zebrafish retina, investigating their role in the regeneration process.\"\n  },\n  {\n    \"title\": \"scRNAseq zf retina\",\n    \"creator\": [\"Daniel Goldman\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"single-cell RNA-seq\", \"scRNA-seq\", \"retina\", \"cell types\", \"gene expression\", \"GFP\", \"retina regeneration\"],\n    \"dataType\": [\"geneExpression\"],\n    \"studyId\": \"syn21650493\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"GFF\"],\n    \"measurementTechnique\": [\"single-cell RNA-seq\"],\n    \"species\": [\"Danio rerio\"],\n    \"description\": \"Single-cell RNA sequencing data from zebrafish retina with GFP labeling, providing high-resolution transcriptional profiles of different cell types involved in retinal regeneration.\"\n  }\n]\n```"}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":8841,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":4107}}}}
{"custom_id":"syn27761862","result":{"type":"succeeded","message":{"id":"msg_015qUh8bycq2WdAtRYadDRnN","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"Based on the provided information, I'll create high-quality dataset metadata that conforms to the specified JSON schema:\n\n```json\n[\n  {\n    \"title\": \"Proteasome-targeting drugs tested on NF2-deficient meningioma models\",\n    \"creator\": [\"Vijaya Ramesh\", \"Lei Xu\"],\n    \"contributor\": [\"Roberta Beauchamp\", \"Anh Nguyet Vu\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"NF2\", \"meningioma\", \"proteasome inhibitors\", \"drug screening\", \"cell viability\"],\n    \"dataType\": [\"drugScreen\"],\n    \"studyId\": \"syn27761862\",\n    \"description\": \"Cell viability data from testing proteasome-targeting drugs on NF2-deficient meningioma cell models, including AC-CRISPR (NF2+ and NF2-), Ben-Men-1, and MN597 cell lines.\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"CTF\"],\n    \"measurementTechnique\": [\"cell viability assay\"],\n    \"species\": [\"Homo sapiens\", \"Mus musculus\"],\n    \"manifestation\": [\"Meningioma\"],\n    \"specimenCount\": 1\n  }\n]\n```"}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":5994,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":337}}}}
{"custom_id":"syn11374341","result":{"type":"succeeded","message":{"id":"msg_01BVyv3u1mGQ53vDiVApYquh","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"I'll create high-quality dataset metadata for the three tables based on the information provided, following the schema requirements carefully.\n\n```json\n[\n  {\n    \"title\": \"Kallionpaa et al., Dermatology 2022\",\n    \"creator\": [\"Roope Kallionp√§√§\", \"Juha Peltonen\", \"Sirkku Peltonen\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"cutaneous neurofibroma\", \"brightfield microscopy\", \"CD117\", \"microscopy\", \"immunohistochemistry\"],\n    \"dataType\": [\"image\"],\n    \"studyId\": \"syn11374341\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"Microscopy data of cutaneous neurofibromas from NF1 patients. This dataset includes brightfield microscopy images of tissue samples that may help understand the roles of immune cells, particularly T-cells and mast cells, in cNF development.\",\n    \"manifestation\": [\"Cutaneous Neurofibroma\"],\n    \"measurementTechnique\": [\"brightfield microscopy\"],\n    \"species\": [\"Homo sapiens\"],\n    \"individualCount\": 61,\n    \"specimenCount\": 183,\n    \"contributor\": [\"University of Turku\"]\n  },\n  {\n    \"title\": \"Kallionpaa et al., Immune cell populations in cNFs, T cell receptor sequencing\",\n    \"creator\": [\"Roope Kallionp√§√§\", \"Juha Peltonen\", \"Sirkku Peltonen\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"cutaneous neurofibroma\", \"T cell receptor\", \"TCR sequencing\", \"immune cells\", \"tumor microenvironment\"],\n    \"dataType\": [\"genomicFeatures\"],\n    \"studyId\": \"syn11374341\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"T cell receptor sequencing data from cutaneous neurofibromas. This dataset provides insights into the adaptive immune cell populations present in cNFs, which may help elucidate the immune surveillance mechanisms in NF1-associated tumors.\",\n    \"manifestation\": [\"Cutaneous Neurofibroma\"],\n    \"measurementTechnique\": [\"T cell receptor repertoire sequencing\"],\n    \"species\": [\"Homo sapiens\"]\n  },\n  {\n    \"title\": \"Kallionpaa et al., Mass spectrometry of human cutaneous neurofibromas and the overlying skin\",\n    \"creator\": [\"Roope Kallionp√§√§\", \"Juha Peltonen\", \"Sirkku Peltonen\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"cutaneous neurofibroma\", \"mass spectrometry\", \"proteomics\", \"NF1\", \"tumor microenvironment\"],\n    \"dataType\": [\"proteomics\"],\n    \"studyId\": \"syn11374341\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"Proteomic characterization of cutaneous neurofibromas and overlying skin using liquid chromatography-tandem mass spectrometry. This dataset helps understand the protein expression profiles in cNFs and may identify potential therapeutic targets.\",\n    \"manifestation\": [\"Cutaneous Neurofibroma\"],\n    \"measurementTechnique\": [\"liquid chromatography/tandem mass spectrometry\"],\n    \"species\": [\"Homo sapiens\"],\n    \"contributor\": [\"University of Turku\"]\n  }\n]\n```"}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":6081,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":923}}}}
{"custom_id":"syn11374337","result":{"type":"succeeded","message":{"id":"msg_01DDsCMWUeQGthAw5hZMTj2c","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"I'll create high-quality metadata for these tables based on the provided information. I'll ensure all fields match the schema requirements and use only predefined values where specified.\n\n```json\n[\n  {\n    \"title\": \"Chronic injuries experiment\",\n    \"creator\": [\"Piotr Topilko\"],\n    \"description\": \"Immunofluorescence imaging data from chronic injuries experiments in mouse models for cutaneous neurofibroma research.\",\n    \"accessType\": \"Controlled Access\",\n    \"contributor\": [\"Piotr Topilko\"],\n    \"individualCount\": 27,\n    \"dataType\": [\"image\"],\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"keywords\": [\"chronic injuries\", \"immunofluorescence\", \"cutaneous neurofibroma\", \"mouse model\"],\n    \"license\": \"UNKNOWN\",\n    \"manifestation\": [\"Cutaneous Neurofibroma\"],\n    \"measurementTechnique\": [\"immunofluorescence\"],\n    \"species\": [\"Mus musculus\"],\n    \"studyId\": \"syn11374337\"\n  },\n  {\n    \"title\": \"Development of cNFs\",\n    \"creator\": [\"Piotr Topilko\"],\n    \"description\": \"Dataset containing information related to the development of cutaneous neurofibromas (cNFs) in mouse models.\",\n    \"accessType\": \"Controlled Access\",\n    \"contributor\": [\"Piotr Topilko\"],\n    \"dataType\": [\"image\"],\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"keywords\": [\"cutaneous neurofibroma\", \"cNF development\", \"mouse model\"],\n    \"license\": \"UNKNOWN\",\n    \"manifestation\": [\"Cutaneous Neurofibroma\"],\n    \"species\": [\"Mus musculus\"],\n    \"studyId\": \"syn11374337\"\n  },\n  {\n    \"title\": \"Grafts of tumor cells into sciatic nerve\",\n    \"creator\": [\"Piotr Topilko\", \"Christina Parry\"],\n    \"description\": \"In vivo tumor growth data from experiments involving grafts of tumor cells into sciatic nerve in mouse models.\",\n    \"accessType\": \"Controlled Access\",\n    \"contributor\": [\"Piotr Topilko\", \"Christina Parry\"],\n    \"individualCount\": 11,\n    \"dataType\": [\"image\"],\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"keywords\": [\"grafts\", \"tumor cells\", \"sciatic nerve\", \"in vivo tumor growth\"],\n    \"license\": \"UNKNOWN\",\n    \"manifestation\": [\"Cutaneous Neurofibroma\"],\n    \"measurementTechnique\": [\"in vivo tumor growth\"],\n    \"species\": [\"Mus musculus\"],\n    \"studyId\": \"syn11374337\"\n  },\n  {\n    \"title\": \"Mouse model cutaneous imaging of chronic injuries\",\n    \"creator\": [\"Piotr Topilko\"],\n    \"description\": \"Imaging data from a mouse model showing cutaneous manifestations of chronic injuries related to neurofibromatosis research.\",\n    \"accessType\": \"Controlled Access\",\n    \"contributor\": [\"Piotr Topilko\"],\n    \"individualCount\": 27,\n    \"dataType\": [\"image\"],\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"keywords\": [\"mouse model\", \"cutaneous imaging\", \"chronic injuries\", \"neurofibroma\"],\n    \"license\": \"UNKNOWN\",\n    \"manifestation\": [\"Cutaneous Neurofibroma\"],\n    \"species\": [\"Mus musculus\"],\n    \"studyId\": \"syn11374337\"\n  },\n  {\n    \"title\": \"NFOSI-RNASeq-To-Process-2023-15-03\",\n    \"creator\": [\"Piotr Topilko\"],\n    \"description\": \"RNA sequencing data from mouse models for NF-OSI processing. Part of ongoing research into cutaneous neurofibroma development.\",\n    \"accessType\": \"Controlled Access\",\n    \"contributor\": [\"Piotr Topilko\"],\n    \"dataType\": [\"geneExpression\"],\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"keywords\": [\"RNA-seq\", \"gene expression\", \"neurofibroma\", \"mouse model\"],\n    \"license\": \"UNKNOWN\",\n    \"species\": [\"Mus musculus\"],\n    \"studyId\": \"syn11374337\"\n  },\n  {\n    \"title\": \"RNAseq Bulk Sphere P0 vs P5\",\n    \"creator\": [\"Piotr Topilko\", \"Kaitlin Throgmorton\"],\n    \"description\": \"RNA sequencing data comparing gene expression between P0 and P5 stages in mouse models relevant to neurofibromatosis research.\",\n    \"accessType\": \"Controlled Access\",\n    \"contributor\": [\"Piotr Topilko\", \"Kaitlin Throgmorton\"],\n    \"dataType\": [\"geneExpression\"],\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"keywords\": [\"RNA-seq\", \"P0\", \"P5\", \"gene expression\", \"mouse model\"],\n    \"license\": \"UNKNOWN\",\n    \"measurementTechnique\": [\"RNA-seq\"],\n    \"species\": [\"Mus musculus\"],\n    \"studyId\": \"syn11374337\"\n  },\n  {\n    \"title\": \"Single cell transcriptomic analysis, for the identification of new markers of supepidermal glia\",\n    \"creator\": [\"Piotr Topilko\"],\n    \"description\": \"Single cell transcriptomic data focused on identifying new markers of supepidermal glia in relation to neurofibromatosis research.\",\n    \"accessType\": \"Controlled Access\",\n    \"contributor\": [\"Piotr Topilko\"],\n    \"dataType\": [\"geneExpression\"],\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"keywords\": [\"single cell\", \"transcriptomics\", \"supepidermal glia\", \"markers\", \"mouse model\"],\n    \"license\": \"UNKNOWN\",\n    \"measurementTechnique\": [\"single-cell RNA-seq\"],\n    \"species\": [\"Mus musculus\"],\n    \"studyId\": \"syn11374337\"\n  },\n  {\n    \"title\": \"Vascular detection with Itae\",\n    \"creator\": [\"Piotr Topilko\"],\n    \"description\": \"Imaging data for vascular detection using Itae in mouse models relevant to neurofibromatosis research.\",\n    \"accessType\": \"Controlled Access\",\n    \"contributor\": [\"Piotr Topilko\"],\n    \"dataType\": [\"image\"],\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"keywords\": [\"vascular detection\", \"Itae\", \"imaging\", \"mouse model\"],\n    \"license\": \"UNKNOWN\",\n    \"species\": [\"Mus musculus\"],\n    \"studyId\": \"syn11374337\"\n  }\n]\n```"}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":7227,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":1815}}}}
{"custom_id":"syn11638893","result":{"type":"succeeded","message":{"id":"msg_019Hn4xRoefkEUdFR8qVQbFt","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"I'll create high-quality dataset metadata for the 8 tables in this project, following the schema requirements precisely.\n\n```json\n[\n  {\n    \"title\": \"Copy Number Variation - CNVkit\",\n    \"creator\": [\"Angela C. Hirbe\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"MPNST\", \"CNV\", \"NF1\", \"copy number variation\", \"sarcoma\"],\n    \"dataType\": [\"genomicVariants\", \"CopyNumberVariants\"],\n    \"studyId\": \"syn11638893\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"Copy number variation data from NF1-MPNST patient-derived xenografts analyzed using CNVkit. This dataset contains CNV data from 10 specimens derived from 5 individuals with NF1-associated Malignant Peripheral Nerve Sheath Tumors.\",\n    \"species\": [\"Homo sapiens\"],\n    \"manifestation\": [\"Malignant Peripheral Nerve Sheath Tumor (MPNST)\"],\n    \"individualCount\": 5,\n    \"specimenCount\": 10,\n    \"contributor\": [\"NF Service\"],\n    \"dataUseModifiers\": [\"General Research Use\"],\n    \"measurementTechnique\": [\"whole genome sequencing\"]\n  },\n  {\n    \"title\": \"Filtered Single Cell RNASeq Data\",\n    \"creator\": [\"Angela C. Hirbe\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"MPNST\", \"single-cell\", \"RNAseq\", \"NF1\", \"sarcoma\", \"gene expression\"],\n    \"dataType\": [\"geneExpression\"],\n    \"studyId\": \"syn11638893\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"Filtered single-cell RNA sequencing data from NF1-MPNST patient-derived xenografts. The dataset includes gene expression data in matrix format with corresponding feature and barcode information, obtained from 8 individuals with NF1-associated MPNSTs.\",\n    \"species\": [\"Homo sapiens\"],\n    \"manifestation\": [\"Malignant Peripheral Nerve Sheath Tumor (MPNST)\"],\n    \"individualCount\": 8,\n    \"dataUseModifiers\": [\"General Research Use\"],\n    \"measurementTechnique\": [\"single-cell RNA-seq\"]\n  },\n  {\n    \"title\": \"Germline Genomic Variants - DeepVariant Pipeline\",\n    \"creator\": [\"Angela C. Hirbe\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"MPNST\", \"DeepVariant\", \"germline variants\", \"NF1\", \"sarcoma\", \"genomic variants\"],\n    \"dataType\": [\"genomicVariants\", \"GermlineVariants\"],\n    \"studyId\": \"syn11638893\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"Germline genomic variants called using the DeepVariant pipeline from whole genome sequencing data of NF1-MPNST patient-derived xenografts. The dataset includes variants from 9 specimens derived from 5 individuals with NF1-associated MPNSTs.\",\n    \"species\": [\"Homo sapiens\"],\n    \"manifestation\": [\"Malignant Peripheral Nerve Sheath Tumor (MPNST)\"],\n    \"individualCount\": 5,\n    \"specimenCount\": 9,\n    \"contributor\": [\"NF Service\"],\n    \"dataUseModifiers\": [\"General Research Use\"],\n    \"measurementTechnique\": [\"whole genome sequencing\"]\n  },\n  {\n    \"title\": \"Germline Genomic Variants - FreeBayes Pipeline\",\n    \"creator\": [\"Angela C. Hirbe\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"MPNST\", \"FreeBayes\", \"germline variants\", \"NF1\", \"sarcoma\", \"genomic variants\"],\n    \"dataType\": [\"genomicVariants\", \"GermlineVariants\"],\n    \"studyId\": \"syn11638893\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"Germline genomic variants called using the FreeBayes pipeline from whole genome sequencing data of NF1-MPNST patient-derived xenografts. The dataset includes variants from 9 specimens derived from 5 individuals with NF1-associated MPNSTs.\",\n    \"species\": [\"Homo sapiens\"],\n    \"manifestation\": [\"Malignant Peripheral Nerve Sheath Tumor (MPNST)\"],\n    \"individualCount\": 5,\n    \"specimenCount\": 9,\n    \"contributor\": [\"NF Service\"],\n    \"dataUseModifiers\": [\"General Research Use\"],\n    \"measurementTechnique\": [\"whole genome sequencing\"]\n  },\n  {\n    \"title\": \"Germline Genomic Variants - Mutect2 Pipeline\",\n    \"creator\": [\"Angela C. Hirbe\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"MPNST\", \"Mutect2\", \"germline variants\", \"NF1\", \"sarcoma\", \"genomic variants\"],\n    \"dataType\": [\"genomicVariants\", \"GermlineVariants\"],\n    \"studyId\": \"syn11638893\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"Germline genomic variants called using the Mutect2 pipeline from whole genome sequencing data of NF1-MPNST patient-derived xenografts. The dataset includes filtered and unfiltered variants from 9 specimens derived from 5 individuals with NF1-associated MPNSTs.\",\n    \"species\": [\"Homo sapiens\"],\n    \"manifestation\": [\"Malignant Peripheral Nerve Sheath Tumor (MPNST)\"],\n    \"individualCount\": 5,\n    \"specimenCount\": 9,\n    \"contributor\": [\"NF Service\"],\n    \"dataUseModifiers\": [\"General Research Use\"],\n    \"measurementTechnique\": [\"whole genome sequencing\"]\n  },\n  {\n    \"title\": \"Germline Genomic Variants - Strelka Pipeline\",\n    \"creator\": [\"Angela C. Hirbe\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"MPNST\", \"Strelka\", \"germline variants\", \"NF1\", \"sarcoma\", \"genomic variants\"],\n    \"dataType\": [\"genomicVariants\", \"GermlineVariants\"],\n    \"studyId\": \"syn11638893\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"Germline genomic variants called using the Strelka pipeline from whole genome sequencing data of NF1-MPNST patient-derived xenografts. The dataset includes genome and variant calls from 9 specimens derived from 5 individuals with NF1-associated MPNSTs.\",\n    \"species\": [\"Homo sapiens\"],\n    \"manifestation\": [\"Malignant Peripheral Nerve Sheath Tumor (MPNST)\"],\n    \"individualCount\": 5,\n    \"specimenCount\": 9,\n    \"contributor\": [\"NF Service\"],\n    \"dataUseModifiers\": [\"General Research Use\"],\n    \"measurementTechnique\": [\"whole genome sequencing\"]\n  },\n  {\n    \"title\": \"NFOSI-WES-To-Process-2024-09\",\n    \"creator\": [\"Angela C. Hirbe\", \"Chang In Moon\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"MPNST\", \"WES\", \"NF1\", \"sarcoma\", \"exome\", \"PDX\", \"patient-derived xenograft\"],\n    \"dataType\": [\"genomicVariants\"],\n    \"studyId\": \"syn11638893\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"Whole exome sequencing raw data (FASTQ files) from NF1-MPNST patient-derived xenografts pending processing. The dataset includes 13 specimens derived from 6 individuals with NF1-associated MPNSTs, including both human tissue and humanized mouse models.\",\n    \"species\": [\"Homo sapiens\", \"Mus musculus (humanized)\"],\n    \"manifestation\": [\"Malignant Peripheral Nerve Sheath Tumor (MPNST)\"],\n    \"individualCount\": 6,\n    \"specimenCount\": 13,\n    \"contributor\": [\"Chang In Moon\"],\n    \"dataUseModifiers\": [\"General Research Use\"],\n    \"measurementTechnique\": [\"whole exome sequencing\"]\n  },\n  {\n    \"title\": \"NFOSIprocessing-2022-26-04\",\n    \"creator\": [\"Angela C. Hirbe\", \"Chang In Moon\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"MPNST\", \"WGS\", \"NF1\", \"sarcoma\", \"PDX\", \"patient-derived xenograft\", \"processed BAM\"],\n    \"dataType\": [\"genomicVariants\"],\n    \"studyId\": \"syn11638893\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"description\": \"Processed whole genome sequencing data (BAM files) from NF1-MPNST patient-derived xenografts. The dataset includes aligned, marked duplicates BAM files from 11 specimens derived from 5 individuals with NF1-associated MPNSTs, including both human tissue and humanized mouse models.\",\n    \"species\": [\"Homo sapiens\", \"Mus musculus (humanized)\"],\n    \"manifestation\": [\"Malignant Peripheral Nerve Sheath Tumor (MPNST)\"],\n    \"individualCount\": 5,\n    \"specimenCount\": 11,\n    \"contributor\": [\"Chang In Moon\"],\n    \"dataUseModifiers\": [\"General Research Use\"],\n    \"measurementTechnique\": [\"whole genome sequencing\"]\n  }\n]\n```"}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":8693,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":2644}}}}
{"custom_id":"syn23662493","result":{"type":"succeeded","message":{"id":"msg_01STWUezAC8yuPChQSdQzEi1","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"I'll create high-quality dataset metadata for each table based on the provided information. Here's the valid JSON according to the schema:\n\n```json\n[\n  {\n    \"title\": \"Affinity Purified ELISA Screen\",\n    \"creator\": [\"Michelle Mattson-Hoss\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"ELISA\", \"antibody\", \"neurofibromin\", \"NF1\"],\n    \"dataType\": [\"immunoassay\"],\n    \"studyId\": \"syn23662493\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"contributor\": [\"Infixion Bioscience, Inc.\"],\n    \"description\": \"Dataset contains ELISA screening results for affinity purified antibodies against neurofibromin. Part of a project to develop improved monoclonal antibodies with increased sensitivity and specificity against neurofibromin.\",\n    \"measurementTechnique\": [\"ELISA\"],\n    \"species\": [\"Homo sapiens\"]\n  },\n  {\n    \"title\": \"Epitope Mapping\",\n    \"creator\": [\"Michelle Mattson-Hoss\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"western blot\", \"epitope mapping\", \"neurofibromin\", \"NF1\", \"antibody\"],\n    \"dataType\": [\"immunoassay\", \"image\"],\n    \"studyId\": \"syn23662493\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"contributor\": [\"Infixion Bioscience, Inc.\", \"Dominic Esposito\"],\n    \"description\": \"Western blot images for epitope mapping of NF1 antibodies. This data identifies binding regions of developed antibodies to neurofibromin, essential for characterizing antibody specificity.\",\n    \"measurementTechnique\": [\"western blot\"],\n    \"species\": [\"Homo sapiens\"]\n  },\n  {\n    \"title\": \"IHC Data\",\n    \"creator\": [\"Michelle Mattson-Hoss\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"immunohistochemistry\", \"neurofibromin\", \"NF1\", \"antibody\", \"tissue staining\"],\n    \"dataType\": [\"image\"],\n    \"studyId\": \"syn23662493\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"contributor\": [\"Infixion Bioscience, Inc.\", \"Michael Frost\"],\n    \"description\": \"Immunohistochemistry (IHC) staining images using the iNF1-07E antibody on various tissue samples, including cerebral and cerebellar cortex. Demonstrates the utility of the developed antibody in IHC applications.\",\n    \"measurementTechnique\": [\"immunohistochemistry\"],\n    \"species\": [\"Homo sapiens\"]\n  },\n  {\n    \"title\": \"Sandwich ELISA\",\n    \"creator\": [\"Michelle Mattson-Hoss\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"sandwich ELISA\", \"neurofibromin\", \"NF1\", \"antibody\", \"protein detection\"],\n    \"dataType\": [\"immunoassay\"],\n    \"studyId\": \"syn23662493\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"contributor\": [\"Infixion Bioscience, Inc.\"],\n    \"description\": \"Sandwich ELISA data demonstrating the functionality of developed NF1 antibodies in this application. This validates the expanded utility of the antibodies beyond standard western blot techniques.\",\n    \"measurementTechnique\": [\"sandwich ELISA\"],\n    \"species\": [\"Homo sapiens\"]\n  },\n  {\n    \"title\": \"Sequence Data\",\n    \"creator\": [\"Michelle Mattson-Hoss\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"mass spectrometry\", \"LC-MS/MS\", \"proteomics\", \"antibody sequencing\", \"neurofibromin\", \"NF1\"],\n    \"dataType\": [\"proteomics\", \"geneExpression\"],\n    \"studyId\": \"syn23662493\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"contributor\": [\"Infixion Bioscience, Inc.\", \"Digital Proteomics, LLC\"],\n    \"description\": \"Mass spectrometry and next-generation sequencing data from antibody characterization. Includes proteomics data from LC-MS/MS analysis of antibody fragments.\",\n    \"measurementTechnique\": [\"liquid chromatography/tandem mass spectrometry\", \"next generation targeted sequencing\"],\n    \"species\": [\"Oryctolagus cuniculus\"],\n    \"individualCount\": 1\n  },\n  {\n    \"title\": \"Titer Report\",\n    \"creator\": [\"Michelle Mattson-Hoss\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"antibody titer\", \"ELISA\", \"neurofibromin\", \"NF1\"],\n    \"dataType\": [\"immunoassay\"],\n    \"studyId\": \"syn23662493\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"contributor\": [\"Infixion Bioscience, Inc.\"],\n    \"description\": \"Report detailing the antibody titers measured via ELISA. This data is critical for understanding the potency and concentration of the developed antibodies against neurofibromin.\",\n    \"measurementTechnique\": [\"ELISA\"]\n  },\n  {\n    \"title\": \"Western Blot Screening\",\n    \"creator\": [\"Michelle Mattson-Hoss\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"western blot\", \"antibody screening\", \"neurofibromin\", \"NF1\", \"Plexiform Neurofibroma\"],\n    \"dataType\": [\"image\"],\n    \"studyId\": \"syn23662493\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"contributor\": [\"Infixion Bioscience, Inc.\", \"Eduard Serra\"],\n    \"description\": \"Western blot images from screening of various antibody candidates, including 05D, 06G, 07E, 08D, and 10D. These results demonstrate the specificity and sensitivity of the antibodies for neurofibromin detection.\",\n    \"measurementTechnique\": [\"western blot\"],\n    \"species\": [\"Homo sapiens\"],\n    \"manifestation\": [\"Plexiform Neurofibroma\"]\n  }\n]\n```"}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":6782,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":1743}}}}
{"custom_id":"syn4939888","result":{"type":"succeeded","message":{"id":"msg_01JSbQH6GFQof22NW32N65KP","type":"message","role":"assistant","model":"claude-3-7-sonnet-20250219","content":[{"type":"text","text":"I'll create metadata for the dataset based on the information provided. Here's the JSON metadata that conforms to the schema:\n\n```json\n[\n  {\n    \"title\": \"Patient Reported Outcomes Dataset for NF1-Associated Plexiform Neurofibromas\",\n    \"creator\": [\"Jin-Shei Lai\"],\n    \"contributor\": [\"Jin-Shei Lai\", \"Sara Gosline\"],\n    \"accessType\": \"Controlled Access\",\n    \"license\": \"UNKNOWN\",\n    \"keywords\": [\"Patient Reported Outcomes\", \"PRO\", \"plexiform neurofibroma\", \"quality of life\", \"HRQOL\", \"questionnaire\", \"NF1\", \"survey data\"],\n    \"dataType\": [\"surveyData\", \"clinical\"],\n    \"studyId\": \"syn4939888\",\n    \"diseaseFocus\": [\"Neurofibromatosis type 1\"],\n    \"funder\": [\"NTAP\"],\n    \"manifestation\": [\"Plexiform Neurofibroma\"],\n    \"measurementTechnique\": [\"questionnaire\"],\n    \"description\": \"Patient Reported Outcome (PRO) data collected from patients with NF1-associated plexiform neurofibromas. The dataset includes various aspects of health-related quality of life as reported by patients, including measures related to pain, stigma, and organ dysfunction. Data were collected through questionnaires administered to both pediatric and adult patients.\",\n    \"dataUseModifiers\": [\"Health or Medical or Biomedical Research\"],\n    \"subject\": [\"Patient Reported Outcomes\", \"Neurofibromatosis\", \"Quality of Life\"]\n  }\n]\n```\n\nThis metadata provides a comprehensive description of the Patient Reported Outcomes Dataset, adhering to the required schema format and using only the predefined enum values where specified. I've included the creator, contributor, relevant keywords, and appropriate categorizations based on the project information provided."}],"stop_reason":"end_turn","stop_sequence":null,"usage":{"input_tokens":5981,"cache_creation_input_tokens":0,"cache_read_input_tokens":0,"output_tokens":445}}}}